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Abstract 
Wnt signalling regulates a wide range of events throughout embryonic development, 
adult homeostasis and the onset of disease. Within the frog Xenopus laevis activation of 
the Wnt pathway results in one of the first major events during embryogenesis: the 
establishment of the dorsal-ventral axis. At the molecular level the Wnt pathway in 
Xenopus embryos is similar to that in many other organisms – including humans – 
therefore what is learned about protein functions from studies in Xenopus can be 
extrapolated to other species.  
My PhD has focussed on the role of ARID1a in the regulation of the Wnt pathway. 
ARID1a is the largest subunit of the chromatin remodelling BAF complex, which is the 
vertebrate homologue of the yeast SWI/SNF complex. The BAF complex functions by 
repositioning nucleosomes within chromatin, and plays a role in a variety of cellular 
functions such as the regulation of transcription, RNA splicing and DNA damage repair.  
 ARID1a was originally identified in the fruit fly Drosophila, where it was implicated as a 
repressor of Wg. My studies verify and expand upon this work, investigating the role of 
ARID1a as a repressor of the Wnt pathway in Xenopus and in Human Embryonic Kidney 
293 (HEK293) cells. I carried out a mass spectrometry screen in HEK293 cells and 
identified two interacting proteins for further study: BCL7a and DDX5. I demonstrate 
that these two proteins are also able to inhibit Wnt signalling in Xenopus, and suggest 
mechanisms by which this repression may occur.   
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Chapter 1: Introduction 
My project focuses on the role of ARID1a in the regulation of the Wnt pathway in 
Xenopus embryos and in Human Embryonic Kidney 293 (HEK293) cells. I first describe 
ARID1a and the complex to which it belongs. I then give an overview of the Wnt 
pathway. 
1.1 ARID1a and the BAF Complex 
ARID1a is the largest subunit of the Brg/Brm-Associated Factor (BAF) complex, which 
is the vertebrate orthologue of the yeast SWI-SNF complex. The BAF is part of the 
chromatin remodelling complex (CRC) family that repositions nucleosomes to affect a 
range of cellular processes. I shall first describe what is known about the BAF complex, 
followed by the specific functions of ARID1a. 
1.1.1 Composition of the SWI-SNF/BAF and RSC/PBAF Complexes 
1.1.1.1 Yeast 
The SWI-SNF complex was first identified in Saccharomyces cerevisiae from two 
independent mutational screens. Sucrose Non-Fermenting 2 (SNF2) was identified as a 
gene that regulated the expression of Suc2, an enzyme required for sucrose 
fermentation (Neigeborn and Carlson, 1984), while mutations in SWI2 prevented 
mating type switching (Egel et al., 1984). Later, it was discovered that SWI2 and SNF2 
are encoded by the same gene (Laurent and Carlson, 1992), and that it forms a complex 
with other proteins identified in the original mutational screens (Cairns et al., 1994; 
Laurent et al., 1991). Subsequently, the SWI-SNF complex has been shown to comprise 
12 core subunits and to have access to at least 18 accessory subunits as determined by 
mass spectrometry experiments (van Vugt et al., 2007), see Table 1.1 for species 
comparison). Stoichiometric analysis revealed that six of the subunits exist as a single 
copy (SWI1, SWI2, SNF5, ARP7, ARP9, SWP73), four are present as two copies (SWI3, 
SNF6, SNF11, SWP82) and one (SWP29) as three copies (Smith et al., 2003). 
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Table 1.1 The SWI-SNF and BAF Complexes 
 
 Yeast Worm Fly Frog Mouse Human 
Conserved 
subunits 
Swi2/Snf2 SWSN-
4/psa-4 
BRM BRG1/SMARCA4 
(BRM/SMARCA2)* 
BRG1/SMARCA4 
BRM/SMARCA2 
BRG1/SMARCA4 
hBRM/SMARCA2 
 Swsn-
8/LET-526 
OSA/eyelid 
 
ARID1a/ARID1a 
BAF250b/ARID1b 
ARID1a/ARID1a 
BAF250b/ARID1b 
ARID1a/ARID1a 
BAF250b/ARID1b 
Swi3 SWSN-
1/psa-1 
MOR/BAP155 (SMARCC1)* 
BAF170/SMARCC2 
BAF155/SMARCC1 
BAF170/SMARCC2 
BAF155/SMARCC1 
BAF170/SMARCC2 
Swp73 SWSN-2.2 + 
SWSN-
2.1/HAM-3 
 
BAP60 BAF60a/SMARCD1 
BAF60b/SMARCD2 
BAF60c/SMARCD3 
BAF60a/SMARCD1 
BAF60b/SMARCD2 
BAF60c/SMARCD3 
BAF60a/SMARCD1 
BAF60b/SMARCD2 
BAF60c/SMARCD3 
Rsc11/Arp7 
Rsc12/Arp9 
SWSN-6 BAP55 
BAP47 
BAF53a/ACTL6a 
(BAF53b/ACTL6b)* 
BAF53a 
BAF53b 
BAF53a 
BAF53b 
Snf5 SNFC-5 SNR1/BAP45 SMARCB1 BAF47/SNF5/SMARCB1 BAF47/SNF5/SMARCB1/ 
INI1 
 PHF-10 
DPFF-1 
E(y)3/SAYP 
TTH + D4 
(PHF10)* 
DPF1/BAF45b 
DPF3/BAF45c 
DPF2/BAF45d 
PHF10/BAF45a 
DPF1/BAF45b 
DPF3/BAF45c 
DPF2/BAF45d 
PHF10/BAF45a 
DPF1/BAF45b 
DPF3/BAF45c 
DPF2/BAF45d 
 SWSN-3 BAP111/dalao BAF57/SMARCE1 BAF57/SMARCE1 BAF57/SMARCE1 
  -actin -actin -actin -actin 
Unique 
Subunits 
Swi1/Adr6, 
Swp82, 
Taf14, Snf6, 
Snf11 
    Brd9 
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Table 1.2 The RSC and PBAF Complexes 
 
 Yeast Worm Fly Frog Mouse Human 
Conserved 
Subunits 
Rsc1, 2, 4 Swsn-7 BAP170 ARID2/BAF200 ARID2/BAF200 ARID2/BAF200 
Rsc9 Pbrm-1 Polybromo BAF180 BAF180 BAF180 
 Swsn-9  BRD7 BRD7 BRD7 
Sth1 SWSN-
4/psa-4 
BRM BRG1/SMARCA4 
 
BRG1/SMARCA4 
 
BRG1/SMARCA4 
 
 SWSN-
1/psa-1 
    
Rsc6 SWSN-2.2 
+ SWSN-
2.1/HAM-
3 
 
BAP60 BAF60a/SMARCD1 
 
BAF60a/SMARCD1 
 
BAF60a/SMARCD1 
 
Rsc11/Arp7 
Rsc12/Arp9 
SWSN-6 BAP55 
 
BAF53a BAF53a BAF53a 
 SNFC-5 SNR1/BAP45 BAF47/SNF5/SMARCB1 BAF47/SNF5/SMARCB1 BAF47/SNF5/SMARCB1 
 SWSN-3 BAP111/dalao ARID2/BAF200   
  -actin -actin -actin -actin 
Unique 
Subunits 
Rsc3, 5, 7, 9, 
10, 30, Htl1, 
Lbd7, 
Rtt102 
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Table 1.1 The SWI-SNF and BAF Complexes 
Species comparison of SWI-SNF and BAF complex subunits across S. cerevisiae, C. elegans, X. 
laevis, M. musculus and H. sapiens. Orthologous subunits are arranged in rows, and proteins with 
multiple names are denoted by “/”.  X. laevis genes marked by ()* are non-curated, machine 
annotated entries in Xenbase. Due to the strong conservation of subunits across large 
evolutionary distances, it is likely that these predicted genes are real and encode subunits of the 
BAF complex. Table is adapted from Hargreaves and Crabtree (2011).  
Table 1.2 The RSC and PBAF Complexes 
Same as for Table 1.1. The entries for X. laevis are predicted based on homology with mammalian 
PBAF complexes. No direct evidence for a Xenopus PBAF complex yet exists.  
 
 
 
In addition to the SWI-SNF complex, yeast also possess a highly homologous 
chromatin remodelling complex named Remodels the Structure of Chromatin 
(RSC). Discovered in 1996, this has 17 subunits, 3 of which (ARP9, ARP7 and 
RSC8) are shared with the SWI-SNF complex (Cairns et al., 1996; van Vugt et al., 
2007). Functionally RSC acts via a similar mechanism to SWI/SNF, however it 
targets different genes in a non-redundant manner (Damelin et al., 2002; 
Hargreaves and Crabtree, 2011).  
1.1.1.2 C. elegans 
The C. elegans SWI-SNF complex subunits have been found through a series of 
mutational screens. swsn-1 and swsn-4 (homologues of SWI3/BAF170 and 
SWI2/BRG1-BRM respectively) were the first components to be identified  
(Sawa et al., 2000). Two orthologues of vertebrate BAF60, swsn-2.1 and 2.2, exist 
in C. elegans, and the duplication of the swsn-2 gene appears to be independent of 
that which occurred for BAF60 in vertebrates (Weinberg et al., 2013). A recent 
paper (Large and Mathies, 2014) has identified the remaining C. elegans SWI-SNF 
components by in silico comparison of the genome with data from the literature. 
This work demonstrated that C. elegans possesses at least one protein for each 
subunit of the BAF complex. However, few experiments have been carried out on 
the C. elegans SWI-SNF complex, and it lacks the biochemical characterisation 
that has been carried out in other species.  
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The animal homologue of the yeast RSC complex is the PBAF complex – so named 
because it contains the protein Polybromo (Mohrmann et al., 2004). The                 
C. elegans PBAF complex contains the same core components as the BAF complex 
with the exception of swsn-8 (ARID1), and it additionally contains swsn-7 
(BAF200), pbrm-1 (BAF180) and swsn-9 (BRD7; (Kuzmanov et al., 2014). These 
findings, along with the extensive work carried out on vertebrate BAF 
complexes, indicate that the SWI-SNF and BAF complexes are highly conserved 
throughout evolution. 
1.1.1.3 Drosophila 
The Drosophila orthologue of SWI2/SNF2, Brahma (Brm), was discovered as a 
suppressor of both Polycomb and Antennapedia mutations (Kennison and 
Tamkun, 1988), and has sequence similarity to SWI2/SNF2 (Elfring et al., 1994; 
Tamkun et al., 1992). Brm is the core component of the Brahma associated 
protein (BAP) complex in Drosophila, which has orthologous functions and 
composition to the yeast SWI-SNF and vertebrate BAF complexes (Mohrmann 
and Verrijzer, 2005). The BAP complex is formed of eight core subunits (see 
Table 1.1) plus -actin, all of which are homologous to the vertebrate BAF 
complex. Unlike other animals studied, Drosophila only has one protein 
homologous to BAF60 – BAP 60.  
The Drosophila PBAP complex was discovered in 2004 (Mohrmann et al., 2004). 
Biochemical characterisation shows that PBAP shares most of its subunits with 
the BAP complex with the noticeable exception of Osa. In addition, the PBAP 
complex also contained two proteins that were not present in the BAP complex: 
Polybromo and BAP170.   
1.1.1.4 Mouse and Human 
Unlike the SWI-SNF/BAF complexes discussed so far, the vertebrate BAF 
complex is highly pleomorphic. Of the ten core subunits in the human BAF 
complex, six have multiple proteins encoded by different genes capable of 
occupying the same functional space within the complex, and they do so in a 
mutually exclusive manner (see Table 1.1, Fig. 1.1). Vertebrates have two core 
ATPases that are orthologous to SWI2/SNF2 – Brahma (Brm) and Brahma-
related gene 1 (Brg1; (Khavari et al., 1993; Muchardt and Yaniv, 1993).  
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Brm and Brg1 are mutually exclusive within the BAF complex (Wang et al., 
1996), though both proteins are often present within the same cell. Other 
subunits with alternative proteins are selectively incorporated into BAF 
complexes. ChIP–reChIP experiments in HeLa cells demonstrated that ARID1a 
and Brg1 are both present on DNA at the CSF1 promoter, whereas ARID1b and 
Brm are not (Ryme et al., 2009). In contrast, ARID1b, Brg1 and Brm (but not 
ARID1a) bind to the ECM1 promoter. These experiments show that distinct BAF 
complexes exist at different promoters within the same cell, and hint at the 
importance of different combinations of subunits for BAF complex functionality. 
 As an additional level of complexity, some BAF components are only expressed 
in certain cell types, leading to cell-type specific complexes. For example, neural 
stem/progenitor cells in the developing mouse nervous system have a specific 
BAF composition, called the npBAF complex. This comprises the core 
components (ARID1a, Brg1, BAF170 or BAF155, BAF60a, BAF57 and -actin) 
and the npBAF specific factors BAF45a and BAF53a (Lessard et al., 2007). As 
these neuronal stem cells differentiate, there is a switch in expression from 
BAF45a and BAF53a to BAF45b, c and d, and BAF53b. This switch has a 
functional significance, because depletion of BAF45a or BAF53a impairs 
proliferation of neural stem cells, indicating that npBAF complexes positively 
regulate the cell cycle.  
Similar cell-type specificity is seen in BAF complexes in mouse embryonic stem 
cells (esBAF). esBAF complexes contain a restricted set of subunits including 
Brg1, ARID1a, BAF155 and BAF45d, and this specific combination of subunits is 
required for the maintenance of pluripotency (Ho et al., 2009).  
There are 3 BAF60 proteins in vertebrates: BAF60a, b and c. BAF60c is 
predominantly expressed in cardiac and skeletal muscle progenitors, and knock-
down of BAF60c using siRNAs causes embryonic lethality by E11 (Lickert et al., 
2004). However, unlike the esBAF and n/npBAF complexes, BAF60b was able to 
rescue deletion of BAF60c, indicating that these two proteins are able to act 
redundantly. This experiment highlights that while there may be significant 
functional relevance in each particular composition of the BAF complex, there is 
still redundancy within the complex.   
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Fig. 1.1 Diagram of the BAF Complex Subunits 
The diagram shows the relative size of the major BAF subunits. Proteins that 
intersect on the diagram have been shown to interact physically by 
immunoprecipitation or mass spectrometry.  
Several mutually exclusive subunits are represented simultaneously: however only 
one of these proteins will be present in any one BAF complex, and not all subunits 
are present in all BAF complexes.  
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Human Polybromo/BAF180 was identified in 2000, and is one of the defining 
members of the PBAF complex (Xue et al., 2000). It is similar to the yeast RSC 
proteins Rsc1, 2 and 4, and is orthologous to Drosophila Polybromo. 
Furthermore, vertebrate BAF and PBAF are more similar to one another than are 
their yeast counterparts SWI-SNF and RSC, and unlike the RSC the range of 
subunits found in the PBAF complex is more restricted than those in the BAF 
complex.   
1.1.1.5 Xenopus 
The vast majority of research carried out on the BAF and PBAF complexes in 
vertebrates has used mice or human cells. Such biochemical characterisation has 
not been carried out in other species, but due to the highly conserved nature of 
the complex it is likely that the BAF and PBAF complexes in other model 
vertebrates are assembled in a similar manner. 
To date, the only BAF subunits to be studied in Xenopus are Brg1 and BAF57 
(Domingos et al., 2002; Seo et al., 2005). However, orthologues for all of the 
human and mouse BAF and PBAF complex subunits can be found in the Xenopus 
genome (see Table 1.1, Xenbase). Based on the homology and presence of these 
factors, it is likely that the Xenopus BAF and PBAF complexes are assembled in a 
similar manner to their mammalian counterparts. 
1.1.2 Molecular Mechanism of BAF Functions 
Each eukaryotic cell contains about 2 m of DNA packaged into a nucleus with a 
diameter of only 6 m. This dense packaging is achieved by wrapping 146 base 
pairs of DNA around histone octamers to form nucleosomes, with linker regions 
of~ 38 bp between them (Luger et al., 1997). However, the existence of 
nucleosomes hinders the ability of trans-acting factors to bind to DNA, thus the 
repositioning of nucleosomes is a key part of processes such as transcription and 
DNA replication. Chromatin remodelling complexes such as the BAF complex act 
to reposition nucleosomes — either by sliding them in cis along the DNA, or by 
ejection or insertion of histone octamers. 
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1.1.2.1 The BAF Complex Repositions Nucleosomes 
In vitro, SWI-SNF and BAF complexes are capable of altering the position of 
nucleosomes on synthetic chromatin in an ATP-dependent manner (summarised 
in Fig. 1.2). The presence of double stranded DNA is sufficient to induce the 
ATPase activity of SWI2/SNF2, and ATP is crucial for the remodelling of 
nucleosomes in vitro (Laurent et al., 1993). All chromatin remodelling complexes 
contain a core ATPase, in the case of the BAF complex these are SWI2/SNF2 in 
yeast, and either Brg1 or Brm in vertebrates (Clapier and Cairns, 2009).  
Much of the evidence from work in vitro suggests that the BAF complex acts to 
slide nucleosomes along DNA. Early experiments used restriction enzyme digest 
assays, as movement of nucleosomes exposed restriction sites and changed the 
pattern of DNA cleavage (Kwon et al., 1994). This repositioning of nucleosomes 
was shown to be a permanent effect, because removal of ATP from the reaction 
did not cause a reversion back to the original DNaseI cleavage pattern 
(Imbalzano et al., 1996). In 2001, Lieber and colleagues directly visualised 
nucleosome remodelling using atomic force microscopy (AFM, (Schnitzler et al., 
2001). They demonstrated that the BAF complex reorganised polynucleosomes 
from evenly spaced “beads on a string” to a clump of nucleosomes at one end 
with a free DNA tail.  
Due to the large size of the BAF complex, no crystal structure is yet available for 
the entire complex. Imaging by electron microscopy (EM) and AFM have both 
revealed that the BAF complex adopts a multi-lobed conformation with a 
nucleotide binding pocket and multiple DNA-binding interfaces (Schnitzler et al., 
2001; Smith et al., 2003). More recent work demonstrated that the yeast SWI-
SNF complex contains a pocket that can contain an entire nucleosome and 
approximately 50 bp of flanking DNA (Dechassa et al., 2008). The authors 
showed that the SNF5 and SWI2 subunits both bind to the histone core of the 
nucleosome close to the dyad axis. The structural information gained from these 
studies has been important for developing mechanistic models for the BAF 
complex.   
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Fig. 1.2 BAF Complex Modification of Nucleosomes 
Schematic representations of the BAF complex acting on nucleosomes. 
A: The BAF complex binds to a nucleosome and repositions it closer to its neighbour. The BAF 
complex spools DNA around the nucleosome, creating a loop that the nucleosome can then be 
slid along to alter its position. 
B:  BAF complex-mediated eviction of a histone (modified from Dechassa et. Al, 2010). The 
BAF complex binds to a nucleosome and begins spooling DNA. This creates torsional strain on 
the distal nucleosome, eventually resulting in the physical displacement of the octamer from 
DNA. 
C: The BAF complex can recruit various histone modifying enzymes to nucleosomes. 
Additionally, the BAF complex itself binds modified histones, the interplay between the BAF 
complex and histone modifying enzymes is complex and not well understood. HAT: Histone 
acetyltransferase. Ac: acetyl residue on histone tail. 
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1.1.2.2 Two Models For BAF Complex Action 
There are currently two models describing how the BAF complex repositions 
nucleosomes: the twist-diffusion mechanism and the loop-recapture model 
(Whitehouse et al., 2000). The twist-diffusion model describes a loosening of a 
base pair that is then propagated around the histone octamer, acting to shift it 
along the DNA one base pair at a time (Fig. 1.3 A). However significant steric 
obstacles such as Holliday Junctions and DNA branches failed to affect the ability 
of the BAF complex to remodel nucleosomes, arguing against a simple twist-
diffusion model (Aoyagi and Hayes, 2002; Whitehouse et al., 1999).  
Instead, a loop-recapture model was proposed based on the observation that 
binding of the BAF complex to chromatin resulted in DNA loops (Bazett-Jones et 
al., 1999). In this model, the nucleosome is anchored by the BAF complex and a 
DNA loop is spooled around the histone octamer. This loop is then passed 
around the octamer, shifting the nucleosome by the length of the loop (Fig. 1.3 
B). The actual size of these loops is unclear: Bazett-Jones and colleagues 
visualised loops of over 1 kb using EM, whereas other groups have reported 
much smaller loops with an average size of 100 bp using AFM and optical 
tweezers (Schnitzler et al., 2001; Zhang et al., 2006).  
An added complication to developing models for BAF complex activity is that 
nucleosomes are not static entities. Even without chromatin remodelling 
complexes, DNA spontaneously unwraps and rewraps around histone octamers 
(Polach and Widom, 1995). FRET measurements revealed that DNA associates 
with the histones much more rapidly than it unwraps, and this step may affect 
the ability of proteins such as PolII and the BAF complex to bind to DNA (Li et al., 
2004). The authors hypothesise that chromatin remodelling complexes may act 
as ratchets to harness this spontaneous unwrapping and rewrapping, however 
the kinetic analysis to test this model has not yet been carried out.  
Recently the twist-diffusion mechanism has come back into favour (Mueller-
Planitz et al., 2013). High resolution FRET experiments demonstrated that DNA 
leaves chromatin remodelling complexes one base pair at a time, and that the 
formation of DNA loops is unlikely (Deindl et al., 2013). It is worth noting that 
these experiments were carried out with the ISWI complex (imitation switch,  
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another chromatin remodelling complex), and the BAF complex may act by a 
different mechanism. Indeed the BAF complex is much larger than the ISWI 
complex, and may use loops in conjunction with base pair twisting to effect the 
remodelling of nucleosomes. More experiments using high resolution imaging 
and kinetic analysis are required to determine which of these two models is 
correct, or whether the BAF complex acts by a combination of the above.  
1.1.2.3 The BAF Complex Can Disassemble Nucleosomes 
In addition to sliding nucleosomes, BAF complexes are able to evict and insert 
histones from chromatin. This was first demonstrated using the yeast RSC 
complex, where free radiolabelled DNA was incorporated into nucleosomes 
(Lorch et al., 1999). Subsequently the RSC and SWI-SNF, but not ISWI complexes 
were shown to catalyse the exchange of H2A/B dimers between nucleosomes 
(Bruno et al., 2003). Convincing evidence from studies at the yeast PHO5 locus 
demonstrated that nucleosomes are lost from closed chromatin loops by 
disassembly and not by sliding (Boeger et al., 2004). In 2010, Dechassa and 
colleagues proposed a model where the BAF complex evicts histone octamers by 
acting simultaneously on two nucleosomes (Dechassa et al., 2010). The proximal 
nucleosome is bound within the BAF pocket and an intranucleotide loop of DNA 
is created, similar to the loop-recapture mode. This loop places torsional strain 
on the distal nucleosome resulting in loss of an H2A/B dimer. Then, as more DNA 
is wound into the BAF complex, the remaining histones are lost and the distal 
nucleosome is displaced. This mechanism is supported by recent work 
suggesting that the predominant method of nucleosome remodelling by the BAF 
complex in vivo is likely to be the eviction or insertion of nucleosomes, rather 
than the translational shifting observed in vitro (Tolstorukov et al., 2013).  
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Fig. 1.3 Two Models For BAF Complex Action. 
Diagrams detailing two models for how the BAF complex repositions nucleosomes.  
A: the twist diffusion model. A single base pair is passed around the nucleosome at a time. 1. 
The BAF complex binds to the nucleosome. 2. A single base pair is freed from the histone 
proteins, creating a small hairpin. 3. The hair pin is propagated around the nucleosome. 4. 
The nucleosome has been moved one base pair to the left.  
B: the loop recapture model. A loop of DNA is spooled from the nucleosome and then passed 
around the nucleosome in a single motion. 1. The BAF complex binds to the nucleosome. 2. A 
single base pair is freed from the histone proteins, creating a small hairpin. 3. More base pairs 
are freed from the histones, creating an intranucleosomal DNA loop. 4. The loop is passed 
around the nucleosome in one movement, shifting the nucleosome to the left by the length of 
the loop (100-1000 bp).  
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1.1.2.4 The BAF Complex As A Regulator Of Transcription  
Early work with the yeast SWI-SNF complex suggested it was a general promoter 
of transcription (Peterson and Herskowitz, 1992). In vitro, movement of 
nucleosomes promoted transcription of an artificial viral fragment (Imbalzano et 
al., 1994), and once remodelling had occurred SWI-SNF was no longer required 
on the chromatin to promote transcription (Côté et al., 1998). In vivo the SWI-
SNF complex is essential for nucleosome eviction at the SUC2 promoter, and may 
act to remove nucleosomes within genes bodies (Schwabish and Struhl, 2007). 
Similarly in Drosophila, Brm acts as a generic activator of transcription 
(Armstrong et al., 2002). SAYP, the Drosophila orthologue of BAF45a, recruits 
Brg1 and TFIID to promoters, and is required for the presence of PolII at these 
promoters (Vorobyeva et al., 2009).  
In addition to activating transcription, the BAF complex also inhibits gene 
expression (Sudarsanam et al., 2000). Indeed, recent profiling of Brg1 binding 
sites shows it is present at a high percentage of total genes, and actually has a 
slight preference for repressed loci (Tolstorukov et al., 2013). These genome 
wide studies of BAF complexes failed to find any binding motifs for the complex, 
indicating that it may be predominantly recruited to DNA by other factors.  
A classic example of BAF complex recruitment is the binding of c-myc to SNF5, 
which was required to activate transcription of a luciferase reporter gene (Cheng 
et al., 1999). Brg1 is also recruited to promoters by heat shock factor 1 (HSF1), 
monoubiquitinated histone H2B and zinc finger transcription factors such as the 
GATA family (Corey et al., 2003; Kadam and Emerson, 2003; Shema-Yaacoby et 
al., 2013). It is noteworthy that Brm cannot bind to GATA family members and 
instead binds to the Notch intracellular domain (ICD), further supporting the 
model that these two highly similar complexes have distinct roles in the 
regulation of transcription.  
Two possible models by which the BAF complex regulates gene expression is by 
the assembly and disassembly of nucleosome barriers, and by the recruitment of 
histone modifying complexes (Fig. 1.4 and below). Nucleosome barriers are 
regions of tightly clustered nucleosomes that interfere with PolII elongation and 
lead to reduced gene expression (Subtil-Rodríguez and Reyes, 2010).  
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Such barriers can be removed by the BAF complex to allow transcription to take 
place (Schwabish and Struhl, 2007). In Drosophila the BAP complex actively lays 
down nucleosome barriers within the ftz-f1 gene and represses transcription 
(Vorobyeva et al., 2012). Thus the assembly and disassembly of nucleosome 
boundaries are a way in which the BAF complex can regulate transcription.  
1.1.2.5 The BAF Complex and Histone Modifying Complexes 
The BAF complex is able to modify histones as well as reposition them. This was 
first noticed as a shift in the tail position of the H2A/B dimer (Lee et al., 1999), 
and compaction of nucleosomes following remodelling (Kassabov et al., 2003).  
In vivo, the BAF complex binds to the Sin3a/HDAC complex (Sif et al., 2001) and 
to Prmt5 to promote transcription of myogenic genes (Dacwag et al., 2009). 
Indeed it has been shown that Prmt5 methylates histones that have been 
deacetylated by Sin3a/HDAC, and this activity requires a functional BAF complex 
(Pal et al., 2003). Drosophila PBAP complexes bind lysine specific demethylase 1 
(LSD1) to regulate wing vein patterning (Curtis et al., 2011), and during in vitro 
cardiogenesis ARID1a recruits the Nucleosome Remodelling and Histone 
Deacetylase (NURD) complex to repress cardiac genes (Singh and Archer, 2014). 
An added complexity is that Brg1, Brm and Polybromo all possess bromo 
domains which facilitate binding to acetylated histones (Mohrmann et al., 2004; 
Tamkun et al., 1992). This raises the question as to whether the histone marks 
observed in the above experiments recruit the BAF complex to particular sites, 
or if the BAF complex directs other histone modifying complexes to the DNA. Due 
to the highly dynamic nature of chromatin it is likely that both are true, though 
careful time course experiments are required to determine the precise nature of 
these interactions.  
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Fig. 1.4 Mechanisms of Gene Regulation By the BAF Complex 
A: Nucleosome barriers (regions of tightly clustered nucleosomes) sterically hinder the elongation of 
PolII and therefore inhibit gene expression. The BAF complex can assemble and disassemble these 
barriers to allow or repress gene expression respectively. 
B: The BAF complex recruits histone modifying enzymes to alter the accessibility of the chromatin 
state. In the example shown the BAF complex recruits a histone acetyltransferase (HAT), which 
acetylates histone tails which results in a loose chromatin state where PolII and associated basal 
transcription factors can bind. The BAF complex can also recruit other families of histone modifiers 
which negatively regulate the binding of PolII to DNA.  
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1.1.2.6 Actin Binding Proteins and the Regulation of Transcription 
-actin and the actin-related proteins (ARP) BAF53a and BAF53b are subunits of 
the BAF complex. Despite the abundance of -actin and the fact that it is a 
common contaminant in immunoprecipitation studies, a series of convincing 
experiments demonstrated that -actin is a bona fide member of the BAF 
complex (Zhao et al., 1998). In conjunction with Brg1, -actin and BAF53 allows 
the BAF complex to bind filamentous (F)-actin (Rando et al., 2002). Expression of 
Brg1 in SW13 cells (that are deficient for Brg1) causes bundling of actin into 
stress fibres by inducing expression of the Rho-kinase ROCK1 (Asp et al., 2002).  
The importance of actin in the regulation of transcription was first noted in 1999 
(Sotiropoulos et al., 1999), where polymerisation of actin filaments was shown 
to be required for activation of serum response factor (SRF) target genes. Since 
then it has emerged that actin plays a diverse role in the regulation of chromatin 
(Miyamoto and Gurdon, 2012). Indeed, PolII transcription is dependent on actin 
polymerisation mediated by the ARP2/3 complex (Yoo et al., 2006). Monomeric 
actin binds to and sequesters transcription factors such as PREP2 (Haller et al., 
2004). This offers an interesting possibility for actin polymerisation to act as an 
activator for transcription.  
Recent structural work has shown that the BAF53 dimer adopts an unusual 
front-to-back arrangement within the BAF complex (Schubert et al., 2013). 
Indeed, the functions of ARPs in the BAF complex may be the regulation of 
ATPase activity rather than any coupling to actin dynamics (Szerlong et al., 
2008).  
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1.1.3 Functions Of BAF Complex 
The BAF complex repositions nucleosomes to regulate many processes 
throughout embryonic development and adult homeostasis.  
1.1.3.1 Embryonic viability  
An intact BAF complex is required for embryogenesis in many species. Mutation 
of Brm in Drosophila and swsn-4 in C. elegans causes embryonic lethality (Elfring 
et al., 1998; Sawa et al., 2000), and in mice a null mutation in Brg1 causes 
embryonic death at pre-implantation stages (Bultman et al., 2000). In contrast, 
Brm–/– mice develop as healthy adults, although they are somewhat larger than 
normal (Reyes et al., 1998). This difference in requirement between Brg1 and 
Brm for embryogenesis can be explained by their expression patterns: Brm is 
expressed at 20-30 fold lower levels than Brg1 in embryonic tissues, and is 
thought to play a minimal role in development. Unlike studies in other animals, 
knock down of Brg1 in Xenopus using morpholinos did not cause embryonic 
lethality (Seo et al., 2005). However, Brg1 may only be partially depleted due to 
the dose of the morpholino used, or by the presence of maternally deposited 
Brg1 protein. 
Similarly, BAF47 (Roberts et al., 2000), ARID1a/Osa (Gao et al., 2008; Treisman 
et al., 1997), and BAF155 (Han et al., 2008) are all required for embryonic 
survival across several species indicating that the BAF complex is crucial for the 
development of metazoans.  
1.1.3.2 Embryonic Stem (ES) Cells 
The requirement for the BAF complex – indeed specific subunits – to complete 
embryogenesis may come from the ability of the BAF complex to maintain 
pluripotency and regulate differentiation. As described in section 1.1.1.4, 
embryonic stem cells have a particular BAF complex composition called esBAF 
(Ho et al., 2009; Yan et al., 2008) and mutation of esBAF subunits has profound 
effects on ES cell biology. Deletion of either Brg1, ARID1a, ARID1b, BAF155 or 
BAF57 causes loss of self-renewal, pluripotency and reduces the capability of ES 
cells to differentiate (Gao et al., 2008; Schaniel et al., 2009; Singhal et al., 2014; 
Yan et al., 2008). Oct4 has been shown to bind to Brg1 and recruit the BAF 
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complex to DNA, so deletion of esBAF members could impair Oct4-mediated 
transcription (Singhal et al., 2014). As Oct4 is a master regulator of pluripotency 
(Jerabek et al., 2014), loss of Oct4 function could explain the observed 
phenotypes. Additionally, Brg1 has also been shown to antagonise the Polycomb 
repressive complex 2 (PRC2) and prevent the accumulation of repressive 
H3K27me3 marks (Ho et al., 2011). Finally, it was observed that the loss of 
pluripotency following esBAF disruption took place over several cell cycles, 
indicating that esBAF may regulate DNA replication (Takebayashi et al., 2013).  
A final piece of evidence in support of a role for the esBAF complex in 
pluripotency is that addition of Brg1 and BAF155 to the four ‘Yamanaka factors’ 
(Oct4, Sox2, Klf4, and c-myc) significantly enhances the reprogramming of 
somatic cells into iPS cells (Singhal et al., 2010; Takahashi and Yamanaka, 2006). 
The mechanism behind BAF action appears to be enhanced de-methylation of 
pluripotency genes. These studies demonstrate that the BAF complex plays 
multiple roles within ES cells, which all contribute to the regulation of 
pluripotency. 
1.1.3.3 Neuronal Development 
Recent work has identified a key role for the BAF complex during neuronal 
differentiation. In the mammalian developing nervous system neural progenitor 
cells divide asymmetrically to give rise to a self-renewed progenitor cell and a 
differentiated daughter cell (Götz and Huttner, 2005). As progenitor cells 
differentiate there is a switch in BAF complex composition from npBAF to nBAF 
(see section 1.1.1.4). npBAF specific subunits are essential for the maintenance 
of progenitor cells. For example, loss of either BAF45a or BAF53a impairs 
proliferation of progenitors, whereas overexpression of BAF45a causes excess 
cell divisions (Lessard et al., 2007). Similarly, the npBAF component SS18 is 
required for neural progenitor maintenance (Staahl et al., 2013). As neuronal 
progenitors differentiate, SS18 is replaced by CREST, which is essential for 
correct outgrowth of dendrites in the daughter cells. Thus the switching of 
subunits is a key mechanism by which BAF complex function is controlled during 
differentiation. 
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Brg1 plays a complex role during neuronal development. In mouse embryos, 
Brg1 is required to maintain gliogenic neural progenitors, and to ensure the 
correct differentiation of astrocytes (Matsumoto et al., 2006). Conversely, in 
adult mice Brg1 controls the differentiation of neurons in conjunction with the 
transcription factor Pax6, and loss of either Brg1 or Pax6 causes stem cells to 
differentiate into glia (Ninkovic et al., 2013). Thus the BAF complex controls 
differentiation into both glia and neurons, although at different developmental 
times. Finally, there is evidence that the BAF complex plays a role in organ 
growth. Brm, BAF170, Pax6 and REST form a complex that acts to regulate 
neurogenesis and control the size of the cortex (Tuoc et al., 2013). Thus the BAF 
complex has roles in many levels of neuronal development, regulating self -
renewal, differentiation and growth of neurons.  
1.1.3.4 Other developmental roles 
In addition to neurogenesis, the BAF complex is involved in many more 
processes during embryonic development. BAF60c has a critical role for heart 
morphogenesis, as mutant mice develop abnormal hearts and die around E10 
(Lickert et al., 2004). During the reprogramming of mesoderm to cardiac tissue, 
BAF60c containing BAF complexes are required to decondense chromatin to 
allow binding of the transcription factors GATA4 and Tbx6 (Takeuchi and 
Bruneau, 2009). Interestingly, during somite differentiation in chick BAF60a and 
b are actively repressed by micro-RNAs (Goljanek-Whysall et al., 2014). 
Inhibition of these micro-RNAs or overexpression of BAF60a or b causes a delay 
in myogenesis, demonstrating how tight regulation of BAF complex subunits is 
important for correct timing and patterning during embryogenesis.  
In Drosophila, BAF complexes control the differentiation of intestinal stem cells 
(Zeng et al., 2013), and in C. elegans an intact SWI-SNF complex is required for 
gonadogenesis (Large and Mathies, 2014). Finally the BAF complex is required 
for both skeletal and smooth muscle myogenesis (Puri and Mercola, 2012; Zhou 
et al., 2009). These examples show that the BAF complex is used widely 
throughout development, often using different subunits in a tissue-specific 
manner. 
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1.1.3.5 Cancer and the Cell Cycle 
There is overwhelming evidence showing that the BAF complex is a critical 
tumour suppressor and negative regulator of the cell cycle. This was first 
discovered in 1998, when it was observed that a large proportion of childhood 
rhabdoid tumours have a mutation in SNF5 (Versteege et al., 1998). Loss of SNF5 
in mice gives rise to similar tumours, confirming that SNF5 is a potent tumour 
suppressor (Roberts et al., 2000). Since then many high throughput sequencing 
experiments have demonstrated that BAF complex subunits are frequently 
mutated in ovarian and breast cancers (Yaniv, 2014).  An in-depth analysis of 
BAF complex mutations across the scientific literature found that the BAF 
complex is frequently mutated over a wide range of cancers, suggesting that the 
complex plays a general tumour suppressive role rather than a tissue-specific 
one (Kadoch et al., 2013). Two other observations deserve mention: firstly, 
mutations in the BAF complex are often mutually exclusive with mutations in 
p53, indicating that loss of the BAF complex is able to drive tumourigenesis to a 
similar degree as loss of p53; and secondly BAF complexes often exhibit 
compound heterozygosity, meaning that rather than a complete knock out of a 
single subunit, several subunits are partially deleted simultaneously, highlighting 
the co-dependency of BAF subunits for the complex to function. 
At the mechanistic level, cell cycle proteins bind to BAF complex members. In 
Drosophila, Osa binds to Cyclin E (Baig et al., 2010). Brg1, BAF60a and SNF5 bind 
to p53, are recruited to p53 regulated loci, and are required for activation of 
transcription of p53 target genes (Lee et al., 2002; Oh et al., 2008). 
In addition to the regulation of proliferative genes, the BAF complex plays a role 
in the repair of DNA damage. Knock down of Brg1 causes an increase in the DNA 
damage marker H2AX (Alessio et al., 2010). BAF complexes are recruited to 
double strand break sites and bind to H2AX, and are required for its 
phosphorylation (Park et al., 2006). In addition to double strand break repair, 
the BAF and RSC complexes mediate base excision repair and nucleotide excision 
repair (Czaja et al., 2014; Lans et al., 2012). The tumour suppressive role of the 
BAF complex is therefore a combination of two effects: the transcriptional 
inhibition of pro-cycling genes and efficient DNA repair in response to damage.  
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1.1.3.6 Signalling pathways 
The BAF complex positively and negatively regulates several signalling pathways 
(Simone, 2006). During left/right patterning in zebrafish BAF60c and Brg1 are 
essential for Notch signalling (Takeuchi et al., 2007). Conversely, Brm negatively 
regulates the Notch pathway during mouse retinal development (Das et al., 
2007). It is likely that the presence of Brg1 or Brm within the complex plays a 
functional role in regulating responses to signalling cascades. For example Brg1 
is required for steroid hormone (Fryer and Archer, 1998; King et al., 2012) and 
MAPK signalling (Simone et al., 2004), whereas Brm promotes non-canonical 
NFκB (Tando et al., 2010) and Hippo pathway activation (Skibinski et al., 2014) 
Direct antagonism between Brg1 and Brm has been observed in Jurkat cells 
(Zhang et al., 2010). Under resting conditions, Brm-containing BAF complexes 
are present on IFNγ activated sequences (GAS) and the associated genes are not 
expressed. Upon IFNγ stimulation Brm is replaced by Brg1, resulting in relaxing 
of chromatin and expression of target genes. Hence in this situation the switch 
between Brm and Brg1 represents a switch between a repressed and an active 
state. However more studies are required to determine whether this is a general 
paradigm for the activity of the BAF complex with respect to signalling pathways.  
There is also growing literature linking the BAF complex with the Wnt signalling 
pathway. Brg1 has been shown to bind to -catenin and is required for 
transcription of Wnt target genes (Barker et al., 2001). In the developing mouse 
heart, Brg1 positively regulates Wnt signalling by promoting transcription of Fzd 
receptors (Griffin et al., 2011). Furthermore, Brg1 enhances Wnt signalling in 
response to the HDAC inhibitor butyrate, possibly by mediating an opening of 
TCF-target chromatin (Bordonaro et al., 2008). However, some evidence 
suggests that, as in other pathways, the BAF complex acts to both positively and 
negatively regulate Wnt signalling. Mutation of SNF5 causes a loss of TCF4 
binding to DNA, and subsequent upregulation of Wnt target genes myc, axin2 and 
msx1 (Mora-Blanco et al., 2014). The BAF60c-containing BAF complex 
upregulates the non-canonical Wnt pathway and reduces nuclear -catenin 
levels (Jordan et al., 2013). Thus the role of the BAF complex in Wnt pathway 
regulation is not straightforward, and requires further investigation. 
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1.1.4 ARID1a 
ARID1a encodes the largest subunit of the BAF complex, sometimes referred to 
as BAF250a. For clarity, I will refer to the gene as ARID1a and the protein 
product as ARID1a.  
ARID1a was first described in Drosophila as a suppressor of a mutation affecting 
eye formation (Treisman et al., 1997). It was named Eyelid, but is more 
commonly known as Osa in flies. Osa was then shown to bind Brm as part of the 
BAP complex (Collins et al., 1999). Shortly after, several groups cloned the 
mouse and human homologues and demonstrated that ARID1a is incorporated 
into the vertebrate BAF complex (Dallas et al., 2000; Hurlstone et al., 2002; 
Kozmik et al., 2001). ARID1a is a 250 kDa protein that only has 2 conserved 
domains: the AT-rich interacting domain (ARID), and the Eyelid-homology 
domain (EHD), which has similarities to Armadillo repeats (Fig. 1.1). The ARID 
region is misleadingly named, as in vitro studies have demonstrated that ARID1a 
possesses no preference for AT-rich sequences (Patsialou et al., 2005; Wilsker et 
al., 2004). A point mutation in the ARID region was shown to abrogate binding to 
DNA and caused de-repression of a reporter construct, demonstrating that the 
ARID region is crucial for the function of ARID1a (Chandler et al., 2012). Despite 
being an integral subunit of the BAF complex, ARID1a has been shown to shuttle 
between the nucleus and cytoplasm (Guan et al., 2012). The authors also 
demonstrated that the major site of ARID1a degradation was the nucleus.  
  
Fig. 1.5 Diagram of the Human ARID1a Protein 
ARID1a is a 250 kDa protein with 2 domains. The AT-Rich Interacting Domain (ARID) spans 
residues 1,000-1,222. The Eyelid Homology Domain (EHD) is positioned at the C-terminus 
between residues 2,213 and 2,283. There is a putative Nuclear Localisation Sequence 
(NLS) centred around residue 1376. All three of these  features are conserved between 
vertebrates. 
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It was later discovered that while Drosophila only has a single Osa gene, 
vertebrates have 2 genes that encode the largest subunit of the BAF complex: 
ARID1a and ARID1b. These are mutually exclusive members of the complex, and 
have some shared and some different functions (Wang et al., 2004b). For 
example, both ARID1a and ARID1b are required for embryonic viability and 
maintenance of stem cells (Gao et al., 2008; Yan et al., 2008), and both positively 
regulate hormone signalling (Inoue et al., 2002). In contrast, ARID1a acts as a 
negative regulator of the cell cycle, whereas ARID1b promotes proliferation 
(Nagl et al., 2007). Within the cell, ARID1a is more abundant that ARID1b in most 
cases studied (Singh and Archer, 2014; Wang et al., 2004a; Yan et al., 2008).  
ChIP experiments have shown that ARID1a is most frequently associated with 
repressed genes, such as c-myc in senescent cells (Nagl et al., 2006). During in 
vitro cardiogenesis ARID1a inhibits cardiac differentiation by repressing 
expression of Gata4, Myl3 and cTnT (Singh and Archer, 2014). However the role 
of ARID1a during cardiogenesis is uncertain, as a previous report showed that 
ARID1a promoted an open chromatin state at the promoters of key myogenic 
genes in the secondary heart field (Lei et al., 2012). These seemingly opposite 
effects may be due to differences in experimental conditions or lineage specific 
contributions. Regardless, at present the role of ARID1a in cardiomyocyte 
differentiation remains unclear.  
In 2010, exonic sequencing revealed that ARID1a is mutated in over half of all 
ovarian clear cell carcinomas (Jones et al., 2010). Since then a large number of 
studies have identified ARID1a as a prevalent mutant in various forms of cancer 
(Mao and Shih, 2013). Mutations in ARID1a are associated with poor prognosis, 
and it has been proposed that ARID1a could be a useful biomarker for 
malignancy (Samartzis et al., 2012). Mechanistically it has been shown that 
ARID1a binds directly to p53, which could explain why ARID1a is such a potent 
tumour suppressor (Guan et al., 2011).  
ARID1a regulates several signalling pathways, including FGF and steroid 
hormones (Collins and Treisman, 2000; Inoue et al., 2002; Terriente-Félix and de 
Celis, 2009). Osa mutant clones in the Drosophila wing disc display ectopic wing 
margin bristles, a phenotype consistent with enhanced Wg signalling (Treisman 
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et al., 1997). Subsequent work showed that overexpression of Osa was able to 
repress the Wg target gene Nubbin downstream of Armadillo (Collins and 
Treisman, 2000). However whether this is a direct effect of Osa on the Wg 
pathway is not clear, and molecular mechanism for the repression remains 
unknown. In order to investigate this further, I have used Xenopus as a model 
organism to ask whether, and if so how, ARID1a represses Wnt signalling in 
vertebrates. 
1.2 The Wnt Pathway 
 
1.2.1 Introduction 
The Wnt signalling pathway regulates many events throughout embryogenesis, 
adult homeostasis and the progression of disease (Clevers, 2006). During early 
Xenopus development, the first role of Wnt/-catenin signalling (also known as 
canonical Wnt signalling) is to specify the dorsal side of the embryo. This occurs 
after fertilisation and cortical rotation, Wnt pathway components activate 
transcription of Siamois (Sia) and Xenopus Nodal related 3 (Xnr3), two key genes 
that establish the dorsal-ventral axis (see Section 1.2.6 for more detail).  
In the absence of Wnt ligand free -catenin is phosphorylated and then degraded 
by the destruction complex, a cytoplasmic complex formed of Axin, APC, CK1 and 
GSK3 (see Section 1.2.4). When Wnt ligands bind their receptors, however, the 
destruction complex is disrupted and -catenin is able to accumulate in the 
cytoplasm. Free -catenin then enters the nucleus, binds to TCF/LEF family 
members, and activates transcription (Fig. 1.2 A). 
Here I discuss the proteins involved in canonical Wnt signalling and the 
proposed mechanism by which the pathway is regulated. I then describe the 
roles of Wnt signalling during early Xenopus development and some of the 
consequences when this pathway is dysregulated in humans. 
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Fig. 1.6 The Wnt Signalling Pathway 
A: overview of the Wnt signalling pathway. In the absence of ligand (left panel) β-catenin 
is phosphorylated, ubiquitinated and degraded by the proteasome. TLE/Groucho 
proteins bind to TCF/LEF proteins at Wnt Recognition Elements (WRE) and repress 
transcription. Wnt ligand binding disrupts the destruction complex (right panel) and β-
catenin accumulates in the cell. Free β-catenin then displaces TLE/Groucho from 
TCF/LEF, binds to WREs and induces transcription. 
B: Signalosome formation. Over extended periods of time, FZD receptor complexes are 
internalised in a Caveolin-dependent manner (left panel). Once internalised these 
receptor complexes form signalosomes, recruiting more GSK3β to multi-vesicular bodies 
(MVBs, middle panel). Signalosomes are internalised by the ESCRT machinery. Once 
within MVBs these endosomes fuse with lysosomes and the FZD complex is degraded 
(right panel). This causes a reduction in cellular GSK3β and subsequent activation of the 
Wnt pathway. 
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1.2.2 Wnt Ligands 
1.2.2.1 Post-Translational Modification Of Wnt Ligands 
Wnt ligands are highly conserved, cysteine-rich proteins consisting of ~250 
amino acids. While individual Wnt proteins are conserved, the number of Wnt 
ligands varies between species: for example humans have 19 Wnt proteins, 
whereas there are only 16 in Xenopus. Following synthesis, Wnts undergo a 
series of post-translational modifications that are essential for their correct 
trafficking, secretion and biological activity (Baarsma et al., 2013). With the 
exception of Wnt8/WntD, all Wnt ligands are N-glycosylated (Herr and Basler, 
2012). This modification requires Porcupine (Tanaka, 2002), and loss of Prc 
phenocopies loss of Wnt signalling in Drosophila (Perrimon et al., 1989). 
However, in tissue culture there seems to be no requirement for N-glysosylation 
for canonical Wnt activity, while in vivo N-glycosylation reduces the potency of 
Wnt ligands (Doubravska et al., 2011), raising the question as to what is the 
function of this modification.  
Wnt ligands are palmitoylated at serine209 and its orthologous positions 
(Takada et al., 2006; Willert et al., 2003). Mutation of this serine in Drosophila 
severely reduces the ability of Wnt ligands to activate signalling (Franch-Marro 
et al., 2008). This palmitoylation of Wnt3a is mediated by Porcupine, and is 
independent of N-glycosylation (Gao and Hannoush, 2013). 
It has been proposed that palmitoylation is required for Wnts to interact with 
Wntless (Wls)/Evi; (Herr and Basler, 2012), which transports Wnt proteins 
through the trans-Golgi network to the plasma membrane (Bartscherer et al., 
2006; Bänziger et al., 2006; Goodman et al., 2006). While Wls/Evi is the major 
mechanism by which Wnt ligands are secreted, there is evidence for an 
alternative secretory pathway. Wnt3a palmitoyl-deficient mutants are secreted 
in the absence of Wls/Evi, although their activity is much reduced (Neumann et 
al., 2009). Additionally Wnt8, which is not post-translationally palmitoylated, is 
secreted via a Wls/Evi independent, Rab1-dependent pathway (Ching et al., 
2008).  
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1.2.2.2 Heparan-Sulphate Proteoglycans and Wnt Ligands 
Once secreted, a large proportion of Wnt ligand is retained at the cell surface. 
This is thought to be mediated by heparan-sulphate proteoglycans (HSPGs) 
which are located on the outer surface of the plasma membrane. HSPGs are 
comprised of a central protein modified with HS and glycosaminoglycans (GAGs; 
(Lin, 2004). Binding of Wnt ligands to HSPGs is crucial for normal signalling, as 
enzymatic removal of surface proteoglycans or chemical inhibition of sulphases 
significantly impairs Wnt signalling (Reichsman et al., 1996). 
There are currently two models for how HSPGs act to potentiate Wnt signalling: 
1) they increase the local concentration of ligand by limiting diffusion to two 
dimensions (i.e. the plasma membrane); or 2) they act as part of the 
FZD/LRP5/6 receptor complex (Lin, 2004). In support of the first model, 
immunostaining of Wnt ligands shows they are retained at the plasma 
membrane of secreting cells (Pfeiffer et al., 2002). Disruption of HSPGs causes a 
loss of this localisation, and in Drosophila HSPG mutants can be rescued by 
overexpressing Wg. These observations indicate that HSPGs act to increase the 
concentration of Wnt ligands (Häcker et al., 1997). Consistent with this model 
healthy, viable adult Drosophila can be obtained when Wg is replaced by a 
membrane tethered, non-diffusible form of Wg, indicating that Wnt ligands 
probably have a very limited range of diffusion (Alexandre et al., 2014). 
Evidence for the second hypothesis comes from recent work investigating other 
GAG-containing proteins that bind to extracellular Wnt ligands. For example, 
biglycan binds to both Wnt3a and LRP6, and is required in calvarial cells for 
retention of Wnt ligand and full activation of the Wnt pathway (Berendsen et al., 
2011). Similarly, in neuroblastoma cells and primary rat hippocampal neurones 
addition of heparin causes activation of the Wnt pathway by enhancing the 
activity of Wnt ligands (Colombres et al., 2008). Thus it is possible that GAG-
containing proteins act both by trapping Wnt ligands at the cell surface, and by 
enhancing formation of ligand-receptor complexes.  
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1.2.2.3 Extracellular Regulators Of Wnt Ligands 
Wnt ligands are subject to extracellular regulation by several different secreted 
proteins: the secreted frizzled related proteins (sFRPs) 1-5, Cerberus, and Wnt 
inhibitory factor 1 (WIF1; (Baarsma et al., 2013).  
sFRPs consist of an N-terminal cysteine-rich domain (CRD) that is 30-50% 
similar to those of Fzd receptors, including 10 highly conserved cysteine 
residues, and a C-terminal domain that shares weak homology with netrin 
(Bafico et al., 1999; Finch et al., 1997). Experiments in tissue culture showed that 
sFRP1 accumulates at the cell surface and binds to Wnt ligands, sequestering 
them and preventing activation of the signalling pathway (Bafico et al., 1999; 
Galli et al., 2006). Somewhat unexpectedly, this ability of sFRP1 to bind Wnt 
ligands does not require the CRD (Uren et al., 2000). 
While sFRPs were originally characterised by their ability to inhibit Wnt 
signalling, this may not be their normal function in vivo. In fact, sFRPs may 
actively promote Wnt signalling. Work in Xenopus showed that sFRP3 (also 
known as Frzb) and Crescent (Cresc) bind to Wnt ligands and enhance their 
diffusion (Mii and Taira, 2009). In this case sFRPs act as chaperones to establish 
a gradient of Wnt ligands across the prospective mesoderm in Xenopus.  
In agreement with this model, sFRPs have two binding sites for Wnt ligands: a 
high affinity site that enhances Wnt signalling, and a lower affinity site that 
inhibits Wnt signalling (Uren et al., 2000). 
Several other secreted proteins interact with Wnt ligands in the extracellular 
space. Cerberus (Cer) and Wif1 bind to Wnt ligands and are able to repress 
pathway activation (Bouwmeester et al., 1996; Hsieh et al., 1999), although Cer 
does not affect Wnt signalling in mice (Belo et al., 2000). However the ability of 
Cer or Wif1 to act as chaperones and enhance the diffusion of Wnt ligands has 
not been tested, so whether this action of sFRPs is a general property of secreted 
Wnt interacting proteins is yet to be determined.  
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1.2.3 Wnt Receptors  
1.2.3.1 Frizzled and LRP5/6 
In 1996, two groups demonstrated that the transmembrane protein Frizzled is a 
receptor for Wnt ligands (Bhanot et al., 1996; Yang-Snyder et al., 1996). The 
Frizzled (FZD) family of receptors consists of ten proteins in mammals (FZD1-10), 
while only four exist in Drosophila (Fz, Dfz2-4; (Schulte, 2010). FZD receptors 
have an extracellular cysteine-rich domain (CRD), seven membrane spanning 
domains reminiscent of G-protein coupled receptors (GCPRs), and an 
intracellular domain (Vinson et al., 1989). Crystal structure of the CRD showed 
that it dimerises to bind Wnt ligands (Dann et al., 2001). This was confirmed in 
Xenopus, where FZD3 forms dimers in response to Wnt signalling. Indeed, forcing 
the dimerisation of FZD3 or FZD7 is sufficient to induce expression of Siamois 
(Sia; (Carron et al., 2003). 
There are 19 Wnt ligands and 10 FZD receptors in humans, and it remains very 
poorly understood how different branches of the Wnt signalling cascade are 
activated in a controlled manner. The ligands and receptors are promiscuous, 
and specificity is not simply defined by particular ligands binding to particular 
receptors. However the large diversity of Wnt and FZD proteins suggests some 
functional relevance to ligand-receptor pairing. For example Wnt5a is most 
commonly thought of as an activator of non-canonical signalling (see section 
1.2.7). However, when it is paired with FZD4, Wnt5a causes stabilisation of -
catenin and activation of TCF reporters (Mikels and Nusse, 2006). While 
systematic analysis of Wnt-FZD affinities has yet to be carried out, the KD values 
for some components in Drosophila have been measured. By titrating soluble 
alkaline phosphatase-conjugated Fz CRDs against membrane bound Wnt 
molecules, the Nusse group determined the binding affinity for several different 
ligand-receptor pairs (Rulifson et al., 2000; Wu and Nusse, 2002). Wg and Wnt2 
bound Fz, Dfz2 and Dfz3, whereas Dwnt8 only bound to Dfz4. Strangely, Dwnt3 
did not bind to any of the Drosophila Fz proteins, but has been shown to bind 
RYK/Derailed receptors to potentiate non-canonical signalling (Lahaye et al., 
2012) see below). 
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As well as FZDs, low-density lipoprotein receptor like proteins 5 and 6 (LRP5/6) 
are absolutely required for Wnt signalling. This was discovered when mutations 
in the Drosophila Arrow gene (a homologue of LRP6) blocked Wg signalling 
upstream of Dishevelled (Dsh in flies, Dvl in vertebrates; (Wehrli et al., 2000), 
while in Xenopus overexpression of LRP6 synergises with Wnt5a to induce 
secondary axes (Tamai et al., 2000). The extracellular portion of LRP6 consists of 
three LDLR repeats and four -propeller domains (He et al., 2004), which bind to 
Wnt ligands (Liu et al., 2009). Indeed Wnt3a and Wnt9 bind to different -
propeller domains simultaneously, indicating that multiple ligands might act 
together to stimulate the same receptor complex (Bourhis et al., 2010). 
Wnt ligands cause LRP5/6 and FZD to form heterodimers to propagate signals 
across the membrane (He et al., 2004). Indeed, artificial dimerisation of FZD and 
LRP6 causes phosphorylation of a PPPSP motif on the C-terminal tail of LRP6, 
which is sufficient to activate the Wnt pathway (Tamai et al., 2004; Zeng et al., 
2008). LRP6 is sequentially phosphorylated, first by GSK3 and then by 
membrane-tethered CK1 (Davidson et al., 2005; Zeng et al., 2005). Phospho-
LRP6/FZD complexes then recruit Axin and GSK3 to the membrane, disrupting 
the destruction complex (see section 1.2.4.1;(Cong et al., 2004; Yang-Snyder et 
al., 1996). Dvl is also recruited to FZD/LRP6 dimers and promotes the formation 
of large, subapical oligomeric complexes termed signalosomes (Bilic et al., 2007), 
which are internalised in a Caveolin-dependent manner (Yamamoto et al., 2006). 
Over time these signalosomes are incorporated into multivesicular bodies 
(MVBs), where Axin, Dvl and GSK3 are degraded (Taelman et al., 2010). The 
phospshorylation and internalisation of LRP5/6 is enhanced by R-spondins 
(Carmon et al., 2011), which are vertebrate specific, secreted proteins that 
promote Wnt signalling (de Lau et al., 2012; Kamata et al., 2004). Curiously,        
R-spondins also enhance degradation of LRP6 and -catenin, suggesting that 
they act to cause a spike in Wnt signalling that is rapidly shut off. 
FZD proteins are atypical G-protein coupled receptors – so much so that they 
have been assigned as a separate subfamily (Schulte, 2010). FZD proteins are 
able to catalyse the breakdown of Go proteins into Go and Go subunits 
(Katanaev and Buestorf, 2009), and Go is essential for both canonical and       
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non-canonical signalling in Drosophila and vertebrates (Katanaev et al., 2005; Liu 
et al., 2001). Indeed, genetic experiments in Drosophila suggest that Go recruits 
Axin to the signalosome, whereas Go recruits Dsh/Dvl, enhancing activation of 
the Wnt signalling pathway (Egger-Adam and Katanaev, 2009). 
Finally, the presence of receptors at the membrane can be a regulatory point 
within the Wnt signalling cascade.  The secreted protein Dickkopf-1 (Dkk1) has 
long been known to be an inhibitor of Wnt signalling (Glinka et al., 1998). Dkk1 
binds to LRP6 using the same -propeller motifs as Wnt ligands, thus acting as a 
competitive inhibitor (Bourhis et al., 2010). Furthermore, Dkk1 binding causes 
internalisation of LRP6 in association with the protein Kremen (Krm; (Mao et al., 
2002). Krm plays a complex role in the regulation of LRP6, as not only is it 
required for Dkk1-mediated inhibition of Wnt signalling, but it also acts to 
increase the levels of LRP6 at the cell membrane in the absence of Dkk1 (Hassler 
et al., 2007). This dual activity has been proposed to create a sharp on/off 
boundary of Wnt signalling in response to a Dkk1 gradient (Cselenyi and Lee, 
2008). Thus the levels of FZD and LRP5/6 protein present at the cell membrane 
play a key role in regulating the ability of cells to respond to Wnt ligands.  
1.2.3.2 Alternative Receptors 
Besides FZD and LRP5/6 several other transmembrane proteins transduce Wnt 
signals. The receptor tyrosine kinase (RTK) ROR2 activates non-canonical Wnt 
signalling and enhances convergent extension in Xenopus animal caps (Hikasa et 
al., 2002; Oishi et al., 2003). The “non-canonical” ligand Wnt5a binds to ROR2, 
inducing receptor dimerization and RTK signalling (Liu et al., 2008). In addition 
to potentiating non-canonical signals, this activation of ROR2 is known to inhibit 
the intracellular canonical Wnt pathway (Mikels and Nusse, 2006). 
RYK is an atypical receptor tyrosine kinase with a WIF1-like extracellular 
domain and non-functional kinase domains (Yoshikawa et al., 2001). RYK 
binding to Wnt5a activates calcium signalling to co-ordinate neuronal 
pathfinding (Yoshikawa et al., 2003); (Li et al., 2009), and during convergent 
extension in Xenopus RYK enhances non-canonical signalling by internalising 
FZD7 (Kim et al., 2008).  
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RYK also plays a role in -catenin-dependent signalling, because a ternary 
complex of RYK, FZD8 and Wnt3a or Wnt1 is able to activate luciferase reporters 
in HEK293 cells (Lu et al., 2004) and induce neuronal differentiation of neural 
progenitor cells in vitro (Lyu et al., 2008). In the latter example the intracellular 
domain of RYK was cleaved and localised to the nucleus in a similar manner to 
that seen for FZD, although the functional consequences of this event is unclear. 
Finally, RYK and the E3 Ubiquitin ligase Mindbomb1 (Mib1) interact to activate 
canonical signalling (Berndt et al., 2011). These observations contradict previous 
findings in Drosophila, where the RYK homologue Derailed could not bind to 
either Wg (Wnt1) or Wnt4 (Yoshikawa et al., 2001). A possible explanation for 
this is that Drosophila has 3 RYK homologues, and the RYK-Wnt interaction could 
exist in one of the untested homologues. 
 1.2.4 Destruction Complex Mediated Degradation of -catenin 
The destruction complex represses Wnt signalling in the absence of ligand by 
first phosphorylating and then ubiquitinating -catenin, which is subsequently 
degraded by the proteasome. It is composed of five core proteins: Axin, 
Adenomatous Polyposis Coli (APC), Glycogen Synthase Kinase 3 (GSK3), 
Casein Kinase 1 (CK1) and -Transducin Repeat Containing Protein (TrCP) 
(MacDonald et al., 2009). Loss of any of these proteins leads to accumulation of 
-catenin and transcription of Wnt target genes.  
1.2.4.1 The Axin Scaffold 
Axin was named for its ability to inhibit axis formation in Xenopus when it is 
overexpressed (Zeng et al., 1997). Axin is a largely unstructured, flexible protein 
with binding sites for many of the destruction complex components (Fig. 1.3). 
Axin binds to APC via an N-terminal RGS domain, and to GSK3 with a central -
helix (Dajani et al., 2003; Spink et al., 2000). -catenin binds to Axin at a site just 
distal to GSK3 (Ikeda et al., 1998), and CK1 and protein phosphatase 2A (PP2A) 
bind more distally still (Hsu et al., 1999; Liu et al., 2002).  
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Fig. 1.7 Physical Interactions Between Members of The 
Destruction Complex 
Diagram showing the relative size and domain composition of the destruction 
complex proteins.  
Physical interactions are represented by lines. Axin homodimerises via its DIX 
domain.  
NTD = N terminal domain 
CTD = C terminal domain 
ARM = Armadillo repeat 
RGS = Regulation of G-protein signaliing 
DIX = dishevelled and axin 
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The C-terminus of Axin contains a DIX domain that allows it to form 
homopolymers and create large destruction complex foci (Luo et al., 2005), 
although the polymerisation of Axin is not required for its ability to inhibit Wnt 
signalling. Axin increases the local concentration of -catenin and its kinases and 
greatly enhances -catenin turnover (Stamos and Weis, 2013). In fact, the 
addition of Axin to in vitro kinase assays increases the phosphorylation of -
catenin by as much as 20,000 fold (Dajani et al., 2003).  
1.2.4.2 Phosphorylation, Ubiquitination and Degradation of -catenin  
In resting cells a large portion of the total -catenin forms cadherin complexes at 
the membranes and does not participate in Wnt signalling (van de Wetering et 
al., 2001). The remaining cytosolic -catenin is phosphorylated within the 
destruction complex by CK1 proteins at Serine45 (S45; (Amit et al., 2002; Liu et 
al., 2002; Stamos and Weis, 2013). This phosphoserine acts as a priming site for 
GSK3, which then phosphorylates T41, S37 and S33 sequentially (Hagen et al., 
2002; Yost et al., 1996). Point mutation at any of these sites results in stabilised 
-catenin that stimulates transcription of Wnt target genes. 
In addition to phosphorylating -catenin, GSK3 has a wide range of substrates 
within the cell (Atkins et al., 2013)—in fact only 5% of cellular GSK3 is bound to 
Axin (Li et al., 2012; Ng et al., 2009). GSK3 phosphorylates both Axin and APC, 
increasing their affinity for -catenin (Salic et al., 2000; Willert et al., 1999; 
Yamamoto et al., 1999).  In this manner GSK3 acts as a feed-forward mechanism 
to enhance phosphorylation of -catenin. While most studies focus on GSK3, 
knock out work in mice has shown that GSK3 and  are functionally redundant 
in the regulation of Wnt signalling (Doble et al., 2007). Thus much of what is 
known for GSK3 is probably true for GSK3.  
Once phosphorylated, -catenin is ubiquitinated by the E3 ligase -TrCP 
(Kitagawa et al., 1999). Polyubiquitinated -catenin is then degraded by the 
proteasome (Orford et al., 1997). Recent work has demonstrated that 
ubiquitinated -catenin remains bound to Axin and that the proteasome is 
recruited to the destruction complex to degrade -catenin (Li et al., 2012). 
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1.2.4.3 The Role of APC In The Destruction Complex 
APC has long been known to be a critical regulator of the Wnt signalling pathway. 
Mutations in APC occur in around 80% of colon cancers and are thought to be 
the driving oncogenic force by constitutively activating the Wnt pathway. Many 
different colorectal carcinoma cell lines with truncated APC proteins have been 
used to demonstrate that loss of APC causes nuclear localisation of -catenin and 
hyperactivation of the Wnt pathway (Minde et al., 2011). However, despite 
focussed research, the mechanistic role of APC in the regulation of Wnt signalling 
is still unclear (Stamos and Weis, 2013). 
APC is a large, 310 kDa protein with a flexible unstructured central region that 
contains docking sites for destruction complex components. This region has four 
15 amino acid (aa) repeats, seven 20 amino acid repeat segments that bind to -
catenin (Eklof Spink, 2001; Rubinfeld et al., 1997), and three SAMP repeats that 
bind to Axin (Behrens et al., 1998). The role of APC in the regulation of -catenin 
phosphorylation is unclear. Su and colleagues showed that addition of APC to in 
vitro reactions did not stimulate -catenin phosphorylation by CK1 or GSK3 
(Su et al., 2008). Instead it protected phospho--catenin from Protein 
Phosphatase 2A. Conflicting data from the Klein lab showed that APC did in fact 
stimulate the activity of GSK3 in vitro (Valvezan et al., 2012). However, this 
study only used a partial fragment of APC, and thus may not reflect the function 
of the intact protein. 
It is more likely that APC acts to positively regulate the ubiquitination of -
catenin. The second and third 20 aa repeats in APC are required for 
ubiquitination of -catenin (Su et al., 2008). SW480 and DLD-1 cell lines have 
truncated APC that lacks the second, or second and third, 20aa repeats 
respectively. -catenin in these cell lines is not ubiquitinated, although it does 
still bind to -TrCP, raising the possibility that APC could be required to catalyse 
the addition of ubiquitin to -catenin (Yang et al., 2006a). 
In addition to regulating the post-translation modification of -catenin, APC has 
been proposed to act as a sink, sequestering -catenin in the cytoplasm and 
therefore dampening Wnt induced transcription (Roberts et al., 2011). 
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Determining the precise role of APC in the destruction complex will be a key step 
towards our understanding of how free -catenin is degraded in the absence of 
Wnt signalling. 
1.2.5 Nuclear Regulation Of Canonical Wnt Signalling 
Free -catenin rapidly enters the nucleus and promotes transcription of Wnt 
target genes by binding to TCF proteins. In the absence of signal, TCF proteins 
bind co-repressors of the TLE/Groucho family and suppress expression of Wnt 
target genes.  
1.2.5.1 The ‘Wnt Off’ State 
Wnt target genes often contain a Wnt Responsive Element (WRE) in their 
regulatory regions, characterised by the motif WWCAAG where W represents A 
or T. These WREs are bound by members of the T-Cell Factor/Lymphoid 
Enhancer Factor (TCF/LEF) family, of which there are 4 in vertebrates (TCF1, 3, 
4 and LEF1) and one each in Drosophila (dTCF/Pan) and C. elegans (POP1; (Mao 
and Byers, 2011). TCF/LEF proteins have three domains: an N-terminal -
catenin-binding domain, a high mobility group (HMG) domain that binds to DNA 
and promotes severe bending, and a cysteine (c)-clamp that is present in some 
but not all TCF proteins and confers DNA binding to extra sites (Atcha et al., 
2007; Love et al., 1995; Molenaar et al., 1996). While the action of each TCF must 
be considered on a gene-by-gene basis, the different TCFs do seem to have 
different preferences: LEF1 is predominantly an activator of transcription while 
TCF3 is mostly repressive. TCF1 and TCF4 act as activators and repressors in 
equal measure (MacDonald et al., 2009). ChIP-seq studies of TCF4 in colorectal 
carcinoma cells showed that over 70% of TCF binding sites are more than 10 kb 
from the nearest transcription start site (TSS; (Hatzis et al., 2008). The remaining 
sites are distributed in an approximately 3 kb region surrounding the TSS, but 
are not as tightly clustered as peaks for other transcription factors. Only 10-15% 
of all TCF binding sites are co-bound in the presence of -catenin, emphasising 
the role of TCF proteins in the regulation of other biological functions (Schuijers 
et al., 2014). 
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Fig. 1.8 Nuclear Regulation Of Wnt Signalling 
A: In the absence of Wnt signalling TCF/LEF proteins bind to co-repressors that recruit 
histone deacetylases. Additional protein-protein interactions prevent the association of 
TCF/LEF proteins with DNA, or beta-catenin with TCF/LEF proteins. 
B: Stablised beta-catenin binds to BCL9 and Pygopus to form a chain of adaptors that 
recruitshistone acetylases and the mediator complex to activate transcription. 
Phosphorylation of TCF/LEF proteins enhances their association with DNA, while Dvl and Jun 
enhance binding of beta-catenin to TCF/LEF. 
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The expression of TCF proteins is highly complex, as each TCF has alternative 
promoters and is alternatively spliced to give rise to different isoforms in a 
tissue-specific manner (van de Wetering et al., 1996). The most striking example 
of this is the skipping of exon1 in LEF1, resulting in the loss of the -catenin 
binding domain and formation of a natural dominant negative that inhibits Wnt 
signalling (Hovanes et al., 2001). However more recent work in osteoblasts has 
demonstrated that Lef1-N is still able to bind -catenin and enhance luciferase 
activity (Hoeppner et al., 2011), highlighting cell-type specific differences in the 
regulation of TCF activity. 
The Wnt target gene Sia contains a WRE in its promoter region. Deletion of the 
WRE causes an increase in activity of a Sia reporter gene in the absence of Wnt 
ligand, indicating that TCF/LEF proteins act to suppress Wnt target genes 
(Brannon et al., 1997). Since this early observation it has become clear that 
TCF/LEF proteins play a vital role in the inhibition of Wnt target genes by 
binding the repressive protein Groucho (Cavallo et al., 1998; Roose et al., 1998). 
Vertebrates have four Groucho homologues, known as either Groucho-related 
genes (Grg1-4) or transducin-like enhancer of split (TLE) proteins (Cadigan, 
2012).  
TLE proteins consist of five domains, the first two of which are involved in Wnt 
signalling. The N-terminal Q domain mediates homotetramerisation of TLE 
proteins, a property that is required for their function (Song et al., 2004), and it 
is this domain that binds to TCF proteins (Brantjes et al., 2001). The GP domain 
binds to histone deacetylases (HDACs), including Rpd3/HDAC3 (Chen et al., 
1999). Treatment of cells with the HDAC inhibitor trichostatin A (TSA) reduces 
the ability of TLE to repress luciferase reporters indicating that this may be the 
major mechanism by which TLE proteins act. 
Non-TLE proteins also act to repress Wnt target genes. Co-repressor of Pan 
(Coop), TIS7 and some myeloid translocation genes (MTGs) bind TCF and recruit 
HDACs in a similar manner to TLE to repress Wnt target genes (Moore et al., 
2008; Song et al., 2010; Vietor et al., 2005). 
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In contrast, Osterix regulates Wnt signalling by preventing the association of 
TCF1 with DNA (Zhang et al., 2008), while Kaiso stops -catenin from binding 
promoter sequences (Park et al., 2005). HIC1 recruits TCF4 into HIC1 bodies, 
sequestering it from the rest of the cell (Valenta et al., 2006). This is of particular 
interest because ARID1a also binds to HIC1 (Van Rechem et al., 2009). Finally, 
post-translational modification of TCF proteins can regulate their activity. Creb-
binding protein (CBP) acetylates dTCF in Drosophila and reduces its capacity to 
bind Armadillo (Waltzer and Bienz, 1998). In HEK293 cells phosphorylation of 
TCF4 or LEF1 by Nemo-like kinase (NLK) reduces activation of luciferase 
reporters and prevents binding of -catenin/TCF complexes to DNA (Ishitani et 
al., 2003). 
Several proteins have been identified that prevent -catenin from binding to 
TCF/LEF proteins. Chibby (Cby) and inhibitor of -catenin and TCF binding 
(ICAT) bind to -catenin and compete with LEF1 and TCF3 respectively (Graham 
et al., 2002; Takemaru et al., 2003). APC shuttles between the cytoplasm and the 
nucleus, and has been proposed to mediate nuclear export of -catenin 
(Henderson, 2000; Sierra et al., 2006). However, APC proteins tethered to the 
cell membrane or mitochondria are able to completely rescue APC mutant cells, 
arguing against a requirement for APC shuttling (Roberts et al., 2012). As these 
experiments used overexpressed APC, it may be that high levels of APC are able 
to compensate for a lack of shuttling. Therefore experiments using inducible or 
shuttling mutants are required to resolve the requirement of APC in the nucleus. 
1.2.5.2 The ‘Wnt On’ State 
Wnt signalling causes -catenin to accumulate in the nucleus within 30 minutes 
(Li et al., 2012). Mathematical modelling suggests that this rapid influx is 
mediated by active transport, although the proteins responsible are unknown 
(Tan et al., 2014). Once nuclear, -catenin binds to the N-terminal -catenin 
Binding Domain (BBD) of TCF/LEF proteins and displaces TLE (Daniels and 
Weis, 2005). This displacement is consistent with work of Sierra and colleagues, 
who used ChIP time course experiments to show that TLE1 and -catenin never 
bind the c-myc enhancer at the same time (Sierra et al., 2006).  
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TCF/LEF proteins are essential for expression of Wnt target genes. Knock down 
of TCF1 in Xenopus completely blocks the Wnt pathway, while mutation of TCF 
binding sites in luciferase reporters renders them incapable of responding to 
Wnt signals (Liu et al., 2005; Veeman et al., 2003). 
Once bound to TCF and DNA, -catenin recruits a wide range of factors to initiate 
transcription. For example, -catenin recruits Pygopus (Pygo) and BCL9/Legless 
to form a “chain of adaptors” (Städeli and Basler, 2005). BCL9 acts as a bridging 
factor, binding to the first ARM repeat of -catenin via its homology domain 1 
(HD1) and to the PHD domain of Pygo via HD2 (see Fig. 1.4; (Hoffmans and 
Basler, 2004; Kramps et al., 2002). Pygo in turn then recruits the Med12 and 
Med13 subunits of the Mediator complex via its NH2 domain to promote 
transcription (Carrera et al., 2008). Alternatively the NH2 domain has been 
shown to bind histone acetyl transferases (HATs) and the histone 
methyltransferase (HMT) MLL2, both of which remodel chromatin to promote 
transcription (Chen et al., 2010).  
The N-terminus of -catenin also recruits C terminal binding protein (CtBP), 
which plays a dual role in the regulation of transcription. While monomeric, CtBP 
enhances -catenin mediated transcription. Conversely, CtBP homodimers act to 
repress -catenin, though the mechanism behind this switch is not clear 
(Bhambhani et al., 2011). Finally TCF/LEF proteins can also recruit cofactors to 
enhance Wnt signalling. Tranduction  like protein 1 (TBL1) and TBLR1 bind to 
TCF and are required for activation luciferase reporters (Li and Wang, 2008). 
Phosphorylation by homeodomain interacting protein kinase 2 (HIPK2) reduces 
the ability of TCFs to repress signalling (Hikasa and Sokol, 2011), while 
phosphorylation by Traf2/Nck interacting kinase (TNIK) actively promotes -
catenin mediated transcription (Mahmoudi et al., 2009).  
In addition to displacing TLE repressors from TCFs, it has been proposed that 
active Wnt signalling causes the replacement of repressive TCF/LEF proteins 
with permissive ones. Over the course of several hours, repressive TCF3 is lost 
from WREs in response to Wnt signalling (Shy et al., 2013). Furthermore, 
repressive TCF1 is exported from the nucleus by the Wnt/Calcium pathway in 
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cancer cell lines while TCF4 is not, changing the balance of 
stimulatory/repressive TCF proteins within the nucleus (Najdi et al., 2009).  This 
switch in TCF proteins represents a feed-forward loop whereby prolonged Wnt 
signalling promotes further activation of the pathway. 
Several proteins that play a role in the cytoplasmic regulation of the Wnt 
pathway are known to enter the nucleus and affect -catenin-mediated 
transcription. Dvl binds to -catenin/TCF4 complexes, recruits c-jun and is 
essential for Wnt stimulated transcription in HEK293T cells (Gan et al., 2008). 
There is some evidence that the intracellular domains of FZD and RYK are 
cleaved following ligand binding and can enter the nucleus to promote 
transcription (Lyu et al., 2008; Mathew et al., 2005). Finally, as noted earlier, a 
subset of cellular APC exists within the nucleus. APC is able to bind WREs 
together with CtBP, but not at the same time as -catenin (Sierra et al., 2006). 
Sierra and colleagues make the interesting observation that during continuous 
Wnt stimulation -catenin/TCF complexes are displaced from chromatin by 
APC/CtBP complexes, which are in turn replaced by repressive TCF/TLE 
complexes. Presumably, -catenin then displaces TLE and the cycle continues. 
This is one of the few studies to assess the dynamics of Wnt signalling and the 
changes at WREs over time. More of these investigations, perhaps with respect to 
chromatin modifications, could shed light onto the long-term effects of Wnt 
stimulation. 
1.2.5.3 Chromatin Modifications During Wnt Signalling 
In order to promote transcription -catenin recruits a range of chromatin 
modifiers. CBP and p300 are histone acetyl transferases (HATs) that bind to the 
C-terminal part of -catenin (Takemaru and Moon, 2000). In depth study of the 
naked cuticle and notum loci showed that TCFs, acetyl H3 and H4, and CBP 
binding is centred on the WRE (Parker et al., 2008), and that loss of CBP inhibits 
Wnt signalling. Protein arginine methyltransferase 2 (PRMT2) binds to -catenin 
and is required for Wnt signalling (Blythe et al., 2010). PRMT2 methylates 
histones at arginine residues, a modification that promotes transcription.  
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Recently, genome-wide investigation of -catenin binding sites by ChIP-seq has 
shown that the majority of -catenin sites contain the pro-transcriptional 
H3K4me3 mark (Watanabe et al., 2014), which have been shown to be deposited 
by the mixed myeloid leukaemia 1 and 2 (MLL1 and 2) complexes (Sierra et al., 
2006). The action of MLL1/2 at -catenin target genes requires ubiquitination of 
Histone H2, which is interesting because ubiquitinated H2 is able to recruit the 
BAF complex (Shema-Yaacoby et al., 2013). A link between -catenin and the 
BAF complex is already well established: -catenin binds directly to Brg1, and 
Brg1 is required for Wnt signalling in certain tissues (Barker et al., 2001); see 
section 1.1.3.6). Furthermore, telomerase reverse transcriptase (TERT) binds to 
-catenin and Brg1 and is required for transcription of Wnt target genes (Park et 
al., 2009).  
1.2.6 Wnt Signalling During Xenopus Development 
The Wnt signalling pathway plays a key role in the embryogenesis of all animals 
studied so far. Wnt signals are required for a range of developmental processes 
including establishing the dorsal-ventral axis, hindbrain patterning, and bone 
formation. Here I discuss the role of Wnt signalling during early Xenopus 
development and in human disease. 
1.2.6.1 The Nieuwkoop Centre and Establishment of the Dorsal-Ventral Axis  
The future dorsal side of Xenopus embryos is determined upon fertilisation 
(Elinson and Holowacz, 1995), when sperm entry causes polymerisation of 
microtubules, which rotate the cellular cortex relative to the cytoplasm 
(Rowning et al., 1997). This cortical rotation and the accompanying microtubule 
network are required for establishment of dorsal structures, as ablation of 
microtubule polymerisation (such as by UV light) results in ventralised embryos 
(Grant and Wacaster, 1972). Furthermore, this ventralisation can be rescued by 
physically tilting embryos to mimic cortical rotation (Scharf and Gerhart, 1980), 
giving rise to the model that cortical rotation acts to localise dorsal 
determinants. These determinants activate the Wnt/-catenin signalling 
pathway (Marikawa and Elinson, 1999), although the molecular identity of these 
factors is still unclear (Houston, 2012). 
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This maternal Wnt signal establishes the dorsal-vegetal Nieuwkoop centre 
during the early blastula (De Robertis and Kuroda, 2004). The Nieuwkoop centre 
was identified as an inducer of dorsal mesoderm by a series of seminal 
experiments. When dissected dorsal vegetal regions were juxtaposed with 
animal cap tissue, embryoids with mesodermal cells and a dorsal-ventral axis 
were formed, demonstrating that signalling by the Nieuwkoop centre is capable 
of establishing a Spemann’s organiser (see below)(Gerhart, 1999). At the 
molecular level -catenin and VegT act together in the Nieuwkoop centre to 
drive expression of Xnr5 and Xnr6 (Takahashi et al., 2000). These and other 
nodal proteins (Xnr1, 2, 4, Agius et al., 2000) are secreted by the Nieuwkoop 
centre and are potent morphogens, inducing dorsal mesoderm at high 
concentrations and ventral mesoderm at low concentrations (Jones et al., 1995). 
Intriguingly the BMP inhibitor Chordin is required for induction of dorsal 
mesoderm by Xnr1 (Vonica and Gumbiner, 2007), indicating that the 
establishment of the organiser by the Nieuwkoop centre involves the integration 
of multiple signalling pathways.  
Whether the Nieuwkoop centre is a bona fide inducer of the organiser has been 
questioned. Excision of Nieuwkoop centre cells results in wounding-activated 
FGF signalling (LaBonne and Whitman, 1997), which together with maternal 
Wnt signalling could establish an organiser-like tissue in the explanted cells 
(Vonica and Gumbiner, 2007). Therefore these explants would not be acting in 
the same way as endogenous Nieuwkoop centres, and interpretation of these 
transplant experiments should be treated with caution.     
Most Wnt target genes are not expressed prior to the mid-blastula transition 
(MBT, ~stage 8), despite the presence of nuclear -catenin from the 16-cell stage 
(Larabell et al., 1997a; Lemaire et al., 1995; Smith et al., 1995). However, changes 
are made to the chromatin at Wnt target genes. For example, at the Siamois (Sia) 
promoter -catenin recruits protein arginine methyltransferase 2 (Prmt2) to 
create a poised chromatin state (Blythe et al., 2010). Siamois and twin are key 
Wnt-target genes during the blastula stages. Sia and twin induce expression of 
organiser specific genes such as goosecoid (gsc) and chordin (chrd)(Carnac et al., 
1996), and when injected into ventral blastomeres induces a complete secondary 
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axis (Lemaire et al., 1995). Thus both the maternal Wnt pathway and its 
immediate targets act to establish the dorsal side of the embryo.  
Like Sia and Twin, Xenopus Nodal related 3 (Xnr3) is a target of maternal Wnt 
signalling (McKendry et al., 1997). Unlike other nodal related proteins, Xnr3 does 
not activate Smad signalling due to a mutation in the cysteine knot (Smith et al., 
1995). Instead, Xnr3 acts as an inhibitor of BMP signalling and induces neural 
tissue in the ectoderm (Glinka et al., 1996), and promotes convergent-extension 
movements by signalling through the FGF receptor (Yokota, 2003). Thus the 
effects of Xnr3 are complementary to those of the organiser (see below).  
1.2.6.2 Spemann’s Organiser and Patterning of the Dorsal Ventral Axis 
 
Spemann’s organiser elaborates the dorsal-ventral axis during Xenopus 
gastrulation, and when transplanted is sufficient to induce a complete secondary 
axis. Somewhat counter intuitively, the organiser establishes dorsal character by 
secreting inhibitors of cell-cell signalling. These inhibitors antagonise signals 
produced by ventral tissue, giving rise to gradients of Wnt, BMP and Nodal 
ligands that are high on the ventral side of the embryo and low on the dorsal side 
(reviewed by Niehrs, 2004). In addition to patterning the mesoderm, inhibition 
of BMP in overlying ectoderm is crucial for the induction of neural tissue 
(Zimmerman et al., 1996). 
As described in section 1.2.2.3, extracellular inhibitors of the Wnt pathway such 
as Cer, sFRPs and Cresc are secreted from the organiser and inhibit Wnt 
signalling. Cerberus is particularly interesting because it binds to Wnt, BMP and 
Nodal ligands, acting as a triple repressor {Piccolo:1999bc}. Some of these 
extracellular regulators, such as sFRP3 and Cresc, also act as chaperones to 
enhance the diffusion of Wnt ligands, and thus act to perpetuate the dorsal-
ventral gradient (Mii and Taira, 2009). 
This phenomenon is not limited to extracellular regulators of the Wnt pathway.  
For example the dorsal-ventral gradient of chordin is controlled by a complex 
interplay between tolloid (a secreted protease that degrades chordin), sizzled 
(an sFRP that is a competitive inhibitor for tolloid) and twisted gastrulation (tsg, 
a protein that enhances the activity of both chordin and BMPs)(described by De 
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Robertis, 2009). The diffusion of these factors within the embryo causes a 
gradient of chordin activity that is more finely controlled than would be 
generated by diffusion alone. 
 
1.2.6.2 The Role of Wnt In Neural Patterning and Neural Crest Specification 
Neural tissue in Xenopus is specified during gastrulation by BMP-antagonists 
emanating from Spemann’s organiser (De Robertis and Kuroda, 2004). During 
this time a posterior-anterior gradient of Wnt signalling exists in the 
presumptive brain and conveys posterior fate (Kiecker and Niehrs, 2001). A 
decrease in Wnt signalling using Dkk1 mRNA or a Wnt3a morpholino causes 
expansion of anterior markers (Elkouby et al., 2010; McGrew et al., 1997). 
Similarly, overexpression of Wnt from stage 10 using inducible constructs or 
plasmid DNA posteriorises the head region, leading to expansion of the 
hindbrain and loss of anterior structures such as the eyes and cement gland 
(Domingos et al., 2001; Elkouby et al., 2010). 
Neural crest (NC) cells are specified at the lateral borders of the neural plate by 
signals secreted by the paraxial mesoderm (Elkouby and Frank, 2010). Once 
specified, NC cells undergo an epithelial-mesenchymal transition (EMT), migrate 
throughout the embryo and differentiate into many different cell types (Pegoraro 
and Monsoro-Burq, 2012). Wnt signalling plays a key role in NC specification, as 
overexpression of Wnt ligands causes an increase in NC cells, whereas depletion 
reduces the number of NC cells (LaBonne and Bronner-Fraser, 1998). 
Surprisingly, recent work shows that the earliest stages of neural crest 
specification also require an inhibition of Wnt signalling (Ben Steventon and 
Mayor, 2012). Therefore assessing the role of Wnt signalling in neural crest 
specification is not trivial and requires consideration of the developmental stage 
at which experiments are carried out. 
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1.2.6.3 Wnt Signalling in Disease 
APC was one of the first tumour suppressor genes to be cloned (Kinzler et al., 
1991), and is mutated in a large number of colon cancers (Clevers, 2006). Loss of 
APC causes hyperactivation of the Wnt pathway (Rubinfeld et al., 1997), which is 
thought to be a key step in the progression of cancers. Similarly, other mutations 
that activate the Wnt pathway, such as loss of the GSK3 phosphorylation site in 
-catenin, are thought to drive tumourigenesis in the colon (Morin et al., 1997).  
Aberrant Wnt signalling is also found in several other tumour types, such as 
pancreatic, ovarian and liver cancers (Barker and Clevers, 2006), and are 
important for tumour progression. 
Dysregulation of the Wnt pathway in human disease is not restricted to cancer. 
Loss of Wnt signalling is associated with reduced bone mass in patients with 
osteoporosis pseudoglioma (Gong et al., 2001), whereas gain of function 
mutations in LRP6 cause an increase in bone formation (Boyden et al., 2002). 
Mutations in TCF/LEF proteins are associated with sebaceous tumours, diabetes 
and Crohn’s disease (Beisner et al., 2014; Grant et al., 2006; Takeda et al., 2006). 
Haploinsufficiency of -catenin causes post-natal developmental delay and 
mental retardation (Dubruc et al., 2014). Inactivation of the Wnt pathway is 
thought to be a key step in the development of Parkinson’s disease, reducing the 
neuroprotective capabilities of astrocytes (L'Episcopo et al., 2014). Finally the 
Wnt pathway plays a complex role in schizophrenia that is poorly understood. 
Some drugs used to treat mental disorders activate the Wnt pathway, while 
others act to repress it (Panaccione et al., 2013). Why opposite effects on the 
same pathway are both able to treat schizophrenia is unclear, though it is likely 
that these drugs are targeting multiple cellular processes simultaneously. 
Due to the wide spectrum of diseases in which the Wnt pathway is involved, 
there is a great deal of interest in developing drugs to manipulate Wnt signalling. 
Thus an improved understanding of which proteins regulate the Wnt pathway 
and the molecular mechanisms by which they act will be informative for drug 
design and developing treatments.  
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1.2.7 Non-Canonical Wnt Signalling 
In addition to “canonical” signalling, binding of Wnt ligands to FZD receptors 
activates many -catenin-independent intracellular pathways, commonly 
referred to as non-canonical Wnt signalling pathways. I will give a brief overview 
of these signalling events. 
The ability of Wnt ligands to activate more than one pathway was first seen in 
Xenopus, where overexpression of Wnt5a disrupted convergent extension 
movements during gastrulation (Moon et al., 1993). Since then many proteins 
involved the establishment of planar cell polarity (PCP) – the orientation of 
apical surfaces across a tissue – have been identified, but the mechanism by 
which they establish polarity is still unclear (Wallingford, 2012). Ligand binding 
to FZD receptors causes activation of Rho and Rac, which subsequently 
reorganise the actin cytoskeleton to cause changes in cell shape (Habas et al., 
2003). How this activity is linked to the establishment of polarity remains 
unknown. As well as mediating convergent extension movements, the PCP 
pathway is required for planar polarity of epithelia, contact inhibition in 
migrating neural crest cells and axonal guidance during neuronal outgrowth 
(Mayor and Theveneau, 2013). 
Binding of Wnt ligands to receptors can also cause an influx of Calcium ions 
(Ca2+). Intracellular Ca2+ activates a wide range of cellular responses such as the 
activation of protein kinase C (PKC), calcineurin and calcium/calmodulin 
dependent kinase II (CaMKII; (van Amerongen, 2012). In Xenopus animal caps, 
Wnt5a-dependent Ca2+ signalling stimulated nuclear translocation of nuclear 
factor of activated T-cells (NFAT), which was able to suppress canonical Wnt 
signalling (Saneyoshi et al., 2002). 
The Wnt signalling pathway is complex, and the preferential activation of 
different branches is poorly understood. By dissecting each aspect of the 
pathway separately we can build up a bigger picture of the molecular activities 
that occur during active Wnt signalling.  
  
 61 
1.3 Aims of the Thesis 
I am interested in the control of signalling pathways during embryogenesis, and 
how they direct tissue specification through the regulation of gene expression. 
Previous work in the lab has shown that Dri3 regulates TGF signalling during 
mesoderm development (Callery et al., 2005). I was therefore interested in 
whether other ARID family members were capable of controlling intercellular 
signalling. ARID1a was a clear candidate as work in Drosophila indicated that it 
could repress the Wnt signalling pathway (Collins and Treisman, 2000).   
ARID1a is the largest subunit of the BAF complex. The nucleosome remodelling 
capabilities of the BAF complex have been well studied in vitro, however its 
functional role within the cell is less clear. Most work to date has focussed upon 
the core ATPase Brg1 and there are few physiological studies of other BAF 
complex subunits.   
The Wnt pathway has been extensively studied since its discovery. Many of the 
cytoplasmic proteins that regulate the Wnt/-catenin pathway have been 
characterised; however events in the nucleus are less well understood. Therefore 
ARID1a offers an interesting opportunity to discover more about the nuclear 
regulation of the Wnt pathway and to investigate the in vivo function of the BAF 
complex. There are 3 aims of this thesis: to assess the effects of gain of function 
and loss of function of ARID1a on Xenopus development; to test whether ARID1a 
regulates the Wnt signalling pathway in a vertebrate model; and to investigate 
the molecular mechanisms by which ARID1a is acting.    
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Chapter 2: Materials And Methods 
2.1 Xenopus Embryological Tools and Techniques  
2.1.2 Solutions and Reagents 
10X Marc’s Modified Ringers (MMR) Solution: 
NaCl 1 M 
KCl 20 mM 
MgSO4 10 mM 
CaCl2 20 mM 
HEPES (pH 7.8) 50 mM 
EDTA 1 mM 
 
10X Normal Amphibian Medium (NAM):  
NaCl 1.1 M 
KCl 20 mM 
Ca(NO3)2 10 mM 
MgSO4 10 mM 
EDTA 1 mM 
NaHCO3 10 mM 
Sodium Phosphate (pH 7.4) 20 mM 
 
Cysteine Solution (for de-jellying embryos): 
L-cysteine hydrochloride monohydrate 
(Sigma-Aldrich) 
2.2% (w/v) 
Sodium Hydroxide (Fisher Scientific) To pH 7.9-8.0 
NAM 0.1X 
 
10X Calcium-Magnesium-Free Medium (CMFM): 
 
NaCl 880 mM 
KCl 10 mM 
NaHCO3 24 mM 
Tris (pH 7.6) 75 mM 
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1X MEMFA:  
MOPS (pH 7.4) 100 mM 
EGTA 2 mM 
MgSO4 1 mM 
Formalin (Sigma) 10% (v/v) 
 
1X Immunofluorescence Blocking Solution (IBS): 
PBS 1X 
Bovine Serum Albumin (Sigma-
Aldrich) 
0.1% (w/v) 
Triton-X (Promega) 0.1% (v/v) 
Goat Serum (Sigma) 10% (v/v) 
 
1X PBST 
PBS 1X 
Tween-20 (Sigma) 0.1% (v/v) 
 
20X Saline-Sodium Citrate (SSC) buffer: 
NaCl 175.3 g 
Sodium Citrate 88.2 g 
NaOH To pH 7.0 
Distilled Water To a final volume of 1 L 
 
1X Bleaching Solution 
SSC 0.5X 
Formamide (Sigma) 5% (v/v) 
37% Hydrogen Peroxide Solution 
(Sigma) 
2% (v/v) 
 
1X Hybridisation Buffer 
Formamide 50% (v/v) 
SSC 5X 
Torula RNA (Sigma) 1 mg/ml 
Heparin (Sigma) 100 g/ml 
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Denhart’s Solution 1X 
Tween-20 0.1% (v/v) 
CHAPS (Sigma) 0.1% (w/v) 
EDTA 10 mM 
 
2X Maleic Acid Buffer (MAB): 
Maleic Acid (Sigma) 200 mM 
NaCl (ph 7.5) 300 mM 
 
10% Blocking Solution 
Make up a 10% stock (w/v) of Blocking Reagent (Roche) in 1X MAB. Heat the 
solution to 65°C for several hours and shake vigorously to ensure it dissolves. 
Store at −20°C. 
 
1X Alkaline Phosphatase (AP) Buffer: 
Tris (Sigma) 100 M 
NaCl 100 M 
Tween-20 0.1% (v/v) 
MgCl2 40 mM 
 
1X Bouin’s Fixative: 
Formalin 25% (v/v) 
Acetic Acid 5% (v/v) 
NB: The picric acid was omitted as it can become dangerously explosive if 
dried out, and is not necessary for the fixation process. 
2.1.2 In Vitro Fertilisation 
 
Female Xenopus were primed, boosted and transferred to 1X Marc’s Modified 
Ringers (MMR) solution to lay. Eggs were collected from the salt solution using a 
plastic pasteur pipette.  
Adult male Xenopus were sacrificed by injection of MS222 anaesthetic (0.32 
g/ml)(Sigma) followed by decapitation with a guillotine and pithing of the brain 
and brain stem with a pair of forceps, in accordance with Schedule 1 killing 
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guidelines. The testes were then dissected and transferred to 60% L-15 (PAA) 
and kept at 4°C.  
For in vitro fertilisation, the 1X MMR solution was removed from the eggs. A 
piece of testis was cut and crushed in a 1.5 ml tube (Eppendorf) using a 
micropestle (Ambion). This solution was mixed with the eggs and left for 3-7 
minutes for the sperm to diffuse. The dish was flooded with 0.1X Normal 
Amphibian Medium (NAM) and left for up to 30 minutes, or until the embryos 
turned with the pigmented pole facing upwards. The embryos were de-jellied 
using cysteine solution, and washed thoroughly in 0.1X NAM. Embryos were 
cultured in 0.1X NAM at 14°C, 18°C or room temperature (~22-24°C).    
2.1.3 mRNA In Vitro Synthesis 
 
To synthesise mRNA, plasmids were first linearised using an appropriate 
restriction enzyme (see Table 2.1). The following reaction was assembled and 
incubated at 37°C for 1-2 hours: 
 
• 10-20 g plasmid 
• 10 l 10X restriction enzyme buffer 
• 2.5 l BSA solution  
• 2.5 l restriction enzyme 
• Water, to 100 l 
 
The reactions were then processed using a PCR Purification Kit (Qiagen) and 
eluted in 30 l of water. mRNA synthesis was carried out using the mMESSAGE 
mMACHINE kit (Ambion). The following reaction was assembled and incubated 
at 37°C for 2-4 hours. To synthesis ARID1a mRNA, 1 l of GTP was included in 
the reaction.   
• 2 l 10X buffer 
• 10 l 2X NTP/Cap 
• 2 l polymerase mix 
• 1 g linearised plasmid 
• Water, to 20 l 
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2 l of Turbo DNase (Ambion) was added to the reaction, and the plasmid DNA 
digested for 30 minutes at 37°C. Then 30 ul of water and 30 l LiCl (Ambion) was 
added and the reaction mixed, and placed at −20°C for at least 2 hours. The 
mRNA solution was then centrifuged at 4°C at 14000 rpm for 30 minutes. The 
resultant pellet was then washed in 80% ethanol, and centrifuged at 4°C at 
14000 rpm for 30 minutes. Then ethanol was removed and the pellet air dried at 
room temperature for 20 minutes, before being suspended in 20 l water. The 
mRNA was then quantitated using a NanoDrop, and analysed by running 0.5 l 
on a 1% agarose gel, checking for the presence of a single band at approximately 
the correct size.  
2.1.4 Microinjection 
 
Glass needles were prepared from 1.2 mm capillaries (Harvard Apparatus) using 
a needle puller (Sutter Instruments). The settings were: 
Pull: 55 
Velocity: 55 
Time: 10 
The tips of the needles were broken with forceps, and the needles were mounted 
onto an IM 300 Microinjector (Narishige). By injecting water into mineral oil 
(Sigma-Aldrich) the needles were calibrated using a graticule to deliver either 10 
nl (diameter of 26.7) or 5 nl (diameter of 21.2). 
50 mm dishes (Sterilin) coated with 1% agarose (Ultra-Pure Agarose, 
Invitrogen) made up in 0.1X NAM, and prior to injection embryos were 
transferred onto these plates in 3% Ficoll solution (Sigma-Aldrich, made up in 
0.1X NAM). Following injection embryos were left in Ficoll solution overnight, 
before being transferred back into 0.1X NAM the following day.  
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2.1.5 Animal Cap Dissections  
 
To dissect the animal pole regions of Xenopus blastulae, the embryos were first 
transferred to agarose-coated dishes containing 0.75X NAM. Using forceps, the 
vitelline membrane was removed, and then the animal cap was excised. The 
dissected animal caps were then transferred to clean agaorse-coated dishes (in 
0.75X NAM) using a glass pipette and allowed to heal. Once all caps had been cut, 
or when sibling embryos reached the desired stage, the caps were transferred to 
1.5 ml tubes and snap frozen on dry ice. 
To dissociate animal caps into single cells, the above procedure was modified 
slightly. Prior to embryo dissection, coverslips or 8 well glass dishes (LabTek) 
were coated with 1.5 g/ml recombinant human E-cadherin (R+D Systems) 
diluted in 0.75X NAM, and left overnight at 4°C. They were then washed in 0.75X 
NAM immediately before use. 
Embryos were dissected and caps cultured in 1X Calcium-Magnesium-Free 
Medium (CMFM). Dishes were coated with low-melting point agarose (Agarose 
MP, Roche) dissolved in 1X CMFM. Once the excised animal caps had begun to 
disperse, the outer, pigmented epithelium was removed with forceps as it does 
not easily dissociate. 200 l of the dissociated cells were then transferred into 
400 l 0.75X NAM and pipetted up and down a few times to ensure even 
distribution of cells on the slide. The cells were then lefts to adhere for a 
minimum of 1 hour at room temperature. 
2.1.6 Immunofluorescence Of Dissociated Cells and Animal Caps 
 
Cells were dissociated and cultured on E-cadherin coated wells as described 
above. They were then fixed by adding an equal volume of 2X MEMFA for 10 
minutes at room temperature, followed by 1X MEMFA for a further 5 minutes. 
The cells were then washed twice in 1X Phosphate Buffered Saline (PBS), and 
either at 4°C or processed immediately. 
Whole animal caps were dissected as described above and cultured in 0.75X 
NAM until the required stage. They were then transferred to Bijou bottles and 
fixed for 20 minutes in MEMFA, followed by a 5 minute wash in PBS. They were 
then transferred into Dent’s fixative and kept at -20°C overnight or longer.     
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Prior to the immunofluorescence protocol detailed below, the animal caps were 
rehydrated in 5 minute washes of 75%, 50%, 25% methanol, followed by two 5 
minute washes in PBST.  
The following procedure was followed for immunostaining of fixed cells or intact 
animal caps. All washes were 250 l, and antibody incubations were in 80 l.  
 
1) Replace PBS with PBS + 0.5% Triton-X for 10 minutes  
2) Wash in PBS 3 times for 5 minutes each     
3) Block for 1 hour at room temperature in Immunofluorescence Blocking 
Solution (IBS)  
4) Add primary antibody (diluted in IBS) for 1 hour at room temperature, or 
overnight at 4°C   
5) Wash in IBS 3 times for 10 minutes each 
6) Incubate with secondary antibodies diluted in IBS for 1 hour in the dark 
7) Wash with PBS 3 times for 10 minutes each 
8) Mount with 80 l Prolong Gold (with or without DAPI, Invitrogen) 
Prepared cells were imaged with an LSM710 confocal microscope (Leica) and 
images were captured using ZEN software.  
2.1.7 RNA Extraction From Xenopus Tissue 
 
RNA was extracted from embryos as described below. Embryos were frozen in 
batches of 10 on dry ice, and stored at −80°C until use.  
 
1)  Embryos were thawed on ice, then homogenised in 500 l Trizol (Invitrogen) 
by pipetting up and down, and then vortexing for approximately 5 minutes. 
2) Meanwhile, Phase-Lock tubes (5 Prime) were prepared by centrifuging at 
14,000 rpm for 1 minute 
3) 100 l chloroform (Sigma) was added to the homogenised embryos and mixed 
by inverting the tubes vigorously. The homogenate was then transferred to 
the prepared Phase-Lock tubes 
4) The tubes were centrifuged for 30 minutes at 14,000 rpm at 4°C 
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5) The upper phase was transferred to Safe-Lock tubes (Eppendorf) and an equal 
volume of cold isopropanol was added (approximately 300 l). The tubes 
were shaken to mix, and then centrifuged for 30 minutes at 14,000 rpm at 
4°C 
6) The supernatant was removed, and the pellet washed in 150 l of cold 80% 
ethanol, followed by centrifugation for 10 minutes at 14,000 rpm at 4°C 
7) The ethanol was removed as thoroughly as possible, and the pellets air dried 
at 37°C for 5-10 minutes. 30 l of water was then added to each tube and 
kept on ice for 1 hour for the RNA to dissolve.  
8) The RNA pellet was suspended by pipetting up and down, and then 30 l of 
LiCl was added. The tubes were then either stored at -20°C overnight, or 
immediately continued on to the next step. 
9) The RNA was centrifuged for 30 minutes at 14,000 rpm at 4°C. 
10) The pellet was washed with cold 80% ethanol as in step 6, then air dried as 
in step 7. 
11) The RNA pellet was then suspended in 21 l of water and left for 1 hour on 
ice to fully dissolve. 
 
1 l of RNA was quantitated using a NanoDrop (Thermo Scientific), and RNA 
quality was assessed by running on a 1% agarose gel (see section 2.3.3). 
 
The same protocol was used to extract RNA from excised animal cap tissue, with 
the following changes:  
• 10-15 caps were frozen for each extraction.  
• Caps were homogenised in 500 l Trizol and 100 l chloroform.  
• RNA pellets were suspended in 11 l water 
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2.1.8 Protein Extraction 
 
Between 5 and 10 embryos were frozen on dry ice for each protein extraction. 
Frozen embryos were stored at −80°C until use. Embryo protein lysate was 
obtained by the followed method: 
 
1) Phosphosafe extraction buffer (Millipore) was prepared by dissolving one 
protease inhibitor tablet (mini-EDTA free, Roche) in 1 ml. This stock was 
then diluted 1:10 in Phosphosafe buffer.  
2) Embryos were homogenized in 100 l diluted Phosphosafe per embryo 
by pipetting up and down. The lysate was left on ice for 15 minutes. 
3) The yolk in the lysate was removed by adding an equal volume of 1,1,2-
Trichloro-Trifluoroethane (FREON, Sigma) and mixing thoroughly, 
followed by centrifugation for 15 minutes at 14,000 rpm at 4°C 
4) The upper phase was transferred into a new safelock tube and either used 
immediately or stored at −80°C. 
Proteins concentration was obtained using a NanoDrop and a Protein Assay Kit 
(660 nm, Pierce). 
2.1.9 Synthesis of Digoxygenin-Labelled Probes 
Digoxygenin-labelled antisense RNA probes were used to detect gene 
expression patterns using in situ hybridisation (see below). To synthesise these 
probes, plasmids were first linearised using an appropriate restriction enzyme 
(see Table 2.1). The following reactions were assembled, and incubated at 37°C 
for 1-2 hours: 
• 10 g plasmid 
• 10 l 10X restriction enzyme buffer 
• 2.5 l BSA solution  
• 2.5 l restriction enzyme 
• Water, to 100 l 
The reactions were then processed using a PCR Purification Kit (Qiagen) and 
eluted in 30 l of water. Linearisation was tested by running the digestion 
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product on a 1% agarose gel. To synthesise the probe, the following was then 
assembled and incubated at 37°C for 2-4 hours: 
• 2 l 10X Transcription buffer (Roche) 
• 2 l Dig RNA Labelling Mix (Roche) 
• 1 l Ribolock RNase Inhibitor (Thermo Scientific) 
• 1 g linearised plasmid DNA 
• 2 l polymerase (Roche) 
• Water, to 20 l 
Following incubation, 2 l of Turbo DNase (Ambion) was added to the reaction, 
and the plasmid DNA digested for 30 minutes at 37°C. Then 30 l of water and 
30 l LiCl (Ambion) was added and the reaction mixed, and placed at −20°C for 
at least 2 hours. The mRNA solution was then centrifuged at 4°C at 14000 rpm 
for 30 minutes. The resultant pellet was then washed in 80% ethanol, and 
centrifuged at 4°C at 14000 rpm for 10 minutes. Then ethanol was removed and 
the pellet air-dried at 37°C for 5-10 minutes, before being suspended in 21 l 
water. The antisense probe was then quantitated using a NanoDrop, and 
analysed by running 0.5 l on a 1% agarose gel, checking for the presence of a 
single band at approximately the correct size.  
2.1.10 In Situ Hybridisation 
 
Embryos were fixed in 5 ml glass vials in 1X MEMFA for 2 hours at room 
temperature or overnight at 4°C. Embryos older than stage 30 were killed with 
MS222 prior to fixation.  
After fixation, the embryos were washed in 1X PBS for 5 minutes and then 
dehydrated in 100% methanol for 2 hours at room temperature. The alcohol was 
removed and replaced with fresh methanol, and the embryos stored at −20°C 
until use. The in situ hybridisation reaction was carried out as below.  
 
For steps 1-4, the embryos were kept in 5 ml glass vials. 
 
1) Embryos were rehydrated by washing in 75% ethanol, 50% ethanol, 25% 
ethanol and PBST, for 5 minutes each. 
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2) For blastula stage embryos, the animal pole was pierced with a pair of 
forceps. This prevents reagents becoming trapped in the blastocoel. 
3) The pigment was then removed by incubating the embryos in bleach 
solution. They were placed on a light box and covered in foil until all the 
pigment had gone. This typically took 2-3 hours. 
4) The embryos were washed twice in PBST for 5 minutes each, followed by 
fixation for 20 minutes in 1X MEMFA. They were then washed twice in 
PBST for 5 minutes each. 
 
The embryos were then transferred to in situ baskets. These baskets were made 
from 2 ml tubes with the lids and bottoms cut off with a sharp scalpel, and plastic  
mesh melted over the bottom of the tubes. The baskets allowed for quick and 
easy transfer of embryos between solutions, and reduced the risk of damaging or 
losing embryos during aspiration of solutions. 
 
5) Once in the baskets, the embryos were washed in 25% Hybridisation 
Buffer (diluted with water) for 10 minutes at room temperature. 
6) The embryos were transferred to Hybridisation Buffer and incubated at 
65°C for 3-5 hours. 
7) 250-500 l of antisense digoxygenin-labelled RNA probes, diluted to 1 
g/ml in Hybridisation Buffer, was added to the embryos and incubated 
at 65°C overnight.  
8) Embryos were then washed in 2X SSC for 20 minutes at 65°C. Repeat for a 
total of 3 washes. This step was then repeated using 0.2X SSC.  
9) Next, the embryos were washed in 1X MAB for 5 minutes at room 
temperature. Repeat for a total of 2 washes. 
10)Embryos were then blocked in 2% Blocking Solution for 1 hour at room 
temperature 
11)The anti-digoxygenin antibody (Roche) was diluted 1:2000 in 2% 
Blocking Solution containing 10% sheep serum. 250-500 l was added to 
each basket, and the reaction was placed at 4°C overnight. 
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12)The third day if the in situ protocol consisted entirely of 1 hour washes in 
1X MAB for 1 hour each at room temperature, followed by a final wash 
overnight at 4°C. 
13)The next day, the embryos were equilibrated in AP Buffer for 5 minutes at 
room temperature 
 
 
Here the embryos were transferred to a 24 well tissue culture dish (Corning) in 
AP Buffer. This allowed easy visualisation of the developing stain. 
 
14)The AP buffer was replaced with BM Purple development solution 
(Roche). The plate was covered with foil and the stain allowed to develop. 
If no stain was visible by the end of the day the reaction was transferred 
to 4°C and continued overnight 
15) The reaction was stopped by washing twice in 1X MAB 
16)The stained embryos were fixed in Bouin’s Solution overnight at 4°C 
17)Finally the embryos were washed 3 times in PBS for 5 minutes each, and 
then stored in PBS at 4°C. 
 
For imaging, embryos were transferred to 50 mm dishes coated in 1% agarose, 
filled with 1X PBS. Images were taken with a Leica M165 FC microscope using 
LAS V3 software.  
Some embryos were cleared to allow visualisation of internal structures. These 
embryos were transferred glass dishes and covered with Murray’s Clear, a 
solution with the same refractive index as a Xenopus embryo, thus rendering the 
embryos mostly transparent. Images were then captured using the same set up 
as above. 
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2.2 Tissue Culture Techniques 
2.2.1 Solutions and Reagents 
 
Protein Lysis Buffer: 
HEPES pH 7.4 40 mM 
NaCl 120 mM 
EDTA 1 mM 
Sodium Fluoride 50 mM 
Sodium Orthovanadate 1.5 mM 
Triton-X 1% (v/v) 
 (Mini) Protease Inhibitor (Roche) 1 tablet 
 
PBST: 
PBS 1X 
Tween-20 0.1% (v/v) 
 
IF Blocking Buffer: 
PBS 1X 
BSA 0.1% (w/v) 
Triton-X 0.1% (v/v) 
Goat Serum 10% (v/v) 
 
 
2.2.2 Cell Maintenance   
Human Embryonic Kidney 293 (HEK293) cells were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) plus 10% foetal bovine serum (FBS), 1% 
Pen/Strep and 6 mM L-glutamine (DMEM +++). 
Cells were split by first washing in PBS (Gibco) and then incubated with trypsin 
solution (Gibco) for 3-5 minutes at 37°C. The cells were then collected in DMEM 
and centrifuged at 1000 rpm for 3 minutes. The pelleted cells were re-suspended 
in 10 ml DMEM +++ and then diluted into tissue culture plates as desired.   
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2.2.3 RNA Extraction 
 
RNA was extracted from confluent dishes of HEK293 cells. The media was 
removed using a vacuum pump and cells were washed in PBS. The PBS was 
removed and the cells frozen at −80°C.  
Cells were thawed on ice. 500 l of trizol was added and the cells allowed to 
homogenise for 5-10 minutes. The homogenate was collected and transferred to 
1.5 ml Eppendorf tubes and 100 l of chloroform was added. The samples were 
then processed as described in section 2.1.7.  
2.2.4 Protein Lysis 
 
Dishes of confluent cells were taken from the incubator and placed immediately 
on ice. They were then washed in cold PBS, before the addition of Protein Lysis 
Buffer: 
 
  Plate size Volume of lysis buffer 
6-well plate 200 l 
10 cm dish 500 l 
15 cm dish 1 ml 
 
Using rubber cell scrapers, the cells were harvested into either 1.5 ml Eppendorf 
tubes, or 50 ml falcon tubes and left on ice for 15 minutes to allow lysis to occur. 
If required, samples were snap-frozen on dry ice or in liquid nitrogen and stored 
at −80°C. 
Samples were thawed in ice water, and then centrifuged at 13,000 rpm for 30 
minutes to pellet cytoskeletal debris. The supernatant was then gathered for use 
in future experiments. Protein concentrations were determined using the Pierce 
Protein Assay Kit and a Nanodrop. 
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2.2.5 Transfection of HEK Cells 
Transfection of HEK cells was performed using Lipofectamine reagent 
(Invitrogen) according to the manufacturer’s recommendations. Briefly, cells 
were grown in DMEM + 10% FBS + L-Glutamine, but without antibiotics prior to 
transfection. The required amount of DNA was diluted in Optimem medium 
(Gibco) and left for 5 minutes. Lipofectamine reagent was then added, and the 
mixture allowed to combine for 20 minutes to 1 hour. This solution was then 
added to the cells, and the cells were grown overnight. 
The following morning, the media was replaced with normal DMEM+++ media. 
2.2.6 Live Imaging Of FRT/GFP-ARID1a Cells 
FRT/GFP-ARID1a cells were seeded onto 8 well dishes (Lab-Tek) and 
maintained in DMEM+++. They were treated with 20 ng/ml doxycycline (Sigma) 
overnight to induce expression of GFP-ARID1a. Nuclei were labelled using 5 M 
DRAQ5 (Biostatus). Cells were imaged using an LSM710 confocal microscope 
(Leica) and processed using ZEN software. 
2.2.7 Immunofluorescence of Tissue Culture Cells 
Cells were seeded onto 8 well dishes (LabTek) and grown as described above. 
Cells were fixed by adding an equal volume of 20% formalin in 2X PBS to each 
well for 10 minutes, then a further 10 minutes in 10% formalin in PBS. The cells 
were then dehydrated in 100% ethanol and stored at −80°C (this dehydration 
step was sometimes omitted). 
All further washes were 250 l unless otherwise stated.   
If dehydrated, the cells were rehydrated in successive washes of 75%, 50%, and 
25% ethanol, followed by PBST for 5 minutes each. Next, the cells were 
incubated in IF Blocking Buffer for 1 hour at room temperature. The Blocking 
Buffer was replaced with primary antibodies diluted in 80 l IF Blocking Buffer 
and incubated overnight at 4°C. 
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The cells were then washed in Blocking Buffer 3 times for 15 minutes each. The 
final wash was removed and replaced with secondary antibodies conjugated to 
flourophores, diluted in 80 l IF Blocking Buffer for 2 hours at room 
temperature. The secondary antibody solution was removed and the cells were 
washed in Blocking Buffer 3 times for 15 minutes. Then the Blocking Buffer was 
removed, and the samples were covered in 80 l Prolong Gold Mounting Medium 
containing DAPI (Promega). If using slides with a removable casket this was 
discarded and a coverslip was placed over the cells.  
The cells were imaged on an LSM710 confocal microscope (Leica) using ZEN 
software.  
 
2.2.8 Creating Stable Cell Lines 
N-terminally GFP-tagged Xenopus ARID1a was cloned into the pcDNAFRT/TO 
vector by the Cloning Facility at the Protein Phosphorylation Unit, University of 
Dundee.   
Generation of pFRT/GFP-ARID1a cells was carried out by Lina Herhaus (Sapkota 
Lab, University of Dundee). T-REx-293 cells (Invitrogen) were maintained in 
DMEM+++ containing 15 g/ml blastidicidin (InvivoGen) and 100 g/ml zeocin 
(Fischer Scientific). For transfection, cells were grown to 60% confluency in a 10 
cm dish, in DMEM+++ lacking blasticidin and zeocin. 9 g of plasmid pOG44 
(which contains the flippase gene) and 1 g of pcDNAFRT/TO/GFP-ARID1a was 
added to 25 l of polyethyleneimine (PEI; 1 mg/ml) in 1 ml DMEM+++. After 15 
minutes, the transfection mixture was added to the cells and grown overnight. 
The cells were split 1:3 and allowed to grow for a day before the media was 
changed to DMEM+++ containing 15 g/ml blasticidin and 100 g/ml 
hygromycin B (Hyclone Laboratories). Surviving colonies were picked and 
expanded under selection.  
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2.2.9 Immunoprecipitations 
For immunoprecipitation experiments, cell lysates were prepared in Protein 
Lysis Buffer as described in section 2.2.1. 10% of the lysate was set aside as input 
material, and the rest used for the immunoprecipitation experiments. The lysate 
was blocked with a 1:1 solution of immobilised protein G on agarose beads 
(Thermo Scientific):Sepharose CL4B beads (Sigma) for 1 hour at 4°C on a rotor 
(approximately 10% the volume of the lysate). The lysate was then spun at 
13,000 rpm at 4°C for 1 minute to pellet the beads, and the supernatant was 
transferred to a new tube. The primary antibody was added at a 1:100 dilution, 
along with a protein G agarose/sepharose CL4B mixture as above, and the lysate 
incubated on a rotor at 4°C overnight.       
The lysate was then spun at 10,000 g for 1 minute at 4°C, and the supernatant 
removed. The beads were washed 3 times in Protein Lysis Buffer. 50 − 100 l of 
1X SDS loading buffer was added and the beads were heated to 70°C for 10 
minutes, with gentle shaking. The mixture was then spun at 13,000 rpm for 1 
minute to pellet the beads, and the supernatant analysed by western blotting 
(see section 2.3.6).  
2.2.10 Luciferase Assays 
Luciferase assays were carried out using the Super8 TOPFLASH and FOPFLASH 
reporter plasmids (Addgene plasmids 12456 and 12457 respectively; (Veeman 
et al., 2003). Cells were seeded into 24 well plates, and transfected as described 
above. For each well, 10 ng Renilla plasmid and 100 ng of either the TOPFLASH 
or FOPFLASH reporter plasmids were transfected with up to 500 ng of plasmid 
of interest. The following morning, the cells were washed in serum-free medium 
and starved for at least four hours before the addition of either 100 l L-cell 
conditioned medium or 100 l Wnt-conditioned medium (gift from K. Dingwell). 
After 24 hours the cells were processed using the Dual Luciferase Reporter Assay 
Kit (Promega). The cells were washed in PBS, then 100 l of 1X Passive Lysis 
buffer was added and the plate placed on a shaker for at least 15 minutes at 
room temperature. For each reaction, 20 l was transferred to a Nunclon 96 well 
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plate (Thermo Scientific). The luciferase activity was then read using a Synergy2 
plate reader (Biotek).  
2.2.11 Mass Spectrometry 
For each mass spectrometry experiment, between ten and twenty 15 cm dishes 
of FRT/GFP-ARID1a cells were grown to confluency and treated with 20 ng/ml 
doxycycline overnight. Each dish was lysed in 1 ml HEPES lysis buffer + 2.5 
mg/ml DSP (Sigma) and left for 30 minutes on ice. The cross-linking reaction 
was quenched by adding 250 l 1 M Tris-HCL pH 7.4 for a further 15 minutes. 
The lysate was then centrifuged at 15,000 rpm at 4°C for 30 minutes, then 
filtered through a 0.45 M column.  
The lysate was then blocked using 15 l CL4B beads and 15 l protein G agarose 
beads for 2 hours on a rotor at 4°C. The beads were pelleted by centrifugation, 
and the lysate was taken. 15 l of CL4B beads and 15 l of GFP-TRAP beads 
(Chromotek) were added, and then incubated at 4°C on a rotor for 2 hours. The 
beads were then collected by centrifugation, and washed four times in HEPES 
lysis buffer + 0.2 M NaCl, followed by a final wash in 10 mM Tris-HCL pH 7.4. The 
beads were then incubated in 100 l LDS sample buffer + 0.1 M DTT and heated 
to 95°C for 10 minutes.  
The beads were removed by passing through a Spin-X column (Thermo 
Scientific). 50 mM iodoacetamide was then added for 30 minutes to alkylate 
cysteine residues and completely disrupt disulphide bonds. The proteins were 
then run on a gradient gel in TGX buffer at 180 V. The gel was stained using 
colloidal blue (Novex) for two hours, and then washed with water overnight.  
The gel was cut with a scalpel into different segments (Fig. 4.6) and each 
processed individually. Each segment was cut into ~0.5 mm cubes and put into a 
1.5 ml Eppendorf tube. The gel slices were then incubated with 500 l of the 
following for 10 minutes each on a shaker at room temperature: water, 50% 
acetonitrile, 100 mM NH4HCO3, 50% acetonitrile + 50 mM NH4HCO3. The final 
wash was repeated at 60°C until all blue colour had been removed. The gel 
pieces were shrunk using 300 l of acetonitrile and then dried using a speed-vac. 
The proteins were then digested by adding 60 l 25 mM Triethylammonium 
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bicarbonate + 5 ug/ml trypsin at 30°C on a shaker. After 30 minutes, a further 
170 l Triethylammonium bicarbonate was added and the reaction left 
overnight.  
The next day, 200 l acetonitrile was added to each sample and then shook for 
15 minutes at 30°C. The supernatant was then transferred to new tubes and 
frozen at -80°C for 30 minutes, then dried using a speed-vac. Meanwhile, 100 l 
50% acetonitrile/2.5% formic acid was added to the gel pieces. The supernatant 
was then added to the dried samples above and dried using a speed-vac. The 
prepared samples were stored at -20°C until they were processed for mass 
spectrometry.  
Raw data from the mass spectrometry runs were matched to the human 
proteome or Xenopus translatome. Mascot scores were generated using the 
formula −10𝐿𝑜𝑔(𝑃), where P is the probability that the peptide matching is a 
random event. Therefore a mascot score of 67 gives a false discovery rate (FDR) 
of 5%.  
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2.3 Molecular Biology Techniques 
2.3.1 cDNA Synthesis 
To synthesise cDNA, 1 g of total RNA was denatured at 75°C for 5 minutes in a 
volume of 4 l of water. The following reaction was then assembled, and added 
to the denatured RNA: 
Reagent Desired 
Concentration 
Volume Added 
/ l 
Manufacturer     
 M-MLV RT 5X 
Buffer 
1X 2 
Promega 
10 mM dNTPs 1 mM 1  
100 M Random 
Hexamers 
10 M 1 Sigma 
MMLV-RT RNase 
(H-) Mutant (200 
units/l) 
4 units 0.2 Promega 
Water   1.8  
 
The reactions were then briefly vortexed to mix, followed by a quick 
centrifugation. cDNA was then synthesised using a BioRad T100 Thermal Cycler 
and the steps below: 
• 25°C for 15 minutes 
• 37°C for 15 minutes 
• 55°C for 45 minutes 
• 85°C for 15 minutes 
• 4°C indefinitely 
Upon completion of the final cycle, 40 l of water was added to the reaction, and 
the synthesised cDNA was stored at −20°C until required. 
2.3.2 Polymerase Chain Reaction (PCR) 
Amplification of DNA for cloning and diagnostics was carried out using a 
BioRad T100 Thermal Cycler. Several different polymerases were used over the 
course of this work, and they are detailed here. In all cases 10 M primer pairs 
were made by diluting 100 M forward and reverse primer stocks 1:10 in water. 
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Red-Taq (Sigma) and KAPA2 (KAPA): 
These two polymerases were used for amplification of short stretches of DNA 
(<2kb) where fidelity was not a primary concern: mostly, these polymerases 
were used for diagnostic PCRs or the synthesis of standards for use in 
quantitative PCR (qPCR). The reactions were identical for both polymerases: 
• 5 l 2X polymerase mix 
• 0.2 l 10 uM primer pair 
• 0.2 l DNA (typically 5 ng plasmid DNA or 50 ng cDNA) 
• 4.6 l water 
Temperature Time Number of Cycles 
95°C 30 s 
X 30 58°C 30 s 
72°C 30 s 
4°C indefinite  
  Pfu Ultra (Agilent) 
Pfu Ultra is a high fidelity enzyme that produces blunt end products, and so 
was used for cloning Xenopus ARID1a from cDNA. Reactions were assembled as 
below: 
• 5 l 10X Pfu Ultra AD buffer 
• 0.4 l 25 mM dNTPs 
• 1 l template DNA 
• 1 l 10 M primer pair 
• 1 l Pfu Ultra 
• 41.6 l water 
Temperature / °C Time Cycles 
95 2 minutes 1 
95  30 seconds 
35 64 30 seconds 
72 6 minutes 
72  10 minutes 1 
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Phusion (NEB) 
Phusion polymerase is a highly progressive and accurate polymerase, and so 
was ideal for amplifying DNA that would subsequently be used for producing 
expression constructs. Reactions were carried out as below: 
• 2 l template DNA 
• 10 l 5X High Fidelity buffer 
• 1.25 l 10 mM dNTP 
• 1.5 l 10 M primer pair 
• 0.5 l Phusion polymerase 
• 34.75 l water 
Temperature / °C Time Cycles 
95 2 minutes 1 
95  30 seconds 
35 64  30 seconds 
72 30 seconds/kb 
72 10 minutes 1 
4 indefinite  
2.3.3 Agarose Gel Electrophoresis 
DNA and RNA was visualised using agarose gel electrophoresis.  For a typical 1% 
gel 0.3 g of UltraPure Agarose (Invitrogen) was dissolved in 30 ml TAE buffer by 
heating in a microwave. 1 l of RedSafe was added to the gel to allow 
visualisation of nucleic acids and the gel poured into a mould. The appropriate 
volume of Gel Loading Dye (NEB) was added to samples where required, and a 1 
kb or 100 bp ladder (NEB) was loaded onto the gel. Gels were run for 20-25 
minutes at 120 V.  
2.3.4 Entry Vector Cloning  
For the creation of expression constructs, desired regions of DNA were amplified 
by PCR and incorporated into Entry vectors (pENTR/D-TOPO, Invitrogen). The 
advantage of the Entry Vector system is that one template plasmid can be used to 
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quickly generate many expression constructs containing different 
immunoreactive tags.  
To use the Entry vector system, forward and reverse primers were designed 
using Primer 3, complementary to the gene of interest with one additional 
consideration: four residues - CACC - were added to the 5’ end of the forward 
primer, ideally just prior to the start codon. This was to allow the incorporation 
of the PCR product into the Entry vector via a TOPO-isomerase-directed insertio. 
Pfu Ultra- or Phusion-derived PCR products were purified using a PCR 
Purification kit (Qiagen) and their concentration determined using a NanoDrop 
1000 (Sigma Biotechnologies). The amount of PCR product to be used was then 
obtained using the following formula: 
 
𝑛𝑔 𝑣𝑒𝑐𝑡𝑜𝑟 ×  𝑘𝑏 𝑠𝑖𝑧𝑒 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡
𝑘𝑏 𝑠𝑖𝑧𝑒 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟
+
𝑣𝑒𝑐𝑡𝑜𝑟
𝑖𝑛𝑠𝑒𝑟𝑡
=  𝑛𝑔 𝑖𝑛𝑠𝑒𝑟𝑡 
 
7.5 ×  𝑘𝑏 𝑠𝑖𝑧𝑒 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡
2.58
+
1
1
=  𝑛𝑔 𝑖𝑛𝑠𝑒𝑟𝑡 
 
The optimal vector:insert ratio is between 0.5:1 and 2:1. I most frequently used 
1:1. 
For the cloning reaction, 0.5 l pENTR/D-TOPO, 0.5 l salt solution (Entry vector 
cloning kit, Invitrogen), and the calculated volume of PCR product were mixed in 
a total volume of 2.5 l and incubated at 22°C for 1 hour. A negative control 
reaction containing no PCR product was always included.  
The plasmids were then transformed into either One Shot (Invitrogen) or highly 
competent bacteria (C2987, NEB) by mixing 2 l of the reaction with 50 l 
bacterial suspension and leaving on ice for 30 minutes, followed by 40 seconds at 
42°C. 250 l SOC (NEB) was added to the bacteria, and they were grown at 37°C 
for 1 hour with continual shaking. The bacteria were then spread onto L-agar 
plates containing 100 g/ml kanamycin and grown overnight at 37°C.  
 85 
 
Colonies were picked using a pipette tip and transferred to 4 ml of Luria Broth 
(LB) containing 100 g/ml kanamycin and grown at 37°C with shaking 
overnight. The following day, the plasmids were isolated using a Mini-Prep Kit 
(Qiagen) following the manufacturer’s protocol. To ensure that the plasmids 
contained the desired insert, each was verified by sequencing (Cogenics). 
To generate useable expression constructs from sequence-verified Entry vectors, 
a subsequent Gateway Cloning (Invitrogen) step had to be carried out. In this 
reaction the gene of interest inserted in the Entry vector is recombined into a 
Destination vector of choice, many of which contain in frame tags such as Green 
Fluorescent Protein (GFP) or the Haemagglutinin (HA) moiety. To this end, 0.75 
l of the Entry vector (100 ng/l), 0.75 l of the desired Destination vector (100 
ng/l), 2.5 l of TE and 1 l Gateway LR Clonase II Enzyme Mix (Invitrogen) 
were combined and incubated at 25°C for 1 hour. 0.5 l proteinase K solution 
(provided with the LR Clonase Kit) was then added to degrade the recombinase, 
and the reaction was heated to 37°C for 10 minutes. 2 l of this reaction was 
then transformed as described above, except that the bacteria were grown on L-
agar plates containing 100 g/ml ampicillin rather than kanamycin. The 
following day colonies were picked and grown in 100 ml LB containing 100 
g/ml ampicillin overnight, and then the plasmids were isolated using a Midi 
Prep Kit (Qiagen) and verified by sequencing (Cogenics).    
 
2.3.5 qPCR 
Quantitative real-time Polymerase Chain Reactions (qPCR) were carried out to 
assess the expression levels of different genes. For these experiments, cDNA was 
prepared as described from the requisite samples. Primer pair solutions were 
made by diluting forward and reverse stock primers (100 M) 1:10, to give a 
final concentration of 10 M of each primer.  
Before beginning a qPCR experiment, a standard curve was made for each new 
set of primers. The following PCR reaction was set up: 
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• 25 l KAPA2 
• 1 l primer pair 
• 1 l appropriate cDNA 
• 23 l water 
 
And the following programme was run: 
Temperature/°C Time Cycles 
95 2 minutes  
95 30 seconds 
20 55 30 seconds 
72 30 seconds 
4 Indefinite  
 
After completion, 10 l of this PCR reaction was taken and run again through the 
same programme. The products from this second round were then run on a 2% 
agarose gel to confirm that DNA of the correct size was created, and that the 
primer pair produced only a single band. The remaining 40 l was used to create 
a standard curve by serial ten-fold dilutions, beginning at 10-3 down to 10-10. 
For the qPCR, the following was assembled for each sample. Every sample was 
done in duplicate: 
• 5 l 2X LightCycler 480 SYBR Green I Master (Roche) 
• 0.5 l primer pair 
• 2 l water 
7 l of this master mix was then put into each well of a 96-well plate as desired, 
using a repeater pipette (Pipetman). 3 l cDNA or diluted standards was then 
added to each sample using a multichannel pipette (Pipet-Lite XLS, Rainin). Once 
complete, the plate was covered using a Clear Adhesive Seal (Rainin), and then 
centrifuged at 1000 rpm for 1 minute. The qPCR was carried out using a 
LightCycler II (Roche). 
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LightCycler 480 SW1.5 software provided concentrations of the amplified 
products using the standard curve included in the run. These data were then 
exported to Excel (Microsoft), and analysed in the following way: technical 
replicates were averaged and divided by the averages of the chosen 
housekeeping gene (most commonly histone H4 or ornithine decarboxylase) 
measured for the same sample.  
2.3.6 Western Blotting 
2.3.6.1 Solutions and Reagents 
SDS Running Buffer 
Trizma Base 30 gm 
Glycine 144 gm 
SDS 10 gm 
Dist. Water 1 l 
 
Wet Transfer Buffer 
Reagent Volume/Mass 
Tris Base 6 g 
Glycine 28 g 
Methanol 400 ml 
10% SDS 2 ml 
Dist. Water  To 2 l 
 
TBST 
TRIS (50mM Ph7.5) 6 gm 
NaCl (150Mm) 8 gm 
Tween 20 (0.20%) 2 ml 
Dist. Water 1 l 
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2.3.6.2 Running Gels and Membrane Transfer 
All western blots were carried out using pre-cast TGX gradient gels (BioRad, 1 
mm Mini-Protean anykD) and SDS running buffer.  
Samples to be analysed by western blotting were prepared as described above. 
4X SDS loading buffer (Licor) was prepared by adding 10% 2-mercaptoethanol 
(Sigma). The buffer was added to the samples and heated to 80°C for 10 minutes. 
Samples were loaded onto the gel, and run at 70-100 mA until the dye front had 
left the bottom of the gel. 8 l of Precision Plus Protein Dual Colour Standards 
(BioRad) was used as a ladder. 
Once separated, the proteins were then transferred onto PVDF membrane 
(Immobilon-FL, Millipore) by wet transfer, running at 100 V for 30 minutes, or 
for larger proteins at 20 V overnight at 4°C. 
2.3.6.3 Detection By Chemiluminescence 
For chemiluminescence visualisation of proteins the membrane was blocked in 
Milk Solution (5% milk powder [Marvel] in PBST) for 1 hour at room 
temperature, or overnight at 4°C. Primary antibodies were then added, diluted in 
Milk Solution between one hundred- and one thousand-fold (see Table 2.4 and 
Table 2.5) for 2 hours at room temperature, or more typically overnight at 4°C.  
The membranes were then washed 3 times in Milk Solution for 10-20 minutes, 
followed by incubation with HRP-conjugated secondary antibodies diluted 
1:1000 in milk solution for 2 hours at room temperature. The membranes were 
then washed 3 times in Milk Solution for 10-20 minutes, followed by two 5-
minute washes in TBS.  
Chemiluminscence detection solution was prepared by mixing both components 
of the Super Signal West Dura Kit (Thermo Scientific) in equal amounts and 
waiting approximately one minute. The membranes were removed from PBS and 
covered with the prepared detection solution for one minute, before pouring off. 
The chemiluminescent signal was then detected using a BioRad Chemi-Doc XRS.  
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2.3.6.4 Detection Using The Odyssey Imager 
For visualisation using the Odyssey Imager (Licor) the membranes were blocked 
using Odyssey buffer (BioRad) for 1 hour at room temperature, or overnight at 
4°C. The membranes were then incubated with the primary antibodies diluted in 
TBST solution for 2 hours at room temperature, or overnight at 4°C. 
The primary antibody solution was then removed and the membranes washed 3 
times for 10 minutes each in TBST at room temperature. Secondary antibodies 
were added in TBST + 0.1% SDS for 2 hours at room temperature, then the 
membranes were washed 3 times in TBST for 10 minutes each, followed by 
rinsing in TBS. The membranes were then placed onto the Licor detector plate, 
and the fluorescence captured using Image Studios software (Licor).  
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2.4 Tables 
Table 2.1 Plasmids 
 
 
 
	
Plasmid	
Name	
Gene	Insert	 Vector	 Source	 Linearisi-
ng	
Enzyme	
Transcribing	
Enzyme	
Expression	Vectors	
ARID1a	 ARID1a	 pCS2+	 ATW	 DraI	 SP6	
GFP-ARID1a	 GFP-ARID1a	 pCS2+	 ATW	 DraI	 SP6	
HA-ARID1a	 HA-ARID1a	 pCS2+	 ATW	 DraI	 SP6	
DUTR-
ARID1a	
ARID1a	 pCS2+	 ATW	 DraI	 SP6	
GFP	 GFP	 pCS2+	 Mary	Wu	 NotI	 SP6	
pCSKA	XWnt-
8	
Wnt8	 pCSKA	 Richard	
Harland	
BamHI	 SP6	
Beta-Catenin	 Beta-catenin	 pSP64T	 Stefan	
Schneider-
Hanson	
BamHI	 SP6	
pSP64T-
eFGF(i)	
FGF4	 pSP64T	 S.	Schulte-
Merker	
EcoRI	 SP6	
DDX5	 DDX5	 pCS2+	 ATW	 NotI	 SP6	
Myc-DDX5	 Myc-DDX5	 pCS2+	 ATW	 NotI	 SP6	
BCL7a	 BCL7a	 pCS2+	 ATW	 NotI	 SP6	
Myc-BCL7a	 Myc-BCL7a	 pCS2+	 ATW	 NotI	 SP6	
In	Situ	Hybridisation	Vectors	
Sox3	 Sox3	 pBS	SK+	 Lab	Stocks	 SmaI	 T7	
Slug	 Snai2	 pMX363	 Mary	Wu	 BglII	 SP6	
21.3C	 ARID1a	 pCMV-SPORT6	 E.	Callery	 NcoI	 T7	
Other	
ARID1a	
pGEM-T	Easy	
ARID1a	 pGEM-T	Easy	 ATW	 N/A	 N/A	
ARID1a	
pENTR	
ARID1a	 pENTR	 ATW	 N/A	 N/A	
ARID1a	pFRT	 GFP-ARID1a	 pcDNA5	
/FRT/TO	
Cloning	facility	
at	Protein	
Phosphoryla-
tion	Unit,	
Univeristy	of	
Dundee	
N/A	 N/A	
pOG44	 Flp	 pOG44	 Sapkota	Lab	 N/A	 N/A	
TOPFLASH	 	 pTA-luc	 R.	Moon.	
Addgene	
plasmid	12456	
N/A	 N/A	
FOPFLASH	 	 pTA-luc	 R.	Moon.	
Addgene	
plasmid	12457	
	 N/A	
BCL7a	pENTR	 BCL7a	 pENTR	 ATW	 N/A	 N/A	
DDX5	pENTR	 DDX5	 pENTR	 ATW	 N/A	 N/A	
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Table 2.2 Morpholinos 
 
  
Table	2.2	Morpholinos	
Name	 Type	 Sequence	5’-3’	
ARID1a	_CO	 Mismatch	control	for	
ARID1a	TB1	
CATcGAcGAgAGAcAAAAGcAC	
ARID1a	_TB	 Translation	blocking	 CATGGAGGACAGAGAAAAGGAC	
	
ARID1a	
_SC1	
Mismatch	control	for	
ARID1a	SB1	
AAaAAcACTTgACTcTACCTcTTGC	
ARID1a	
_SC2	
Mismatch	control	for	
ARID1a	SB2	
ATATGcAcACATCTcTGcAcCAAAT	
ARID1a_	
SB1	
Splice	blocking	 AATAAGACTTCACTGTACCTGTTGC	
ARID1a	
_SB2	
Splice	blocking	 ATATGGAGACATCTGTGGAGCAAAT	
DDX5	CO1	 Mismatch	control	for	DDX5	
TB1	
CCaTGTCaTTAAATaCGGaCATaGC	
DDX5	TB1	 Translation	blocking	 CCCTGTCGTTAAATCCGGGCATGGC	
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Table 2.3 Primers 
 
 
 
	
Name	 Sequence	5’-3’	
Cloning	
ARID1a	pENTR	
Forward	
CACCATGGCCTCTCCTCCTACTCTCTAC	
	
ARID1a	pENTR	
Reverse	
TCATGACTGGCCAATCAAGAAGA	
	
ARID1a	5’UTR	
Forward	
TCCAGCTCCAGTTCCTGTCT	
BCL7a	pENTR	
Forward	
CACCATGTCAGGACGATCTGTCAG	
BCL7a	pENTR	
Reverse	
AGTTTCTCTGAAGCCCCTGG	
DDX5	pENTR	
Forward	
CACCATGCCCGGATTTAACGACAG	
DDX5	pENTR	
Reverse	
AGTCACCACTGCAGTTACCT	
Sequencing	And	Morpholino	Verification	
ARID1a	Seq	1	 AAAGGAGCCGAAGGTTATAC	
ARID1a	Seq	2	 TTCTCACCTCACACTTCCCC	
ARID1a	Seq	3	 CGAGGGTACATGCAGAGGAA	
ARID1a	Seq	4	 AATGTGGGCACTTCAAGCAG	
ARID1a	Seq	5	 AAAGAGTGTCTGCTGCTCCT	
ARID1a	Seq	6	 GTTGGGCCGCTTACAAGAAT		
ARID1a	Seq	7	 AGTTTCAGCAGAGTCAGGCT	
ARID1a	Exon	2	
Forward	
GTCCATGCAAGGAAGACCAC	
ARID1a	Exon	4	
Reverse	
TGGTTGCATTCCCATACTCA	
qPCR	
ODC	Forward	 GCCATTGTGAAGACTCTCTCCA	
ODC	Reverse	 TTCGGGTGATTCCTTGCCAC	
H4	Forward	 CGGGATAACATTCAGGGTATCACT	
H4	Reverse	 ATCCATGGCGGTAACTGTCTTCCT	
ARID1a	Forward	 AGAAATTGTATGGGACCTTG	
ARID1a	Reverse	 TGTCACCTTGAGCTAGATTG	
Siamois	Forward	 TCAACCCTTATCCAGACTTT	
Siamois	Reverse	 ATGTCTGGCTCTTCTGTTCT	
Xnr3	Forward	 TCCACTTGTGCAGTTCCACAG	
Xnr3	Reverse	 ATCTCTTCATGGTGCCTCAGG		
Xbra	Forward	 GAGCATGGAGCACAAACAGA	
Xbra	Reverse	 CAATTCAGCCCAGGAAATA	
Goosecoid	Forward	 TGTTGTGGAGCAGTTCAAGC	
Goosecoid	Reverse	 CCAGTGCTTCCAGTTGTTCA	
BCL7a	Forward	 GAAACAAGAAGTCGGGCGAA	
BCL7a	Reverse	 CACTTTGGGCTCTGCAACAG	
DDX5	Forward	 TGGAAGCGATTAAACGGCAG	
DDX5	Reverse	 ATCTCCCCGCTGTAGGAATG	
ARID1a	HEK	
Forward	
GGTAATGATGTCCCTCAAGT	
ARID1a	HEK	Reverse	 GATCCAGTAGCGTTCTCTGT	
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Table 2.4 Primary Antibodies 
 
Table 2.5 Secondary Antibodies 
Antibody	
Name	
Protein	
Recognised	
Species	
Raised	In	
Manufacturer	 Dilution	
HA-7	 Haemaggluti
nin	epitope	
Mouse	
Sigma	
1:1000-
1:5000	
H-90	 ARID1A	 Rabbit	
Santa-Cruz	
Biotechnology	
1:1000	
PSG3	 ARID1A	 Mouse	
Santa-Cruz	
Biotechnology	
1:1000	
H-88	 BRG1	 Rabbit	
Santa-Cruz	
Biotechnology	
1:1000	
G-7	 BRG1	 Mouse	
Santa-Cruz	
Biotechnology	
1:1000	
H-102	 CTNB1	 Rabbit	
Santa-Cruz	
Biotechnology	
1:1000/1
:200	
AP7459c	 DDX5/p68	 Rabbit	 Abgent	 1:200	
S268B	 GFP	 Sheep	 Sapkota	Lab	 1:5000	
9E10	 Myc	 Mouse	
Santa-Cruz	
Biotechnology	
1:2000	
	
Antibody	
Name	
Protein	
Recognised	
Species	
Raised	In	
Manufacturer	 Dilution	
Stabilised	
Peroxidase	
Conjugated	Goat	
Anti-Rabbit	
(32460)	
Rabbit	IgG	 Goat	
Thermo	Scientific	 1:1000	
Stabilised	
Peroxidase	
Conjugated	Goat	
Anti-Mouse	
(32430)	
Mouse	IgG	 Goat	 Thermo	Scientific	 1:1000	
Odyssey	Goat	
Anti-Mouse	IRDye	
800CW	(926-
32210)	
Mouse	IgG	 Goat	 LiCor	 1:15000	
Odyssey	Goat	
Anti-Mouse	IRDye	
680LT	(926-
68020)	
Mouse	IgG	 Goat	 LiCor	 1:20000	
Odyssey	Goat	
Anti-Rabbit	IRDye	
800CW	(926-
32211)	
Rabbit	IgG	 Goat	 LiCor	 1:15000	
Odyssey	Goat	
Anti-Mouse	IRDye	
680	(926-32221)	
Rabbit	IgG	 Goat	 LiCor	 1:15000	
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Chapter 3: ARID1a During Xenopus 
Development 
3.1 Introduction 
Xenopus is an excellent model organism for studying embryogenesis. Females 
can be induced to lay eggs by injection of Human Chorionic Gonadotropin (HCG). 
This procedure is not harmful, and the frogs can be re-used every 3 months. Each 
spawn produces hundreds of eggs, which when fertilised develop synchronously. 
These embryos can be accurately staged and collected at the desired times. Gene 
expression can be readily manipulated by microinjection of mRNA or antisense 
morpholino oligonucleotides. Furthermore, the detailed fate map of the early 
blastula allows targeting of different tissues by injection of specific blastomeres. 
While this is cruder than genetic approaches available in the mouse, this method 
is significantly faster and can be carried out on a large scale. Finally, the large 
size of Xenopus embryos makes them amenable to dissection. Classic 
transplantation experiments established many of the paradigms of Xenopus 
embryology, and are still valuable techniques in modern research.  
I have assessed the expression pattern of ARID1a during Xenopus embryogenesis. 
I then examined the effects of loss and gain of function of ARID1a on Xenopus 
development.  
3.2 Results 
3.2.1 Cloning of Xenopus laevis ARID1a 
Xenopus laevis is pseudotetraploid, owing to a hybridisation event between two 
species ~40 million years ago (Bisbee et al., 1977; Evans et al., 2004). This 
property has meant that sequencing the X. laevis genome has proven 
exceptionally challenging, and to date only partial scaffolds exist. In order to 
clone Xenopus ARID1a I sought to design primers against the open reading frame. 
Unfortunately, no genomic sequence nor expressed sequence tag (EST) 
containing the entire ARID1a coding sequence was available.  
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I therefore adopted a different strategy, designing primers against ARID1a using 
sequence from the closely related species X. tropicalis, which has a sequenced 
genome. Using these primers I carried out PCR on cDNA from stage 1 X. laevis 
embryos and cloned the resultant product into an Entry vector (Invitrogen). X. 
laevis ARID1a was then subcloned into pCS2+ using the Gateway system, 
producing expression vectors that were either untagged, or contained an N-
terminal HA or GFP tag that were then verified by sequencing.  
X. laevis ARID1a is 6159 base pairs long, coding for a 2053 amino acid protein 
with a predicted mass of 220 kDa (Fig. 3.1, top line). The X. laevis ARID1a protein 
has two predicted domains: an ARID region from residue 812 to 932, and a 
Domain of Unknown Function (DUF3518) spanning residues 1742-1998. The 
DUF domain corresponds to the previously described Eyelid Homology Domain 
(EHD) in the Drosophila Osa protein. I looked for sequence similarities by 
aligning the X. laevis ARID1a protein with ARID1a proteins from X. tropicalis, 
human, mouse, fly and yeast (Fig. 3.1). The Xenopus laevis ARID1a protein is 
97.7% identical to the Xenopus tropicalis protein, and is well conserved with the 
human and mouse ARID1a proteins (87.2% and 87.1% identical, respectively). 
As expected, conservation with fly and yeast is lower (73.3% and 73.0% identity, 
respectively), with the ARID and DUF as the most highly conserved regions. Due 
to the degree of conservation observed between these proteins, I conclude that I 
have successfully cloned the entire open reading frame for X. laevis ARID1a. From 
here on I will refer to Xenopus laevis as Xenopus and X. laevis ARID1a as ARID1a 
unless otherwise stated. 
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Fig. 3.1: Species Comparison of ARID1a Proteins 
Protein sequences for ARID1a from 5 different species were aligned against the in silico 
translated sequence for X. laevis ARID1a using Clustal X and were visualised using Jalview. 
They are displayed with the ARID region overlapping. The similarity score is a representation 
of the degree of conservation for each residue - with 11 being identical and 1 being 
completely unconserved. The heights of the bars correspond to the similarity score.   
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3.2.2 Expression Pattern Of ARID1a During Xenopus Embryogenesis 
To understand what functions ARID1a carries out within the embryo, it was first 
important to know when and where it is expressed throughout development. To 
assess this I carried out quantitative PCR (qPCR) using cDNA synthesised from 
embryos collected at different developmental stages (Fig 3.2 A).  
ARID1a transcripts were detectable throughout embryogenesis. Following 
fertilisation levels of ARID1a mRNA dropped, perhaps indicating decay of 
maternally deposited transcripts. During gastrulation the expression of ARID1a 
increased, and continued to rise until stage 16 and thereafter remained high. 
These experiments were also normalised to Ornithine decarboxylase (ODC) and 
showed a similar trend (data not shown). 
To complement these qPCR data I carried out in situ hybridisation to assess the 
spatial expression pattern of ARID1a. In the fertilised zygote ARID1a transcripts 
were localised to the animal pole, with very little expression visible in the vegetal 
hemisphere (Fig 3.2 B and B'). By mid-gastrulation ARID1a was expressed 
throughout the ectoderm and involuting mesoderm (Fig. 3.2 C and C'). At stage 
19, ARID1a expression was clearly visible in the epidermis and developing neural 
tissue, and at stage 25 had become further restricted, with strong staining in the 
developing eye, brain and migrating streams of neural crest cells (Fig 3.2 D, E). In 
stage 33 embryos ARID1a was highly expressed in cranial structures such as the 
eye, brain, branchial arches and otic vesicles. Staining was also observed in a 
lateral stripe immediately ventral to the somites, though it is unclear what this 
tissue is. Sectioning would reveal whether this is real or background staining, 
and could also clarify where in the embryo ARID1a is expressed during 
gastrulation. 
The yolky vegetal region of early Xenopus embryos stains poorly during the in 
situ hybridisation procedure (Sive et al., 2010). To assess whether the animal 
pole localisation I observed was real or an artefact of the procedure, I bisected 
stage 1 embryos and assayed the expression of ARID1a in either the animal or 
vegetal hemispheres by qPCR (Fig 3.2 G). ARID1a transcripts were twofold 
higher in animal hemispheres than in vegetal hemispheres.   
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Fig. 3.2: Expression Of ARID1a In Xenopus Embryos 
A: qPCR timecourse of ARID1a expression over the first four days of Xenopus 
development. Data are shown normalised to histone H4, and are the average of 3 
independent experiments. 
B-F: In situ hybridisation for ARID1a carried out on different developmental stages. B’ 
and C’ are bisected embryos corresponding to B and C respectively. B, B’ are lateral 
views with the animal pole at the top of the image. C is a vegetal view with the dorsal 
side on the right, C’ is a lateral view with the animal pole uppermost and the dorsal side 
to the right. D is a dorsal view with the anterior to the left. E and F are lateral views 
with the anterior to the left. Staining is ubiquitous until neurula stages (D), when 
ARID1a becomes more strongly expressed in the neural tissue.  From tailbud stages 
onwards (E,F) staining is visible in the migrating neural crest, branchial arches, eyes, 
otic vesicles and cranial regions.. 
G: qPCR of bisected Xenopus zygotes. Expression of ARID1a is higher in the animal  
hemisphere, confirming the localisation observed in B and B’. Data are shown  
normalised to histone H4. Data are representative of two independent experiments. 
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This is less than would be expected based on the apparent difference seen by in 
situ hybridisation, though it does confirm that ARID1a is expressed more 
strongly in the animal hemisphere.  
3.2.3 Depletion of ARID1a Using Translation-Blocking Morpholinos 
To study the function of ARID1a during Xenopus embryogenesis I used a 
translation blocking mopholino to deplete ARID1a protein (ARID1a_TB, designed 
by E. Callery, Smith Lab. Fig. 3.3 A). A 5-base mismatch morpholino was used as a 
control (ARID1a_CO). I first validated these ARID1a morpholinos using in vitro 
transcription-translation reactions (Fig. 3.3 B). The mismatch control 
morpholino had no effect on ARID1a protein synthesis (lane 2) whereas 20 ng 
ARID1a_TB1 caused a marked reduction in ARID1a protein (lane 3). A construct 
lacking the morpholino recognition sequence was unaffected by the translation 
blocking morpholino (lane 4). 
Embryos were injected with either 10 ng ARID1a_CO or 10 ng ARID1a_TB at the 
one cell stage. Those injected with ARID1a_CO appeared phenotypically normal 
throughout development (Fig. 3.3 C, E), whereas embryos injected with 
ARID1a_TB had diminished forebrains and were significantly delayed in their 
development (Fig. 3.3 D). Furthermore, 53% of the ARID1a_TB morphants 
developed oedema around the heart, although the hearts were still beating. 
Injection of a higher dose (20 ng) caused a more severe phenotype: the 
morphants underwent gastrulation and neurulation as normal but failed to 
progress to the tailbud stage. This arrest was coupled with epidermal shedding 
and embryo death (Fig. 3.3 F). This lethal phenotype indicates that ARID1a is 
required for embryogenesis. 
To assess whether ARID1a_TB caused apoptosis I carried out TUNEL assays on 
stage 18 embryos injected with 20 ng of either ARID1a_CO or ARID1a_TB 
morpholino (Fig. 3.4 A-C). As expected, there was no detectable cell death in the 
control morphants (Fig. 3.4 A). Treatment of control morphants with DNase 
prior to the TUNEL assay provided a positive control (Fig. 3.4 B), with staining 
throughout the epidermis.  
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Fig. 3.3: Loss Of ARID1a Was Embryonic Lethal 
A: Diagram showing the position of the control and translation blocking morpholinos relative 
to the ARID1a gene. ARID1a_TB: translation blocking morpholino. ARID1a_CO: mismatch 
control morpholino.  
B: Morpholino validation. ARID1a protein was produced by in vitro transcription-translation 
reactions using biotinylated lysines and then run on a polyacrylamide gel. A western blot using 
streptavidin was then carried out. Due to the large nature of ARID1a only small amounts of 
protein were produced, Lane 1: no plasmid. No ARID1a detectable. Lane 2:  ARID1a plasmid 
with 20 ng ARID1a_CO morpholino. ARID1a detectable as an ~220 kDa band. Lane 3: ARID1a 
plasmid with 20 ng ARID1a_TB morpholino. Marked reduction in the amount of ARID1a 
protein present. Lane 4: an ARID1a plasmid lacking the morpholino recognition sequence. 20 
ng ARID1a_TB has no effect on the expression of this protein.   
C-F: embryos injected with either control or translation blocking morpholinos. All images are 
lateral views with the anterior of the embryo to the left. 
C, E: ARID1a_CO morpholino has no effect on Xenopus development. 
D, F: Injection of 10 ng ARID1a_TB caused oedema around the heart and shortened forebrains 
(D). Injection of 20 ng ARID1a_TB caused embryonic death and epidermal shedding (F). 
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Fig. 3.4 Loss Of ARID1a Caused Widespread Apoptosis 
A-C: TUNEL staining (blue) to show apoptotic cells. There is no apoptosis in control 
morphants at stage 17 (A). Treatment of control morphants with DNaseI created nicked 
ends that could be recognised by the TUNEL antibodies and acted as a positive control (B). 
Injection of embryos with ARID1a_TB caused a large degree of apoptosis, particularly 
around the neural tube and dorsal epidermis (C). 
Embryos were all fixed at the same time. Images are dorsal views with the anterior to the 
left.  
 
 102 
Embryos injected with ARID1a_TB were heavily stained throughout the 
epidermis and neural tube, indicating that there was significant cell death caused 
by this morpholino (Fig. 3.4 C). This large degree of apoptosis could be caused 
by, or be the cause of, the developmental arrest (see section 3.3).  
The apoptosis observed here could be due to toxic, off target effects of the 
morpholino rather than being a consequence of loss of ARID1a. In zebrafish a 
common test for morpholino toxicity is to co-inject a p53 morpholino to abrogate 
the phenotype – however injection of p53 morpholinos into Xenopus embryos 
disrupts mesodermal patterning (Takebayashi-Suzuki, 2003). Instead I 
attempted rescue experiments co-injecting 1 ng ARID1a mRNA along with 20 ng 
ARID1a_TB, however the embryos still underwent epidermal shedding and died. 
As rescue experiments are notoriously difficult, it may be that I did not use the 
correct dose of ARID1a mRNA, or that it did not diffuse efficiently as it is such a 
large transcript. As the mismatch morpholino has no effect on embryonic 
development even at very high doses (50 ng), and the previously demonstrated 
requirement for ARID1a during embryonic development (see Chapter 1) it is 
likely that the embryonic death phenotype observed here is real and not caused 
by a toxic translation blocking morpholino.  
3.2.4: Depletion of ARID1a Using Splice Blocking Morpholinos 
Due to the GC-rich nature of the 5’ UTR of ARID1a it was not possible to create a 
second translation blocking morpholino, so instead I designed a pair of splice 
blocking morpholinos against Intron 2. The draft Xenopus laevis genome was 
searched using ARID1a sequence from the cDNA that I cloned. Two genes 
matched ARID1a, which I termed ARID1aa and ARID1ab. Unusually, the putative 
exon sequences for these two genes were exactly identical, although the intronic 
sequences did vary. The 5’ UTR was identical for both genes, so the translation 
blocking morpholino described earlier would knock down both ARID1aa and 
ARID1ab with equal efficiency. To design splice blocking morpholinos I verified 
the sequence of Intron 2 experimentally by carrying out PCR on genomic DNA 
from 10 pooled embryos. Only one intronic sequence was retrieved from this 
experiment, which matched ARID1aa. Due to the highly unusual nature of the 
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complete exonic conservation between ARID1aa and ARID1ab, and the fact that I 
only retrieved intronic sequence for ARID1aa, I concluded that ARID1ab was 
probably an artefact of the genome assembly and did not represent a real gene. 
Since carrying out this work a new X. laevis genome has been published and only 
ARID1aa is present.  
I designed morpholinos ARID1a_SB1 and ARID1a_SB2 across the Exon 2-Intron 2 
and Intron 2-Exon 3 boundaries of ARID1aa respectively (Fig. 3.5 A). These 
morpholinos had a 2 and 3 base pair mismatch with ARID1ab respectively, and 
so if this allele is expressed they would have a reduced efficiency blocking 
efficient splicing of the mRNA. The morpholinos should cause the retention of 
Intron 2, which would introduce a premature stop codon and lead to a truncated 
protein product. To test this I designed primers spanning Exon2-4 (Fig. 3.5 A) 
and carried out PCR on cDNA derived from stage 20 embryos injected with either 
control or splice blocking morpholinos (Fig. 3.5 B). Stage 20 was chosen because 
by this time maternal transcripts of ARID1a would have been depleted. As 
maternal transcripts not affected by splice blocking morpholinos, carrying out 
the experiment at this later time point prevented false negatives that might be 
found at earlier stages. A band 400 bp in size was amplified from uninjected 
embryos or control morphants, corresponding to correctly spliced ARID1a 
mRNA. Injection of ARID1a_SB1 alone, or together with ARID1a_SB2 reduced the 
intensity of this band, and a new band >1 kb in size was detected. This band 
appears to be slightly smaller than expected, but that may be due to the high 
percentage agarose gel used to visualise the PCR products. Sequencing of this 
product showed that it matched Intron2 of ARID1a and that a premature stop 
codon had been introduced, indicating that these morpholinos are capable of 
depleting ARID1a.  
Injection of ARID1a_SB1 or ARID1a_SB2 alone into stage 1 embryos had no effect 
on development, even at high doses. However, co-injection of ARID1a_SB1 and 
ARID1a_SB2 together caused embryos to develop small heads and ventral 
oedema similar to that observed with low doses of ARID1a_TB (Fig. 3.5 B). 
Additionally, melanocyte migration was mildly affected, with more diffuse 
scattering over the body walls and in the anterior head.  
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Fig. 3.5: Splice Block Morpholinos Knock Down ARID1a 
A: Schematic representation of the first 4 exons of ARID1a. The location of the splice blocking 
morpholinos and the primers (half arrows) used in B are shown.  
B: PCR validation of the splice blocking morpholinos measured at stage 20. Injection of SB1 and 
SB2 caused a decrease in correctly spliced mRNA (lanes 1, 2, 5, 6) and gain of a larger PCR 
product representing mRNA containing the second intron (lanes 3, 4, 7, 8). 
C: Injection of the two control morpholinos SC1 and SC2 had no effect on Xenopus development.  
D: Injection of the two splice blocking morpholinos SB1 and SB2 caused a mild phenotype, with 
oedema around the heart, shortened brain structures and mild melanocyte defects. Embryos are 
lateral views with the anterior to the left. 
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Fig. 3.6 Neural Crest Specification Is Impaired In ARID1a 
Morphants 
(A, B): Dorsal view with the anterior to the left of in situ hybridisation for 
Snai2 on stage 13 embryos injected with 20 ng of either control or 
translation blocking morpholino. Depletion of ARID1a severely reduced 
expression of Snai2 in the neural crest (B). 
(C, D): Anterior view with dorsal side uppermost of in situ hybridisation for 
Sox3 on stage 13 embryos injected with 20 ng of either control or translation 
blocking morpholino. Depletion of ARID1a reduced placodal expression of 
Sox3 (D, white arrows) but did not affect expression in the neural tube. 
(E, F): Dorsal view with the anterior to the left of in situ hybridisation for 
MyoD on stage 14 embryos injected with 20 ng of either control or 
translation blocking morpholino. Depletion of ARID1a had no effect on MyoD 
expression. 
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3.2.5 Assay of Neural and Neural Crest Genes By In Situ Hybridisation 
As ARID1a is strongly expressed in neural tissue, I assayed the effects of knock 
down of ARID1a on neural development. Embryos were injected with either 
control or translation-blocking morpholino and fixed at stage 13. Expression of 
the pan-neural marker Sox3, the neural crest marker Snai2 and the myogenic 
gene MyoD were assessed by in situ hybridisation (Fig. 3.6). Knock down of 
ARID1a caused a striking reduction in Snai2 expression (Fig. 3.6 compare A with 
B), indicating a loss of neural crest cell specification. Expression of Sox3 in neural 
tissue was not affected, but there was a subtle reduction in placodal staining (Fig. 
3.6 D, arrows). MyoD was unaffected by knock down of ARID1a  (Fig. 3.6 E, F). 
These data indicate that ARID1a is required for neural crest specification in 
Xenopus. Carrying out in situs at different developmental stages, and with 
additional specific markers such as twist for neural crest cells and Six1 or Pax8 
for the placodes (Schlosser and Ahrens, 2004) would further explore the extent 
to which ARID1a controls the specification of these tissues. 
Injection of morpholinos into one of the two blastomeres at the 2 cell stage is a 
useful way to explore changes in gene expression – the uninjected side acts as an 
internal control and can help to distinguish between changes in expression level 
and timing. Unfortunately, injection of ARID1a_TB morpholino into one of the 
two blastomeres at the 2 cell stage caused embryonic lethality, perhaps due to 
developmental delay of one half of the embryo during gastrulation.  
3.2.6 Overexpression of ARID1a In Xenopus Embryos 
ARID1a is part of the BAF complex and is predominantly nuclear (Hargreaves 
and Crabtree, 2011). To verify that exogenous ARID1a is localised to the nucleus 
I carried out immunofluorescence on dissociated animal cap cells injected with 
ARID1a mRNA. The commercial antibodies tested were unable to detect 
endogenous or overexpressed Xenopus ARID1a, so instead I injected HA-ARID1a 
mRNA and stained cells with an anti-HA antibody (Fig. 3.7 A-F). Some 
background fluorescence was detected as cytoplasmic speckles in cells from both 
conditions (Fig. 3.7 B, E). Strong nuclear fluorescence was seen in cells from 
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embryos injected with HA-ARID1a mRNA, indicating that exogenous ARID1a is 
nuclear in Xenopus cells (Fig. 3.7 E, F).   
Preliminary experiments injecting ARID1a mRNA into animal blastomeres or 
equatorially had little effect on embryonic development. As ARID1a has been 
suggested to be a Wnt inhibitor I injected ARID1a mRNA into the dorsal 
blastomeres at the 4 cell stage to see whether axis specification was affected (Fig. 
3.7 G, H). Injection of GFP mRNA into the dorsal blastomeres had either no effect, 
or caused a slight bend in the tail (Fig. 3.7 G). Injection of GFP-ARID1a mRNA 
dorsally caused loss of anterior structures including the eyes and cement glands 
(Fig. 3.7 H).  
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Fig. 3.7: ARID1a Overexpression Caudalises Xenopus Embryos 
A-F: Immunofluorescence of dissociated animal cap cells using an anti-HA antibody from embryos 
injected with or without 1 ng HA-ARID1a mRNA. Magnification is 40X. Images are of single cells. 
DAPI was used to visualise nuclei (A, D). Cells from uninjected embryos show some background 
HA staining (B). HA-ARID1a is localised to the nucleus in Xenopus cells (E). Scale bars represent 
20 m.  
G, H: Injection of mRNA into the 2 dorsal blastomeres at the 4 cell stage as shown on the diagram.  
Injection of GFP mRNA had little or no effect on development (G). Injection of GFP-ARID1a mRNA 
caused a loss of anterior head structures (H). Images are lateral views with the anterior to the left.  
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3.3 Discussion 
ARID1a encodes the largest subunit of the BAF complex. The function of ARID1a 
has been briefly investigated in mouse, but no detailed studies exist in 
vertebrates. Experiments with the Drosophila homologue of ARID1a, Osa, showed 
that it was embryonic lethal and that Osa may act as an inhibitor of Wg signalling. 
I have shown that ARID1a is deposited as maternal mRNA in Xenopus and is 
expressed throughout embryogenesis. I have also investigated the effects of loss 
of function and gain of function of ARID1a during Xenopus development.  
3.3.1 Depletion Of ARID1a 
Loss of ARID1a in mice, Drosophila and C. elegans is embryonic lethal (Gao et al., 
2008; Large and Mathies, 2014; Treisman et al., 1997). In Xenopus depletion of 
ARID1a caused developmental arrest and embryonic death at the end of the 
neurula stages (Fig. 3.3). This occurred later than the lethality observed in 
ARID1a–/– mice, which die during gastrulation (Gao et al., 2008). This difference 
is likely due to maternally deposited ARID1a mRNA, and possibly protein. 
Morpholinos are not efficient at inhibiting maternal transcripts, and cannot 
affect proteins that have already been synthesised, and this residual ARID1a may 
be sufficient to delay the onset of embryonic lethality. Without an antibody that 
recognises Xenopus ARID1a it was not possible to test when ARID1a protein was 
significantly depleted. 
The splice blocking morpholinos and translation blocking morpholinos did not 
produce identical phenotypes (Fig. 3.3 and 3.4). Injection of a high dose of splice 
blocking morpholinos caused a similar phenotype to a low dose of translation 
blocking morpholino, although there are differences. The forebrain of embryos 
injected with ARID1a_TB was more severely reduced than those injected with 
ARID1a_SB1+SB2, and the onset of the phenotype occured earlier. A likely 
explanation for the difference between the morpholinos is that ARID1a_TB is 
able to prevent translation of maternally deposited mRNA, whereas ARID1a_SB 
is not. Therefore the splice blocking morpholinos will only deplete zygotically 
transcribed ARID1a, and no phenotype will be evident until the maternal 
transcripts and their protein products have been degraded.  
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The neural crest marker Snai2 was severely reduced in ARID1a morphants (Fig. 
3.5 B). This loss of expression could represent a direct requirement for ARID1a in 
the specification of neural crest cells. Alternatively, neural crest specification is 
sensitive to Wnt signalling with too much or too little signalling leading to loss of 
the neural crest (Ben Steventon and Mayor, 2012; LaBonne and Bronner-Fraser, 
1998). In Drosophila Osa has been implicated as an inhibitor of Wg signalling 
(Collins and Treisman, 2000). If this function exists in vertebrates, then loss of 
ARID1a would cause an increase in Wnt signalling, which would lead to a loss of 
neural crest specification and Snai2 expression.   
3.3.2 Overexpression Of ARID1a 
The Xenopus fatemap is a valuable tool for investigating gene function. By 
injecting mRNA into dorsal blastomeres it is possible to target expression to the 
organiser and future dorsal-anterior structures such as the head. Overexpression 
of ARID1a in the dorsal blastomeres caused a loss of anterior structures, 
indicating that these embryos have been posteriorised. Such phenotypes are 
associated with an increase in Wnt3a signalling (Elkouby et al., 2010), which is 
inconsistent with a possible role of ARID1a as a repressor of Wnt signalling 
(Collins and Treisman, 2000). However, the observed phenotype may not be a 
direct effect of ARID1a on the Wnt signalling pathway, as Wnt antagonists, 
retinoic acid signalling and fibroblast growth factor (FGF) signalling are all able 
to caudalise neural tissue (Kudoh et al., 2002). Secondly, the organiser itself 
contributes to both the notochord and anterior head structures (Sakai, 2007), 
therefore changes in the organiser could lead to a loss of anterior head 
structures. In situ hybridisation of markers for the processes described above 
could discern between these possibilities.   
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Chapter 4: ARID1a Is An Inhibitor Of 
Wnt Signalling 
4.1 Introduction 
The Drosophila homologue of ARID1a, Osa, has been suggested to inhibit the Wg 
pathway in wing disc clones (Collins and Treisman, 2000). Since this discovery 
fourteen years ago, the link between ARID1a and Wnt signalling has remained 
unexplored. As depletion and overexpression of ARID1a in Xenopus caused 
phenotypes consistent with changes Wnt signalling (Chapter 3), I used the 
animal cap assay to directly assess what effects ARID1a has on the Wnt pathway.   
4.2 Results 
4.2.1 The Animal Cap Assay 
The animal pole ectoderm of blastula stage Xenopus embryos, known as the 
animal cap, is an excellent system for studying signalling pathways. Animal 
ectoderm cells are naïve and able to differentiate into many cell types from 
neuronal and mesodermal lineages (Guille, 1999). During development, animal 
pole cells are not exposed to inducing signals and become epidermis “by default”. 
They are, however, competent to respond to a range of signalling molecules such 
as Wnt, activin and FGF (Green et al., 1992; Guger and Gumbiner, 1995; Lamb et 
al., 1993; Larabell et al., 1997b). By excising the animal pole ectoderm prior to 
the MBT and culturing ex vivo, signalling pathways can be directly analysed away 
from the noisy context of the whole embryo. Furthermore, as most genes are not 
expressed before the MBT changes in target gene expression are likely to be 
direct interference with the pathway itself. 
Injection of Wnt8 or -catenin mRNA induces ectopic expression of Organiser 
genes Siamois (Sia) and Xenopus nodal related 3 (Xnr3; (Carnac et al., 1996; 
Nelson and Gumbiner, 1998). I have used these genes as readouts of Wnt 
signalling in animal caps to assess the effects of ARID1a on the Wnt pathway.  
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4.2.2 Depletion Of ARID1a Enhances Wnt Signalling In Animal Caps 
If ARID1a is acting as a repressor of the Wnt pathway in Xenopus then depletion 
of ARID1a should cause an increase in Wnt signalling. Embryos were injected 
with 2 pg Wnt8 mRNA at the one cell stage to stimulate the Wnt pathway, 
together with either 10 ng ARID1a_CO or ARID1a_TB morpholino (Fig. 4.1). 
Animal caps were cut at stage 8 and cultured until stage 10. RNA was then 
extracted, cDNA synthesised and qPCR carried out for the Wnt-target genes Sia 
and Xnr3. Injection of ARID1a_CO or ARID1a_TB alone failed to induce either Sia 
or Xnr3 (Fig. 4.1 A and B). Injection of Wnt8 mRNA alone or together with the 
control morpholino induced transcription to an equal degree, whereas 
concomitant depletion of ARID1a using the translation blocking morpholino 
caused a marked upregulation of both Sia and Xnr3 expression 
I next sought to determine where in the Wnt pathway ARID1a was acting. As 
ARID1a is localised to the nucleus I tested whether depletion of ARID1a was able 
to enhance -catenin mediated stimulation of the Wnt pathway. 200 pg of -
catenin mRNA was co-injected with either 10 ng ARID1a_CO or ARID1a_TB 
morpholino (Fig. 4.1 C and D). Injection of either the mismatch or translation 
blocking morpholinos did not induce expression of Sia or Xnr3, whereas injection 
of -catenin alone or together with ARID1a_CO caused transcription of both 
genes. Co-injection of ARID1a_TB and -catenin mRNA caused an increase in Sia 
and Xnr3 expression compared to -catenin alone. Therefore ARID1a is acting 
downstream of -catenin, as loss of ARID1a caused a de-repression of -catenin-
mediated transcription. These data show that ARID1a is an inhibitor of the Wnt 
pathway. 
Due to large variations between the biological replicates for these experiments 
(this section and the remainder of Chapter 4) it was not possible to carry out 
statistical analysis. However, the same trend was observed for each of the three 
replicates, and normalisation with an alternative housekeeping genes (ornithine 
decarboxylase, ODC) showed the same result (data not shown).   
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Fig. 4.1 Loss Of ARID1a De-Represses Wnt Signalling 
Animal cap assays. Embryos were injected at the 1 cell stage with 2 pg Wnt8 mRNA 
(A,B) or 200 pg -catenin mRNA (C,D). 10 animal caps were cut at stage 8 for each 
treatment and cultured until stage 10, then processed for qPCR. The expression of 
Sia(A,C) and Xnr3 (B,D)  was measured by qPCR.  
Depletion of ARID1a by morpholino injection caused an increase in Sia and Xnr3 
expression. Data are presented normalised to histone H4. Each experiment is 
representative of 3 biological replicates. Due to large variations between biological 
replicates it was not possible to conduct statistical analysis, however the same trend 
was observed in each experiment. The same data were also normalised to ODC and the 
same trend was observed. 
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4.2.3 Overexpression of ARID1a Inhibits Wnt Signalling In Animal Caps 
If ARID1a is an inhibitor of Wnt signalling, then overexpression of ARID1a should 
inhibit expression of Sia and Xnr3. I therefore carried out reciprocal experiments 
to those above, stimulating the Wnt pathway and overexpressing ARID1a. 
Embryos were injected at the one cell stage with 2 pg Wnt8 mRNA with or 
without 2 ng ARID1a mRNA and qPCR carried out. In the absence of Wnt8 mRNA 
no expression of Sia or Xnr3 was detectable (Fig. 4.2 A, B). Co-injection of ARID1a 
mRNA with Wnt8 mRNA caused a 2-fold reduction in Sia expression when 
compared to Wnt8 alone (Fig. 4.2 A). Xnr3 was more markedly affected, with 
expression almost completely abolished by the overexpression of ARID1a (Fig. 
4.2 B). These data show that ARID1a is capable of repressing the Wnt pathway in 
Xenopus.  
As ARID1a was acting below the level of -catenin in depletion experiments, I 
next asked whether overexpression of ARID1a was capable of repressing -
catenin-induced transcription. 200 pg -catenin mRNA was injected into 1 cell 
embryos with or without 2 ng ARID1a mRNA and animal caps processed for 
qPCR. As before, Sia and Xnr3 were only induced when -catenin was present 
(Fig. 4.2 C, D). When ARID1a was co-expressed with -catenin, both Sia and Xnr3 
were almost undetectable. Therefore ARID1a is a Wnt inhibitor in Xenopus, 
acting below the level of -catenin in the pathway.  
4.2.4 N-Terminal Tags Do Not Affect The Biological Activity Of ARID1a 
For several experiments it was beneficial to use forms of ARID1a tagged with 
either HA or GFP. I therefore wanted to assess whether these N-terminal tags 
would affect the activity of ARID1a, and I chose the animal cap assay from 
Section 4.2.3 to test this. Embryos were injected with 200 pg -catenin mRNA 
alongside 2 ng of ARID1a, HA-ARID1a or GFP-ARID1a mRNA. Animal caps were 
cut and the expression of Sia and Xnr3 measured by qPCR. As shown in Fig. 4.3, 
both tagged and untagged forms of ARID1a were equally able to repress -
catenin-mediated transcription in animal caps. I therefore conclude that these N-
terminal tags do not affect the ability of ARID1a to regulate the Wnt pathway.  
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Fig. 4.2 Overexpression of ARID1a Inhibits Wnt Signalling 
Animal cap assays. Embryos were injected at the 1 cell stage with 2 pg Wnt8 mRNA (A,B) or 200 pg -
catenin mRNA (C,D). 10 animal caps were cut at stage 8 for each treatment and cultured until stage 10, 
then processed for qPCR. The expression of Sia(A,C) and Xnr3 (B,D) was measured by qPCR.  
Overexpression of ARID1a by mRNA injection caused loss of Sia and Xnr3 expression. Data are 
presented normalised to histone H4. Each experiment is representative of 3 biological replicates. Due to 
large variations between biological replicates it was not possible to conduct statistical analysis, however 
the same trend was observed in each experiment. The same data were also normalised to ODC and the 
same trend was observed. 
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Fig. 4.3: N-Terminal Tags Do Not Affect The Ability Of ARID1a To 
Repress Wnt Signalling 
Embryos were injected with or without 2 pg Wnt8 mRNA and 2 ng of either ARID1a, GFP-
ARID1a or HA-ARID1a mRNA. Animal caps were cut at stage 8, harvested at stage 10 and 
expression of Sia (A) and Xnr3 (B) was measured by qPCR.  
Both tagged and untagged forms of ARID1a repressed expression of Sia (A) and Xnr3 (B) 
in response to Wnt signalling. Data are presented normalised to histone H4. Data are 
representative of two independent experiments.  
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4.2.5 ARID1a Inhibits The Formation Of Secondary Axes 
As ARID1a inhibited Wnt signalling in the in vitro animal cap assay, I sought to 
confirm this property using the in vivo secondary axis assay. Stimulation of the 
Wnt pathway in the ventral blastomeres at the 4-cell stage induces a Spemann 
organiser, which causes the embryos to develop a complete second body axis.  
Injection of 200 pg -catenin mRNA into a single ventral blastomere at the 4-cell 
stage was sufficient to induce a complete secondary axis (Fig. 4.4 B). GFP mRNA 
was included as a lineage tracer. Co-injection of 2 ng GFP-ARID1a mRNA with 
200 pg -catenin mRNA markedly reduced the secondary axis to structures 
ranging from a slight bulge to a short outgrowth lacking any head structures (Fig. 
4.4 C). Indeed, only 2/135 embryos had a complete secondary axis (Fig. 4.4 D), 
demonstrating that ARID1a is an effective inhibitor of -catenin in this assay. 
Embryos injected ventrally with ARID1a mRNA alone did not exhibit a 
phenotype. 
4.2.6 ARID1a And The Nuclear Localisation Of -Catenin 
As ARID1a is nuclear (Fig. 3.6) and acts downstream of -catenin (Fig. 4.2, 4), 
then it is possible that ARID1a directly interferes with the nuclear accumulation 
of -catenin. To test this I carried out immunofluorescence on animal caps. 
2 ng HA-ARID1a mRNA was injected together with 200 pg -catenin mRNA at the 
one cell stage. Animal caps were cut at stage 8 and cultured until stage 10, then 
immunofluorescence was carried out (Fig. 4.5). Animal caps from uninjected 
embryos showed -catenin staining around the cell periphery corresponding to 
adherens junctions, and no nuclear fluorescence (Fig. 4.5 left column). Injection 
of -catenin mRNA caused some nuclear fluorescence (Fig. 4.5 centre column), 
while co-injection of HA-ARID1a mRNA (right column) had little effect. These 
experiments were inconsistent and I never observed the strong nuclear -
catenin fluorescence described elsewhere (Vincan, 2008), despite using 2 
different antibodies for -catenin. Quantification of nuclear -catenin 
fluorescence using Imaris software revealed no consistent trend between 
experiments.  
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Fig. 4.4 ARID1a Inhibits Secondary Axis Formation 
Overexpression of ARID1a in Xenopus inhibited secondary axis formation.  
A: Diagram showing the injection site on 4-cell embryos. 
B: Injection of 200 pg β-catenin mRNA with 200 pg GFP mRNA as a control produced complete 
secondary axes with defined head structures. Dorsal view with anterior to the left. 
C: Co-injection of 2 ng GFP-ARID1a mRNA with 200 pg β-catenin mRNA significantly reduced 
secondary axis formation. Most embryos displayed similar or lesser secondary axes than the one 
shown. Lateral view with the anterior to the left.  
D: Quantitation of phenotypes from the above experiment. Values are shown as percentages of the 
total samples for each treatment. GFP column represents 21 embryos that were all indistinguishable 
from uninjected sibling embryos.  
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Fig. 4.5: Nuclear Localisation Of -Catenin In The Presence of ARID1a 
Immunofluorescence of stage animal caps cut at stage 8 and fixed at stage 10. Embryos were 
injected at the one cell stage with 200 pg -catenin mRNA with (middle column) or without 
(right hand column) 2 ng ARID1a mRNA.   
The caps were stained with DAPI to visualise nuclei (top row) and an anti--catenin antibody 
(middle row). Injection of -catenin mRNA resulted in nuclear detection of -catenin (central 
image). Co-injection of -catenin and ARID1a mRNA produced ambiguous results, with no 
consistently measurable change in nuclear -catenin. Scale bars represent 100 m. 
Despite using several different -catenin antibodies and fixation conditions, clear nuclear 
localisation of -catenin was not observed consistently as reported elsewhere. Quantification 
of these experiments using Imaris software revealed no consistent trend in the effect of 
ARID1a on -catenin localisation. I am therefore hesitant to make any conclusions from these 
data.  
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These experiments were carried out in parallel to those described in Section 
4.2.4, and induction of Sia and Xnr3 was always observed upon injection of -
catenin mRNA. The difficulties experienced here could be circumvented by 
injecting an epitope-tagged form of -catenin, which would allow the use of 
alternative antibodies that work well for immunofluorescence. 
4.2.7 ARID1a Does Not Regulate FGF or Activin Signalling 
As ARID1a inhibits Wnt signalling, I next asked whether it was able regulate 
other signalling pathways. I therefore carried out animal cap assays using 
fibroblast growth factor (FGF) and transforming growth factor  (TGF) 
signalling. FGF signalling in animal caps induces Brachyury (Xbra), whereas TGF 
signalling causes expression of goosecoid (gsc). I used these target genes to 
assess the effects of overexpression and depletion of ARID1a on FGF and TGF 
signalling.  
Embryos were injected with 50 pg FGF4 mRNA and either 10 ng ARID1a_CO, 10 
ng ARID1a_TB or 2 ng ARID1a mRNA. Animal caps were cut and the expression 
of Xbra measured by qPCR (Fig. 4.6 A). Xbra was not expressed in the absence of 
FGF signalling, and was induced by FGF4. Neither depletion nor overexpression 
of ARID1a affected the level of Xbra expression. Therefore ARID1a does not 
regulate FGF signalling in the early embryo. 
I next carried out similar experiments using Activin as an agonist for the TGF 
pathway. Embryos were injected with either 10 ng ARID1a_CO, 10 ng ARID1a_TB 
or 2 ng ARID1a mRNA and left to develop until stage 8. Animal caps were then 
cut and treated with 16 U/ml activin until sibling embryos had reached stage 11. 
gsc expression was then measured using qPCR. No gsc expression was detectable 
in untreated caps, whereas addition of activin induced gsc (Fig. 4.6 B). Knock 
down or overexpression of ARID1a did not have any effect on gsc expression, 
showing that ARID1a does not affect TGF signalling.  
These experiments indicate that ARID1a specifically regulates Wnt signalling, 
and is not a general inhibitor of signalling-mediated transcription.  
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Fig. 4.6 ARID1a Does Not Affect FGF or TGFb Signalling 
Animal cap assays. 10 caps were cut for each treatment at stage 8 and cultured 
to stage 10, then gene expression measured by qPCR.  
A: Embryos were injected with 50 pg FGF4 mRNA alongside either 10 ng ARID1a 
morpholinos or 2 ng mRNA. Loss or gain of function of ARID1a did not affect 
Xbra expression. 
B: Embryos were injected with either 10 ng ARID1a morpholino or 2 ng mRNA. 
Caps cut at stage 8 were treated with 16 U/ml activin until stage 10. Loss of gain 
of function of ARID1a did not affect expression of gsc. 
Data are presented normalised to histone H4. They were also normalised to ODC 
and exhibited a similar trend. Data are representative of 3 independent 
experiments however due to large variations between biological replicates it 
was not possible to carry out statistical analysis.  
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4.3 Discussion 
4.3.1 ARID1a Inhibits The Wnt Pathway 
Using both loss and gain of function approaches I have shown that ARID1a is an 
inhibitor of the Wnt pathway in Xenopus. This is the first time that ARID1a has 
been demonstrated to affect Wnt signalling in vertebrates, although previous 
work in Drosophila has suggested that Osa inhibits Wg signalling (Collins and 
Treisman, 2000). This work used the Gal4-UAS system to clonally overexpress 
Osa in the wing disc and then measure expression of the target gene Nubbin by in 
situ hybridisation. However, it is not possible to tell whether Osa is directly 
repressing Wg in these experiments: change in expression of Osa could result in 
differences in Wg-regulating proteins, which would in turn give rise to the 
observed changes in Nubbin. The animal cap assay I used in my experiments 
measured gene expression shortly after the onset of zygotic transcription, 
therefore there is insufficient time for changes in Wnt-regulatory gene 
expression to take effect. Instead, the observed changes in Wnt-target gene 
expression were likely due to direct interaction of ARID1a with Wnt pathway 
components or by changing the chromatin state of Wnt-responsive genes.  
ARID1a could repress Wnt signalling by mediating the export of -catenin from 
the nucleus. My attempts to address this possibility remain inconclusive (Fig. 
4.5). ARID1a is thought to shuttle between the nucleus and cytoplasm (Guan et 
al., 2012), and could therefore act as a chaperone to facilitate nuclear export of -
catenin. Alternatively ARID1a could be acting as part of the BAF complex to 
create a repressive chromatin state that prevents the transcription of -catenin 
target genes. For more detail see section 7.1. 
Other members of the BAF complex are regulators of Wnt signalling. Loss of 
SNF5 in mice is sufficient to activate the Wnt pathway (Mora-Blanco et al., 2014). 
This observation is in agreement with the current work, indicating that the BAF 
complex acts to repress Wnt signalling. Conversely, Brg1 binds to -catenin and 
enhances transcription (Barker et al., 2001; Griffin et al., 2011). How two 
proteins that are part of the same complex can have opposite effects on Wnt 
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signalling is not known, however the modular composition of the BAF complex 
may provide an answer. It is possible that the presence of either ARID1a or SNF5 
changes BAF complexes into Wnt repressors, and without them Brg1 is capable 
of promoting -catenin-mediated transcription. As different conformations of the 
BAF complex exist within the same cell (Wang et al., 2004b), it is possible that 
Wnt signalling causes a switch between two BAF complexes at target promoters. 
It is also possible that a switch between ARID1a and ARID1b containing 
complexes at Wnt-target gene promoters could act to regulate gene expression 
(see Chapter 7 for further discussion). Detailed ChIP time course experiments 
could provide evidence to support or refute this model.  
4.3.2 ARID1a Does Not Affect FGF or TGF Signalling In Early Embryos  
ARID1a is an enhancer of steroid hormone signalling (Inoue et al., 2002) and an 
inhibitor of the Wnt pathway (Collins and Treisman, 2000); this work). I 
therefore tested whether ARID1a was able to regulate other signalling pathways. 
Data from animal cap experiments showed that ARID1a did not affect either the 
FGF or TGF signalling pathways (Fig. 4.6). The latter result is intriguing, as Brg1 
is required for maximal TGF responses in tissue culture (Xi et al., 2008). In this 
system, Brg1 and ARID1b form a complex with Smad3 to activate transcription. 
It would be interesting to see whether ARID1b is able to regulate TGF signalling 
in Xenopus.  
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Chapter 5: Mass Spectrometry 
Approach To Identify Interactors of 
ARID1a 
5.1 Introduction 
In order to investigate the molecular mechanism by which ARID1a was acting I 
performed a mass spectrometry screen to identify interacting proteins. This 
screen was designed and carried out in collaboration with L. Herhaus and G. 
Sapkota at the MRC Protein Phosphorylation Unit, University of Dundee. 
Preliminary experiments using Xenopus embryo lysate were inconclusive, so 
instead I expressed Xenopus ARID1a in Human Embryonic Kidney 293 (HEK293) 
cells and looked for conserved interactors.   
HEK cells were used because they have an intact and well-characterised Wnt 
signalling pathway (Gujral and MacBeath, 2010). Additionally, the commercially 
available T-REx cells offered a convenient system for generating cells lines stably 
expressing an inducible form of GFP-tagged ARID1a, which was desirable for the 
mass spectrometry screen (see section 5.2.2). An N-terminal GFP tag was used 
for several reasons: firstly, no antibodies tested recognised endogenous Xenopus 
ARID1a; secondly, GFP-ARID1a represses Wnt signalling to the same extent as 
untagged ARID1a (Fig. 4.3); finally, GFP tags have been used extensively by the 
Sapkota lab and they have generated a comprehensive list of GFP-interacting 
proteins that can be discarded from any pull down experiment. Together with 
the Sapkota lab I used these tools to identify interaction partners for Xenopus 
ARID1a. 
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5.2 Results 
5.2.1 Xenopus ARID1a Represses Wnt Signalling in HEK293 Cells 
It was first important to test whether HEK293 cells were a suitable system for 
the mass spectrometry screen. ARID1a was detected by PCR and western blot in 
HEK293 cells (Fig. 5.1 A, B) indicating that ARID1a is physiologically relevant to 
these cells.  
Next, I established that Xenopus GFP-ARID1a was capable of inhibiting Wnt 
signalling in HEK293 cells using the TOPFLASH dual luciferase reporter assay 
(see Section 2.2.10). Cells were transfected with GFP or Xenopus GFP-ARID1a 
alongside the luciferase constructs, and then treated with either Wnt-
conditioned media (WCM, a gift from K. Dingwell) or control L-cell-conditioned 
media (LCM). Transfection of GFP-ARID1a caused a 5-fold reduction in Wnt 
activity compared to GFP, showing that Xenopus ARID1a is capable of inhibiting 
Wnt signalling in HEK293 cells (Fig. 5.1 C). No luciferase activity was detected 
using the control FOPFLASH plasmid (Fig. 5.1 D).  
5.2.2 Generation and Characterisation of Inducible GFP-ARID1a HEK293 Cells 
While transfection is a very efficient way of expressing a gene of interest in 
tissue culture cells, it often leads to very high and heterogeneous expression. 
Stable cell lines have lower heterogeneity in expression of introduced genes, and 
also provide a convenient tool for large-scale work. Therefore HEK293 cells were 
generated that expressed GFP-ARID1a under the control of a doxycycline-
inducible promoter. The strategy used is outlined in Fig. 5.2 A.   
HEK293 T-rex cells constitutively express the tetracycline repressor (TetR) 
protein, which in the absence of doxycycline binds to the TetO2 promoter and 
represses transcription (Hillen and Berens, 1994). Doxycycline allosterically 
inhibits TetR, allowing transcription from the TetO2 promoter (Fig. 5.2 B). T-rex 
cells were transfected with GFP-ARID1a and Flp recombinase and selected for 
using blasticidin and hygromycin B. These cells were called FRT/GFP-ARID1a.  
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Fig. 5.1: Xenopus ARID1a Inhibits Wnt Signalling In HEK Cells 
A: PCR of GAPDH and ARID1a using cDNA synthesised from HEK total RNA. 
B: Western blot showing expression of endogenous ARID1a in HEK cell lysates. 
β-tubulin is shown as a loading control. 
C: TOPFLASH analysis of HEK cells. Cells were transfected with plasmids encoding 
either GFP or GFP-ARID1a (Xenopus) alongside Renilla luciferase and the TOPFLASH 
reporter plasmid. The cells were treated for 16 hours with Wnt3a-conditioned media 
(WCM) to induce Wnt signalling, or L-cell conditioned media (LCM) as a negative 
control. Luciferase activity was then measured using the Dual Luciferase Assay Kit. 
GFP-ARID1a significantly reduced WCM-induced luciferase activity. Data are from 
three experiments. 
D: FOPFLASH luciferase activity. Experimental set up is identical to C, except that the 
FOPFLASH reporter was used in place of the TOPFLASH reporter. As expected, no 
FOPFLASH activity was observed under any conditions. 
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Fig. 5.2: Generating FRT/GFP-ARID1a Cells 
 
A: Schematic representation of parental T-rex cells, recombination with transfected 
plasmid and the resultant FRT/GFP-ARID1a cells. Recombination between the FRT 
sites causes insertion of GFP-ARID1a and the Hygromycin B resistance gene, while 
simultaneously disrupting the Zeocin resistance gene. FRT/GFP-ARID1a cells 
constitutively express TetR, Blasticidin and Hygromycin B resistance genes, and 
express GFP-ARID1a in response to doxycycline. 
B: Schematic representation of the doxycycline inducible system.  In the absence of 
doxycycline the TetR protein binds to the pO2 promoter that regulates GFP-ARID1a 
expression and represses transcription. Doxycycline allosterically inhibits TetR, 
preventing it from binding the promoter and allows GFP-ARID1a to be expressed. 
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In order to confirm that FRT/GFP-ARID1a cells were able to express GFP-ARID1a 
they were treated with doxycycline overnight and then imaged using 
fluorescence microscopy. However, no fluorescent signal was detectable using a 
conventional inverted microscope, so I instead used a confocal microscope (Fig. 
5.3). Nuclei were visualised by staining the cells with DRAQ5 (Fig. 5.3 A, D). In 
the absence of doxycycline, no GFP fluorescence was detectable (Fig. 5.3 B) 
whereas cells treated with doxycycline showed weak nuclear signal (Fig. 5.3 E). 
This localisation is consistent with my previous findings in Xenopus. Treatment 
with doxycycline sometimes caused the cells to adopt a more spindle-shaped 
morphology (compare A with D), which could be due to changes in gene 
expression caused by an increase in ARID1a expression.  
To verify that full-length GFP-ARID1a was being produced, and to determine the 
onset of expression, a western blot time course was carried out (Fig. 5.4 A). An 
~250kDa band corresponding to GFP-ARID1a was detectable after 3 hours of 
treatment with doxycycline. At subsequent time points the expression of GFP-
ARID1a increased, along with the appearance of an ~25 kDa band. The initiator 
methionine of ARID1a is cleaved (Gauci et al., 2009), so this smaller band could 
represent a degradation product of the fusion protein. These results show that 
FRT/GFP-ARID1a cells contain a stable insert of Xenopus GFP-ARID1a that is 
expressed only in the presence of doxycycline. However, it is notable that these 
cells grow much more slowly than the parental HEK T-rex cells, even in the 
absence of selective antibiotics – a phenotype consistent with the ability of 
ARID1a to repress the cell cycle (Nagl et al., 2007). Thus while no GFP-ARID1a 
was detected in the absence of doxycycline it is possible that there is some basal 
expression of GFP-ARID1a in these cells.  
Finally I tested whether doxycycline treatment was capable of inhibiting Wnt 
signalling in FRT/GFP-ARID1a cells using the TOPFLASH assay (Fig. 5.4 B). Cells 
treated with doxycycline showed a two-fold reduction in luciferase activity when 
compared with untreated cells, indicating that GFP-ARID1a was expressed at 
sufficient levels to inhibit Wnt signalling.  
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Fig. 5.3 Live Imaging Of FRT/GFP-ARID1a Cells 
FRT/GFP-ARID1a cells treated with (D-F) or without (A-C) doxycycline. Nuclei were 
visualised using DRAQ5 (A, D). Treatment of cells with doxycycline induced GFP-ARID1a 
expression (E) which was localised to the nucleus (F).  
Scale bars represent 50 m. 
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Fig. 5.4: FRT/GFP-ARID1a Cells Respond to Doxycycline 
A: FRT/GFP-ARID1a cells were treated with 20 ng/ml docycyline as indicated and 
then processed for western blot. GFP-ARID1a expression began at 3 hours and was 
maximal from 16 hours onwards. Anti-sheep antibody was used 1:2000. 
B: TOPFLASH assay in FRT/GFP-ARID1a cells. Cells were transfected with the 
TOPFLASH reporter and Renilla luciferase plasmids. The cells were treated with or 
without 20 ng/ml doxycycline and either L-cell conditioned media (LCM) or Wnt 
conditioned media (WCM) overnight. Luciferase activity was measured using the 
Dual Luciferase Assay kit. Treatment with doxycycline caused an approximately 2 
fold reduction in luciferase activity. While this reduction is less than observed using 
transfected plasmids (Fig. 5.1) the reduction is still statistically significant.  
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5.2.3 The Mass Spectrometry Screen 
5.2.3.1 Carrying Out The Screen 
The original strategy for the mass spectrometry screen was to induce FRT/GFP-
ARID1a cells with doxycycline and isolate GFP-ARID1a to use produce as bait to 
probe Xenopus embryo lysate for interaction partners. FRT/GFP-ARID1a cells 
were treated with doxycycline and GFP-ARID1a was immunoprecipitated using 
GFP-TRAP beads. The precipitate was then incubated with stage 9 Xenopus 
lysate, and proteins analysed by mass spectrometry. Stage 9 was chosen because 
it corresponded to the time the animal cap experiments in chapter 4 were 
carried out. Components of the BAF complex were identified from this 
experiment, however all of the remaining proteins were either cytoskeletal, 
ribosomal or unidentifiable (see Appendix for complete list of proteins). Trying 
to discern which proteins represented real interactions from this noisy system 
was not possible, so instead I decided to examine interactions between Xenopus 
GFP-ARID1a and human proteins within FRT/GFP-ARID1a cells.  
The experimental approach for the mass spectrometry screen is outlined in Fig. 
5.5. FRT/GFP-ARID1a cells were treated with doxycycline for 16 hours, as this 
was the time from which GFP-ARID1a was maximally expressed (Fig. 5.4 A). As a 
negative control, FRT/GFP cells were used in parallel, which express GFP in 
response to doxycycline (developed in the Sapkota Lab). GFP or GFP-ARID1a was 
then immunoprecipitated using an anti-GFP antibody in the presence of the 
weak cross-linking agent DSP. The isolated complexes were run on a gradient gel 
and visualised using colloidal blue staining (Fig. 5.6 A). Immunoprecipitation of 
GFP from FRT/GFP cells pulled down the bait protein (white arrowhead) and 
very few other interacting proteins, demonstrating that the antibody against is 
GFP specific and that GFP does not bind to many proteins within the cell. 
Immunoprecipitation of GFP-ARID1a from FRT/GFP-ARID1a cells yielded the 
bait (black arrowhead) along with many other bound proteins. To avoid masking 
of interactors by particularly abundant peptides the gel was cut into 14 pieces 
(Fig. 5.6 B) and each one individually processed for mass spectrometry analysis. 
This was repeated for a final of 3 biological replicates.  
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Fig. 5.6: Visualisation Of ARID1a Interacting Proteins 
A: Immunoprecipitation of GFP or GFP-ARID1a from FRT/GFP or FRT/GFP-ARID1a 
respectively, run on a 4-12% gradient gel and stained using colloidal blue. The GFP bait 
(white arrow) and GFP-ARID1a bait (black arrow) are clearly visible. 
B: The GFP-ARID1a lane was cut into 14 pieces as indicated, and each one processed 
separately. 
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5.2.3.2 Analysis Of Identified Proteins 
Each MALDI-TOF run yielded over 1000 proteins with matching peptides. To 
remove any erroneously identified proteins the following computational filtering 
steps were carried out. Firstly, proteins known to bind to GFP were subtracted 
from the dataset. This list has been compiled by the Sapkota lab from many 
experiments and represents a comprehensive GFP interactome (see Appendix). 
Secondly, all proteins with a mascot score of less than 70 were discarded. The 
mascot score is a measure of the false discovery rate (FDR), and a score of 70 
represents an FDR of 5% (www.matrixscience.com). Finally, the remaining 
proteins were cross-referenced with the Contaminant Repository for Affinity 
Purification database (CRAPome), and likely contaminants were removed (for 
list of identified proteins see Appendix).  
From the three screens I identified 182, 70 and 54 proteins that bind to GFP-
ARID1a respectively (see Appendix for protein lists). Gene Ontology (GO) 
analysis of the pooled proteins was then carried out using the Panther database 
(Fig. 5.7 A). 26.7% of the identified proteins are involved in transcriptional 
regulation, consistent with the role of the BAF complex as a chromatin 
remodeller. 20.5% of the proteins were characterised as having structural 
molecule activity. These proteins are predominantly cytoskeletal and ribosomal, 
and probably represent non-specific interactions with ARID1a. Finally, 34.1% of 
the total protein pool was annotated as proteins with binding activity. Of these 
proteins, over half have chromatin or nucleic acid-binding properties, which is a 
good indicator that they may be involved in the function of the BAF complex.  
The three datasets were then overlaid to identify proteins that were common to 
all three mass spectrometry replicates (Fig. 5.7 B). This resulted in a list of 34 
core proteins, which are displayed in Table 5.1. All of the BAF complex 
components were present, indicating that Xenopus ARID1a is capable of being 
incorporated into mammalian BAF complexes. This is also a good indicator that 
the mass spectrometry experiments have produced useful data, as the expected 
proteins are present as the most abundant peptides.  
 135 
 
 
129
15
2
3411
10
8
Set 1
Set 2
Set 3
A
B
7.1%
26.1%
4.8%
20.5%
34.1%
2.3%
2.0%
0.6%
1.1%
1.4%
Fig. 5.7: Mass Spectrometry Identifies Interactors of ARID1a in 
HEK293 Cells 
A: Gene Ontology analysis for all the 3 mass spectrometry experiments after filtering.  
Generated using the Panther Classification System. 
B: Overlay of the 3 datasets. 34 proteins are common to all 3 replicates.   
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Table 5.1: Core Interactors Of ARID1a As Identified By Mass 
Spectrometry 
The 34 proteins core interactors identified by mass spectrometry. The summary of 
function and localisation are derived from Uniprot, and the ranking is generated 
from average mascot scores.  *: these proteins have both cytoplasmic and nuclear 
localisation. They are organised by the predominant compartment.  
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5.2.3.3 Proteins Of Interest  
Of the 34 proteins present in all three screens, four are of particular interest. 
SNRPA1 is a component of the splicing machinery. As the BAF complex interacts 
with splicing factors the presence of SNRPA1 in this screen agrees with what is 
already known (Batsché et al., 2005). Whether the BAF complex influences the 
splicing of Wnt target genes or of Wnt pathway components has not been 
investigated, so further studies are required to explore this possibility.  
BCL7a and BCL7c are uncharacterised proteins and that have not appeared in 
any other mass spectrometry screen carried out by the Sapkota lab. BCL7a is 
present in only 9 out of 411 experiments in the CRAPome database, while BCL7c 
is present in 10. These two proteins are therefore highly likely to be bona fide 
interactors of ARID1a, and may have functional roles in the BAF complex. 
DDX5 is present in the nucleus and has been implicated in Wnt signalling (Yang 
et al., 2006b). It is therefore a strong candidate for a co-regulator of the Wnt 
pathway with ARID1a, and I chose to investigate DDX5 further. I also chose 
BCL7a as a second candidate, as nothing is known about it. 
5.2.4 Verifying The Interaction Between ARID1a, BCL7a and DDX5  
I cloned BCL7a and DDX5 from Xenopus cDNA into pCS2+ vectors containing an 
N-terminal myc tag. HEK cells were co-transfected with either myc-BCL7a or 
myc-DDX5 together with GFP or GFP-ARID1a, and immunoprecipitations carried 
out using an anti-GFP antibody (Fig. 5.8). GFP-ARID1a successfully precipitated 
both BCL7a (Fig. 5.8 A) and DDX5 (Fig. 5.8 B), while GFP alone could not. These 
experiments verify the mass spectrometry screen and identify BCL7a and DDX5 
as interactors of ARID1a. Both BCL7a and DDX5 were expressed more strongly 
when co-transfected with GFP-ARID1a compared with GFP (Fig. 5.8 Input lanes). 
Due to the large molecular weight of the GFP-ARID1a plasmid the molar ratio of 
BCL7a/DDX5:GFP-ARID1a was likely higher than that for GFP, which would 
result in stronger expression. While this difference could explain why GFP did 
not immunoprecipitate BCL7a or DDX5, GFP is expressed much more strongly 
than GFP-ARID1a in these experiments. Therefore if an interaction between GFP 
and BCL7a or DDX5 existed it is probable that it would have been detected.  
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Fig. 5.8 Co-Immunoprecipitation Of GFP-ARID1a, BCL7a and DDX5 
Co-immunoprecipitation experiments carried out in HEK cells. Cells were transfected with 
plasmids encoding Xenopus proteins as indicated and left overnight before harvesting. 
A) Interaction between GFP-ARID1a and myc-BCL7a. myc-BCL7a is precipitated by GFP-ARID1a 
(centre panel, rightmost lane) but not GFP (centre panel, 3rd lane). Note that there is more myc-
BCL7a in the input lane for cells transfected with GFP-ARID1a than GFP: this is probably due to 
the large size of the GFP-ARID1a plasmid affecting the molar ratio of the two transfected 
plasmids. 
B) Myc-DDX5 is precipitated by GFP-ARID1a (centre panel, rightmost lane) but not GFP (centre 
panel, 3rd lane). Note that there is more myc-DDX5 in the GFP-ARID1a input lane than the GFP 
input lane for the reasons described in (A).  
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5.3 Discussion 
5.3.1 The Mass Spectrometry Approach 
As mentioned above, the initial approach for the mass spectrometry screen was 
to identify proteins from Xenopus embryo lysate using bait purified from 
FRT/GFP-ARID1a cells. This approach was used rather than injecting embryos 
with GFP-ARID1a mRNA because mRNA does not diffuse well in the embryo, and 
using purified bait eliminated any heterogeneity that would have been 
introduced by microinjection. 
However, analysis of the Xenopus mass spectrometry proved problematic. 
Matching of peptides to the translatome is stringent, and as the X. laevis genome 
is still incomplete the translatome is of poor quality. It is therefore possible that 
real proteins of interest are present within the dataset, but are not 
computationally accessible at this time. A second difficulty with carrying out 
mass spectrometry in Xenopus is the high abundance of “sticky” yolk proteins 
that bind to bait non-specifically in many experiments. Although efforts were 
made to minimise the presence of yolk within embryo lysates, a large amount of 
non-specific binding occurred when lysates were incubated with GFP.  
These two issues combined meant that extracting useful data from this mass 
spectrometry experiment was not possible, and instead I chose to look for 
proteins in FRT/GFP-ARID1a cells. This new approach had certain caveats. This 
screen was testing for interactions between Xenopus bait and human proteins 
that physiologically would never take place. However, as Xenopus ARID1a was 
able to inhibit Wnt signalling in FRT/GFP-ARID1a cells (Fig. 5.1), then functional 
interactions were taking place between frog and human proteins. Therefore the 
proteins identified in this screen could facilitate the ARID1a-mediated 
repression of Wnt signalling observed in this thesis. 
Due to the nature of this cross-species approach some interaction sites may not 
be conserved, and therefore some binding partners may have been missed. The 
proteins identified here are likely to be the most conserved interactors, which 
could provide insight in to the evolution of the BAF complex. 
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5.3.2 Mass Spectrometry Hits 
5.3.2.1 The BAF Complex 
Each BAF complex component was found in the core 34 proteins, which is an 
excellent indicator that Xenopus GFP-ARID1a is incorporated into a functional 
complex in FRT/GFP-ARID1a cells. ARID1b was not identified, which is 
consistent with the fact that ARID1a and ARID1b exist in mutually exclusive BAF 
complexes (Wang et al., 2004b). DPF1, a member of the neural-specific BAF 
complex, was present in the dataset. This is to be anticipated, as despite their 
name HEK cells are actually derived from a neural lineage (Shaw et al., 2002).  
A histone H3 protein, HIST2H3A, was identified in all 3 experiments. While 
association of GFP-ARID1a with histones is expected, eight other histones were 
removed from the dataset during the filtering process. Whether this particular 
histone represents a preferred binding partner for ARID1a is not clear.  
5.3.2.2 Actin Binding Proteins 
6 proteins in the list have actin binding properties, and all of them are localised 
to the cytoplasm. It is therefore tempting to dismiss them as cytoskeletal 
contaminants, and indeed that may well be the case. However, the BAF complex 
binds to filamentous actin (F-actin; (Rando et al., 2002). F-actin is required for 
PolII transcription (Yoo et al., 2006), while monomeric actin is an essential 
subunit for several nuclear complexes, including the BAF complex (Zhao et al., 
1998). It is therefore feasible that interactions with actin-binding proteins 
facilitates binding of the BAF complex to actin, though the exact functional 
significance of this interaction remains unknown.  
5.3.2.3 Possible Contaminant Proteins 
7 proteins are likely to be contaminants. Flotillin 1 (FLOT1) and FLOT2 are 
localised to the plasma membrane where they create a microdomain that 
mediates endocytosis (Otto and Nichols, 2011). As flotillins associate with the 
cytoskeletal cortex (Ludwig et al., 2010), and cytoskeletal proteins are often 
contaminants in mass spectrometry experiments (Gingras et al., 2007), then it is 
probable that FLOT1 and 2 are not physiologically associated with ARID1a. 
 141 
Peripherin (PRPH) is an integral membrane glycoprotein that is required for 
photoreceptor morphology (Boon et al., 2008). Similar to FLOT1 and FLOT2, the 
membrane localisation of PRPH makes it an unlikely binding partner for ARID1a. 
However, ARID1a has been reported in the cytoplasm at low levels (Guan et al., 
2012). While unlikely, it is therefore possible that these proteins interact 
physiologically.  
RPS18 and RPL12 are ribosomal subunits, and are most likely bound to nascent 
GFP-ARID1a that is still being translated. Twelve other proteins of the RPS and 
RPL families were removed when the dataset was compared to the CRAPome, 
indicating that such ribosomal proteins are common in mass spectrometry 
experiments and should be treated with caution. Likewise, PPIA is a chaperone 
involved in protein folding (Liu et al., 2013) and PSMD2 is a proteasome 
component. Both are likely to be involved in the synthesis and turnover of 
ARID1a rather than its cellular function. Therefore these proteins are not likely 
to be co-effectors of ARID1a. 
5.3.3 Verification Of The Mass Spectrometry Screen 
The mass spectrometry screen identified an interaction between Xenopus 
ARID1a and human BCL7a and human DDX5. This interaction was verified by co-
immunoprecipitation between Xenopus proteins (Fig. 5.8). Ideally the reciprocal 
experiment of immunoprecipitating myc-tagged BCL7a or DDX5 and blotting for 
GFP-ARID1a would have been carried out. Preliminary experiments did not 
detect GFP-ARID1a, although the protocol could have been optimised further. 
Verification of the interaction by a third method such as proximity ligation 
assays (PLA) would also have been beneficial. However, as both BCL7a and DDX5 
were identified in all three mass spectrometry replicates, and they co-
immunoprecipitated with ARID1a, I am confident that these two proteins are 
bona fide interactors of ARID1a. I spent the remainder of my PhD investigating 
the role of BCL7a and DDX5 in the regulation of the Wnt pathway.   
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Chapter 6: Characterisation of BCL7a 
and DDX5 In Xenopus 
6.1 Introduction 
6.1.1 BCL7a 
B-cell CLL/lymphoma protein 7a (BCL7a) was identified as a three-way 
translocation fusion gene in a Burkitt Lymphoma cell line (Zani et al., 1996). In 
this instance, the first exon of BCL7a had been replaced with the first exon of 
Myc, though whether a protein was produced was not tested. Since then, loss of 
BCL7a has been correlated with aggressive lymphoma, indicating that BCL7a is a 
anti-malignancy factor (Blenk et al., 2007; Carbone et al., 2008). In adult humans 
BCL7a expression is restricted to lymphocytes lineages (Ramos-Medina et al., 
2013), although the expression pattern during embryogenesis has not been 
tested in any species. To date, no biochemical or functional investigation of 
BCL7a exists. 
6.1.2 DDX5 
DEAD-box helicase 5 (DDX5), also known as p68, is an RNA helicase with diverse 
functions (Janknecht, 2010). DDX5 binds to the spliceosome and mediates 
alternative splicing (Guil et al., 2003; Lin et al., 2005). Its RNA helicase ability is 
also required for ribosome biogenesis (Jalal et al., 2007) and Drosha-mediated 
micro-RNA processing (Fukuda et al., 2007). DDX5 promotes transcription by 
binding to to CREB-binding protein (CBP) and PolII (Rossow and Janknecht, 
2003). Like ARID1a, DDX5 positively regulates expression of oestrogen receptor 
(ER) targets (Watanabe et al., 2001), and can act as a cofactor for several other 
transcription factors such as MyoD and p53 (Bates et al., 2005; Caretti et al., 
2006).  
DDX5 is an activator of -catenin. DDX5 and -catenin physically interact and 
bind to Wnt target gene promoters (Clark et al., 2013; Shin et al., 2007). 
Furthermore, phosphorylation of DDX5 by platelet-derived growth factor (PDGF) 
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is sufficient to cause nuclear localisation of -catenin and subsequent 
transcription (Yang et al., 2006b). Consistent with a role in Wnt signalling, 
overexpression of DDX5 together with -catenin causes an increase in 
TOPLFASH activity over -catenin alone (Shin et al., 2007). However one report 
showed that DDX5 does not promote nuclear localisation of -catenin, nor does it 
activate the Wnt pathway. Furthermore, siRNA-mediated knock down of DDX5 
had no effect on Wnt signalling (Stucke et al., 2008). Why this study differs from 
other work in the field is unclear, though despite the controversy the proposed 
role of DDX5 as a regulator of -catenin makes it an interesting protein for my 
research. 
6.2 Results 
6.2.1 Expression Pattern of BCL7a and DDX5 
First I assessed the expression of BCL7a and DDX5 during Xenopus development. 
qPCR was carried out using cDNA collected from a range of embryonic stages 
(Fig. 6.1). BCL7a was present as maternally deposited mRNA (Fig. 6.1 A). 
Expression was maintained at low levels throughout embryogenesis except for a 
spike during gastrulation, where BCL7a expression was 3 fold higher than at 
other stages. DDX5 mRNA was also expressed maternally (Fig. 6.1 B). DDX5 
levels showed little change until stage 35, when a two-fold increase in expression 
was observed.  
The expression of both genes was then visualised using in situ hybridisation. 
Unfortunately no BCL7a staining was observed, which may be due to its low 
expression levels during development. DDX5 was ubiquitous at stage 11 (Fig. 6.1 
C). The vegetal hemisphere was not stained in this image, however DDX5 
expression was observed in samples that were allowed to develop further.  
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Fig. 6.1 Expression Pattern Of BCL7a and DDX5 
A, B: qPCR for BCL7a (A) and DDX5 (B) during Xenopus development. Data are 
normalised to stage 1. Representative of two independent experiments. 
C-E: In situ hybridisation for DDX5 on Xenopus embryos.  
C: Lateral view of stage 11 embryo, with the animal pole uppermost. DDX5 was 
ubiquitous throughout the ectoderm. 
D: Lateral view of a stage 25 embryo with the anterior to the left. DDX5 was 
expressed in the eye and neural crest streams, with faint staining in the posterior 
tailbud region.  
E: Lateral view of a stage 32 embryo, with the anterior to the left. DDX5 was 
expressed throughout the cranial region, including eyes, otic vesicle and branchial 
arches. Unfortunately no staining was observed using a BCL7a probe.  
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During the tailbud stage DDX5 was present in the eye and migrating streams of 
neural crest cells (Fig. 6.1 D), and in the tailbud. At stage 33 DDX5 was expressed 
throughout the head including the eye and otic vesicles (Fig. 6.1 E). The tailbud 
staining was also present at this stage. 
The expression pattern of DDX5 is remarkably similar to that of ARID1a 
(compare with Fig. 3.2). However, there are subtle differences. Firstly, at stage 
25 DDX5 was visible within the otic vesicle whereas ARID1a staining was not 
detected in the vesicle until later stages. Secondly, the branchial arches are 
clearly visible in embryos stained for ARID1a expression, but are less well 
demarcated by the DDX5 probe. The tight co-localisation of ARID1a and DDX5 
transcripts suggests a functional relationship between the two genes.  
6.2.2 Overexpression of BCL7a and DDX5 Results In Different Phenotypes 
To test whether ARID1a, DDX5 and BCL7a co-localised within the cell I carried 
out immunofluorescence on dissociated animal cap cells. Embryos were injected 
with 2 ng HA-ARID1a and 250 pg of either myc-BCL7a or myc-DDX5 and 
harvested at stage 8 (Fig. 6.2 C-L). These experiments showed that exogenous 
BCL7a and DDX5 were localised to the nucleus, as seen by overlapping 
fluorescence with DAPI. ARID1a co-localised with both BCL7a and DDX5, 
supporting the in vitro data from Chapter 5 that these proteins physically 
interact.  
I then overexpressed BCL7a and DDX5 in Xenopus by injecting mRNA into the 
two dorsal blastomeres at the 4-cell stage (Fig. 6.2). Injection of 250 pg BCL7a 
mRNA had little effect on embryo development (Fig. 6.2 A). Some embryos 
developed mild oedema around the heart or exhibited a slight developmental 
delay, but otherwise developed normally. In contrast embryos injected with 250 
pg DDX5 mRNA exhibited severe defects (Fig. 6.2 B). These embryos developed 
short body axes and were significantly delayed in their development. This 
phenotype falls into the “shortened axis” synphenotype group, and is similar to 
those caused by loss of organiser genes such as Lim1 and Xnr3 (Rana et al., 
2006). 
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Fig. 6.2: Co-Localisation Of DDX5 and BCL7a and ARID1a 
A-J: Immunofluorescence of dissociated animal cap cells injected with HA-ARID1a and myc-
BCL7a (A-E) or myc-DDX5 (F-J). Nuclei were visualised using DAPI (A, F) and the cell 
periphery by phalloidin (D, I). Both BCL7a and DDX5 co-localise with ARID1a (E, J). Scale 
bars represent 50 m.  
K, L: lateral views of embryos injected dorsally with BCL7a (K) or DDX5 (L) mRNA. 
Injection of BCL7a mRNA had little to no effect on development (K). Injection of DDX5 
caused shortening of the body axis and loss of neural crest derived melanocytes. An 
uninjected embryo is included in both images for comparison (wt).  
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6.2.3 BCL7a and DDX5 Inhibit Wnt Signalling In Xenopus 
The aim of the mass spectrometry screen was to identify interactors of ARID1a 
that could explain how it is able to inhibit Wnt signalling. I therefore tested 
whether BCL7a or DDX5 were able to repress expression of Sia and Xnr3 when 
overexpressed in the animal cap assay.  
Embryos were injected at the one cell stage with 2 pg Wnt8 mRNA along with 
250 pg of either BCL7a or DDX5 mRNA and target gene expression measured by 
qPCR (Fig. 6.3). Both BCL7a and DDX5 reduced expression of Sia by >2 fold and 
Xnr3 by >4 fold (Fig. 6.3 A, B). These assays show that, like ARID1a, both BCL7a 
and DDX5 act to inhibit Wnt signalling in Xenopus.  
As ARID1a acts below the level of -catenin, I next confirmed that BCL7a and 
DDX5 were also acting at this level of the pathway. Both BCL7a and DDX5 
repressed Sia and Xnr3 to the same extent as ARID1a in this assay (Fig. 6.3 C, D).  
I next used the TOPFLASH assay to test whether BCL7a and DDX5 could repress 
Wnt signalling in HEK293 (Fig. 6.3 E). Cells were transfected with the TOPFLASH 
and Renilla luciferase plasmids alongside Xenopus BCL7a, DDX5 or GFP-ARID1a. 
GFP was used as a negative control. GFP-ARID1a and DDX5 both reduced 
luciferase activity to similar degree when compared with GFP transfected cells. 
However, BCL7a had no effect on TOPFLASH activity. Unfortunately the data 
from these experiments are not statistically significant. This is probably due to 
the large variance observed between the data sets (Fig. 6.3, the error bars are 
unusually large). Why this experiment had higher variance than other luciferase 
experiments I have carried out is unclear, though it could be that the batch of 
assay kit I used was getting old. If more biological replicates were carried the 
variance between experiments may be reduced, and the significance of the data 
could be more easily queried.  However, there is clearly a qualitative difference 
between cells transfected with BCL7a and those transfected with DDX5, 
indicating that BCL7a – in contrast to Xenopus animal cap tissue – is unable to 
repress -catenin-mediated signalling in HEK cells.  
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Fig. 6.3 DDX5 and BCL7a Inhibit Wnt Signalling 
A-C: Animal cap assays. Embryos were injected at the 1 cell stage with either 2 pg Wnt8 
mRNA (A, B) or 200 pg -catenin mRNA (C,D) alongside 250 pg of either BCL7a or DDX5 
mRNA. Animal caps were cut at stage 8 and incubated until stage 10 and qPCR carried 
out to measure the expression of Sia (A, C) and Xnr3 (B, D). Data are normalised to 
histone H4 expression. Data are representative of 3 independent experiments, however 
due to large variations between replicates it was not possible to carry out statistical 
analysis on these data.  
E: TOPFLASH luciferase assay. HEK cells were transfected as indicated alongside 
TOPFLASH and Renilla reporter plasmids. Cells were treated with either L-cell 
conditioned media (LCM) or Wnt conditioned media (WCM) overnight and then 
luciferase activity measured.  GFP-ARID1a and DDX5 caused an approximately 2 fold 
reduction in luciferase activity, whereas BCL7a had no effect. Data are the average of 
three experiments and are presented normalised to Renilla luciferase. Unfortunately 
these differences are not statistically significant (see text for discussion).  
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6.2.4 Loss Of DDX5 Causes Phenotypes Similar To Loss of ARID1a 
As BCL7a did not have a phenotype when overexpressed (Fig. 6.2) and had 
different potentials to repress Wnt signalling between Xenopus and HEK cells 
(Fig. 6.3), I therefore focused on DDX5. I designed a translation blocking 
morpholino (DDX5_TB) to deplete DDX5 in Xenopus embryos and an associated 5 
base pair mismatch control (DDX5_CO). Injection of 20 ng DDX5_CO had no effect 
on development (Fig. 6.4 A). Injection of the translation blocking morpholino 
caused ventral oedema and malformation of head structures (Fig. 6.4 B). These 
embryos had smaller eyes and flattened forebrains. This phenotype is similar to 
that seen for low doses of ARID1a_TB suggesting that DDX5 and ARID1a regulate 
similar processes during embryogenesis.  
I then attempted to validate the morpholinos by carrying out western blots 
against endogenous DDX5 (Fig. 6.4 C). Unfortunately the antibody I used did not 
recognise Xenopus DDX5 (lanes 1-3). DDX5 protein was detected in HEK293 cell 
lysate, indicating that this antibody is capable of detecting DDX5 (lane 4), 
however the epitopes it recognises must not be well conserved between the 
human and Xenopus proteins. Due to time constraints I was not able to attempt 
validation by other methods such as in vitro transcription-translation reactions, 
injecting mRNA coding for epitope-tagged DDX5 (such as HA-DDX5 or GFP-
DDX5), or rescue experiments co-injecting DDX5_TB with DDX5 mRNA. Before 
continuing with these experiments it will be crucial to demonstrate that the 
DDX5_TB morpholino specifically knocks down DDX5.  
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Fig. 6.4 Morpholino Knock Down Of DDX5  
A: Embryos were injected with 20 ng mismatch control morpholino at the one cell stage 
an allowed to develop. Control morphants developed without gross phenotypic changes. 
B: Embryos were injected with 20 ng translation blocking morpholino at the one cell 
stage. DDX5 morphants developed oedema around the heart, small eyes and facial 
abnormalities.  
C: Western blot against endogenous DDX5 against Xenopus embryo lysate (lanes 1-3) or 
HEK293 cells (lane 4). DDX5 protein was only detected in HEK293 cells and not in 
Xenopus lysates (Arrowhead. Compare lane 4 with lanes 1-3). 
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6.2.5 ARID1a Can Repress -catenin-Mediated Transcription In The Absence 
Of DDX5 
As overexpression of DDX5 inhibited Wnt signalling, then the reciprocal 
experiment should cause an increase in expression of Wnt target genes. I 
therefore carried out animal cap assays by injecting 20 ng of either DDX5_TB or 
DDX_CO morpholino together with 200 pg -catenin mRNA and then measuring 
gene expression by qPCR (Fig. 6.5). Injection of DDX5_TB had no effect on the 
expression of Sia (A) or Xnr3 (B) in the absence of -catenin. Injection of the 
translation blocking morpholino enhanced expression of both Sia and Xnr3 
compared with the control morpholino in the presence of exogenous -catenin, 
although to a lesser extent than depletion of ARID1a. This upregulation is 
consistent with DDX5 being a repressor of -catenin in this assay.  
As both ARID1a and DDX5 had the same effect on -catenin dependent 
transcription and they physically interact, I next asked whether ARID1a was 
capable of repressing -catenin-mediated signalling in the absence of DDX5. To 
this end I co-injected -catenin and ARID1a mRNA along with either DDX5_CO or 
DDX5_TB morpholinos. Overexpression of ARID1a was sufficient to inhibit 
expression of both Sia and Xnr3 in the absence of DDX5, indicating that DDX5 is 
not required for ARID1a to inhibit Wnt signalling.  
These experiments are preliminary, and require repeating before firm 
conclusions can be drawn.    
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Fig. 6.5 Morpholino Depletion Of DDX5 Caused An Increase In Wnt 
Signalling 
Animal cap assays. Embryos were injected at the one cell stage with 200 pg -catenin 
mRNA plus either 20 ng DDX5 control or translation-blocking morpholino, 20 ng ARID1a 
control or translation-blocking morpholino, 2 ng ARID1a mRNA or 2 ng ARID1a mRNA 
plus 20 ng DDX5 morpholino. The expression of Sia (A) and Xnr3 (B) were measured by 
qPCR. Data are normalised to histone H4. The data are from a single preliminary 
experiment.  
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6.3 Discussion 
6.3.1 BCL7a As A Member of the BAF Complex 
BCL7a bound to ARID1a and they co-localised in the nucleus. However, 
overexpression of BCL7a had no effect on Xenopus development. This may 
because the BCL7a protein is highly regulated in Xenopus, or that in these 
experiments it was expressed in tissues that lack essential co-factors for BCL7a 
function. This lack of a phenotype is not consistent with the repression of Wnt 
target genes Sia and Xnr3 as seen by the animal cap assays. Furthermore, BCL7a 
was an effective inhibitor of Wnt in Xenopus but not in HEK293 cells. These three 
systems – whole embryos, explanted animal caps and tissue culture cells – have 
different properties, which may explain these differences. Perhaps Xenopus 
BCL7a is unable to interact with human proteins that regulate nuclear Wnt 
signalling, or HEK293 cells lack a critical co-factor. Whatever the mechanism, the 
role of BCL7a with respect to the BAF complex merits further study.  
6.3.2 DDX As A Repressor Of The Wnt Pathway 
In Xenopus animal cap assays DDX5 acted as an inhibitor of the Wnt pathway. 
Furthermore, TOPFLASH experiments in HEK293 cells showed that DDX5 
repressed Wnt signalling to a similar degree as ARID1a. These data contradict 
the current literature, which states that DDX5 is an activator of Wnt signalling. 
Several groups have shown an interaction between DDX5 and -catenin, and 
have demonstrated that gain of DDX5 function corresponds with activation of 
the Wnt pathway (Clark et al., 2013; Shin et al., 2007; Yang et al., 2006b). Why 
then, is there this discrepancy? Firstly, all of the studies cited so far have been 
carried out in colon cancer-derived cell lines, which are notorious for having 
dysregulated Wnt signalling pathways (Minde et al., 2011). However, 
experiments in mouse Gc1-Spg cells – which are derived from spermatogonial 
cells – have also shown that DDX5 activates the Wnt pathway (Arun et al., 2012), 
arguing against this property being an artefact of colon carcinoma cell lines. 
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In contrast to previous studies that were carried out in cell lines derived from 
adult tissues, my experiments were done using embryonic cell types. Another 
difference is that I used the Xenopus DDX5 protein, which while 85% conserved 
with human DDX5 may contain sufficient differences to switch it from an 
activator to a repressor of Wnt signalling. The crucial phosphorylation residue 
that allows DDX5 to interact with -catenin is conserved between human and 
frog, indicating that this function could be maintained (Yang et al., 2006b). 
However, immunofluorescence of DDX5 showed it was nuclear in Xenopus 
animal cap cells (Fig. 6.2), suggesting that the mechanism that allows DDX5 to 
become cytoplasmic is not present in these cells. As only cytoplasmic DDX5 is 
able to bind to -catenin (Shin et al., 2007) then nuclear retention of DDX5 would 
prevent it from activating -catenin mediated signalling. This retention model 
could be tested by proximity ligation assays between -catenin and DDX5, which 
would determine whether these proteins are interacting in Xenopus and if so in 
which cellular compartment. Furthermore, animal cap experiments similar to 
those described in Fig. 6.3 using human DDX5 would test whether Xenopus and 
human DDX5 have intrinsically different abilities to regulate Wnt signalling 
within the same system.  
6.3.3 ARID1a May Not Require DDX5 To Regulate The Wnt Pathway 
Preliminary animal cap experiments showed that ARID1a is able to repress -
catenin dependent transcription in the absence of DDX5 (Fig. 6.5). As mentioned 
above, the DDX5 morpholinos must be validated and these experiments repeated 
before drawing conclusions. If these data are confirmed, then the implication is 
that DDX5 is inhibiting Wnt signalling independently to ARID1a and not as part 
of the BAF complex. Alternatively, DDX5 may be acting to recruit the BAF 
complex to -catenin target sites, and once ARID1a is overexpressed DDX5 
becomes redundant. Further experiments are required to investigate the 
relationship between ARID1a and DDX5 with respect to Wnt signalling (see 
section 7.1.3 for more detail).   
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Chapter 7: Discussion And Future 
Directions 
Despite years of research there is still much we do not know about how the Wnt 
pathway is regulated. In particular, events that occur in the nucleus before and 
after -catenin translocation from the cytoplasm remain insufficiently 
understood. Nuclear -catenin displaces TLE/Groucho from TCF/LEF proteins 
and recruits co-factors to alter the chromatin landscape, changing it from a 
transcriptionally repressive to a permissive state (see Chapter 1). One such 
chromatin remodelling complex is the BAF complex, which binds to -catenin via 
the core ATPase Brg1 (Barker et al., 2001). However, other members of the BAF 
complex such as SNF5 act to supress Wnt signalling (Collins and Treisman, 2000; 
Mora-Blanco et al., 2014). Previous work on Osa, the Drosophila homologue of 
ARID1a, suggested that it inhibits the Wg pathway (Collins and Treisman, 2000). 
My study focussed on testing and expanding these findings, showing that ARID1a 
is a direct inhibitor of Wnt signalling in vertebrates.  
Two proteins, BCL7a and DDX5, were identified as interaction partners for 
ARID1a by mass spectrometry. Individually, overexpression of these proteins 
prevented -catenin mediated transcription in Xenopus indicating that they 
might act together with ARID1a to regulate transcription of Wnt target genes. I 
will now discuss potential mechanisms for how ARID1a could be functioning at 
the molecular level (Fig. 7), and suggest experiments that would validate or 
refute these models.  
7.1 Possible Models For ARID1a and DDX5 Function 
7.1.1 Creation of a Repressive Chromatin State 
The BAF complex re-positions nucleosomes to both positively and negatively 
regulate gene expression (Tolstorukov et al., 2013). In Drosophila SAYP-
containing BAP complexes lay down nucleosome “barriers” within the ftz-f1 gene 
(Vorobyeva et al., 2012). These barriers are regions of tightly clustered 
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nucleosomes that interfere with PolII elongation and lead to reduced gene 
expression (Subtil-Rodríguez and Reyes, 2010). Such barriers are also removed 
by the BAF complex to allow transcription to take place (Schwabish and Struhl, 
2007). Therefore ARID1a could act to repress Wnt signalling either by actively 
positioning nucleosome barriers within -catenin target genes, or by preventing 
the BAF complex from disassembling barriers already present (Fig. 7 A). This 
model could be tested by DNase footprinting experiments, which would identify 
the location of nucleosomes within -catenin target genes, and assess whether 
the position or occupancy of these nucleosomes is changed upon manipulation of 
ARID1a. 
Alternatively, the BAF complex is able to recruit histone deacetylases (HDACs) 
(Sif et al., 2001). HDACs prevent transcription by condensing chromatin and 
denying transcription factors such as -catenin access to DNA (Haberland et al., 
2009). Therefore localisation of HDACs to -catenin target genes by ARID1a 
could be sufficient to repress Wnt signalling (Fig. 7 B).  
Both of these models assume that ARID1a is present at -catenin target genes, 
and that it is inhibiting -catenin dependent transcription as part of the BAF 
complex. Neither of these assumptions have been directly tested. Chromatin 
immunoprecipitation (ChIP) followed by sequencing or qPCR would show 
whether ARID1a is present at -catenin target genes. A time course experiment 
similar to that carried out by Sierra and colleagues (Sierra et al., 2006), where 
cells were stimulated with Wnt and ChIP-qPCR carried out at short time 
intervals, would provide information as to when ARID1a is present on chromatin 
with respect to -catenin. ChIP experiments using antibodies that recognise 
histone acetylation and methylation marks could also be used to test the second 
hypothesis directly, as it predicts that perturbation of ARID1a would result in 
measurable changes in histone modifications.  
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 Fig. 7 Models Of BAF250a Repression of Beta Catenin 
A: ARID1a may establish nucleosome barriers within target genes, or prevent their disassembly 
by the BAF complex. These barriers prevent efficient transcription. Upon ARID1a knock down 
these nucleosomes are no longer positioned within the gene, or are now able to be displaced by 
ARID1b containing complexes. With the barrier removed, PolII is able to transcribe target genes. 
B: ARID1a creates a repressive chromatin state by recruiting histone modifying enzymes that 
prevent -catenin from binding to target genes, and thereby inhibit transcription. Loss of 
ARID1a prevents association of these enzymes with beta-catenin sites, and -catenin is able to 
bind DNA and promote transcription. 
C: ARID1a prevents Brg1 from binding -catenin, and therefore sequesters the BAF complex away 
from -catenin target genes, preventing their transcription. Loss of ARID1a increases the amount 
of Brg1 able to bind -catenin, sensitising cells to the Wnt pathway. 
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7.1.2 ARID1a Could Prevent Brg1 From Associating With -catenin 
Brg1, the core ATPase of the BAF complex, binds to -catenin (Barker et al., 
2001). However, -catenin was not identified in my mass spectrometry screen 
for ARID1a interacting proteins. This may be because the weak cross-linking 
agent used did not allow detection of proteins that were not directly bound to 
ARID1a, or ARID1a may prevent association between Brg1 and -catenin. If the 
latter were the case, ARID1a-containing complexes would not be recruited to 
Wnt target genes; instead -catenin dependent transcription would be mediated 
by complexes containing the alternative subunit ARID1b. ARID1a and ARID1b 
are mutually exclusive subunits of the BAF complex (Wang et al., 2004), and have 
opposite roles in several cellular processes, such as control of the cell cycle (Nagl 
et al., 2007). It is therefore possible ARID1a and ARID1b have opposing roles in 
Wnt signalling, although ARID1b has not been tested in this regard. 
If Brg1 were limiting, this could explain the changes in Wnt target gene 
transcription that I observed. Depletion of ARID1a would increase the pool of 
Brg1 bound to ARID1b (and therefore available to bind -catenin), sensitising 
cells to Wnt signals (Fig. 7 C). Likewise, overexpression of ARID1a would 
sequester Brg1 from ARID1b and prevent interaction with -catenin, leading to a 
loss of Wnt target gene transcription. This model can be directly tested by 
carrying out co-immunoprecipitations between Brg1, -catenin, ARID1a and 
ARID1b. It would also be interesting to carry out animal cap experiments similar 
to those in Chapter 4 to test the effects of ARID1b on Wnt signalling. 
7.1.3 ARID1a, BCL7a and DDX5 
To date, no studies have investigated the molecular properties of BCL7a. It has 
no identifiable domains and few known binding partners. The experiments 
described in my thesis show that BCL7a is capable of inhibiting Wnt/-catenin 
signalling in Xenopus animal cap assays, but was not able to inhibit Wnt 
signalling in HEK293 cells. Further experiments with both Xenopus and human 
BCL7a such as secondary axis induction and depletion experiments would  
contribute towards resolving this discrepancy. 
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DDX5 was identified as an interaction partner for ARID1a from the mass 
spectrometry screen, and was shown to inhibit Wnt signalling to a similar degree 
as ARID1a. However, preliminary work showed that DDX5 was not required for 
ARID1a-mediated repression of -catenin (Fig. 6.5). If these findings are 
confirmed by further repeats, then it may be that ARID1a and DDX5 regulate -
catenin independently, or that DDX5 represses -catenin by recruiting ARID1a-
containing complexes. DDX5 can bind to DNA together with proteins such as 
MyoD and p53 (Bates et al., 2005; Caretti et al., 2006), therefore it is possible that 
DDX5 binds DNA together with ARID1a. Additionally, BAF complexes have little 
specificity for DNA sequence and are often recruited to specific genes by 
cofactors (Tolstorukov et al., 2013), though whether DDX5 is capable of this has 
yet to be tested.  Reciprocal experiments depleting ARID1a and overexpressing 
DDX5 would determine whether DDX5 requires ARID1a to repress Wnt 
signalling. If not, then it is likely that these two proteins are regulating -catenin 
independently. 
In addition to inhibiting -catenin dependent transcription, ARID1a and DDX5 
share several other properties. Both have embryonic lethal phenotypes (Fukuda 
et al., 2007; Gao et al., 2008), both regulate transcription of target genes, for 
example in response to oestrogen signalling (Inoue et al., 2002; Watanabe et al., 
2001) and both interact with the spliceosome (Batsché et al., 2005; Guil et al., 
2003). Therefore it may be that DDX5 is a frequently recruited co-factor, or may 
even be an integral BAF subunit. Co-sedimentation experiments such as those 
described by Hargreaves and Crabtree (2011) could be used to test whether 
DDX5 is a bona fide subunit of the BAF complex.  
7.2 Mass Spectrometry Screens In Xenopus 
My first attempt at mass spectrometry was carried out in Xenopus and produced 
data that proved difficult to analyse. Many of the proteins identified were 
cytoplasmic contaminants, or annotated as being uncharacterised. Despite these 
issues, Xenopus has the potential to be a very powerful proteomic model 
organism in the near future. A single Xenopus embryo contains enough protein to 
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carry out mass spectrometry, although more will be needed for the 
immunoprecipitation style screens as carried out in this thesis (Wühr et al., 
2014). A recent study used mass spectrometry to characterise proteins present 
during the first hours of Xenopus development (Smits et al., 2014). These recent 
studies successfully overcame the problem of removing the abundant yolk 
proteins that complicated the interpretation of my experiments. However, the 
issue of matching peptides to an incomplete proteome still remains. By more in 
depth exome sequencing a more detailed translatome can be derived, which will 
aid the interpretation of mass spectrometry experiments. Finally, recent work 
has adapted the INTACT system for use in Xenopus (Amin et al., 2014). This 
technique allows extraction of nuclei from a desired subset of cells within the 
embryo, allowing cell-type specific examination of nuclear proteins by mass 
spectrometry. Further elaboration of this system has great potential for 
expanding our understanding of how proteins interact to control development 
processes.  
7.3 Links between ARID1a, Wnt and Cancer 
Many members of the BAF complex are tumour suppressor genes (Yaniv, 2014) 
including ARID1a (Wang et al., 2004a). High throughput sequencing has 
identified ARID1a mutations in a range of cancers, including ovarian clear cell 
carcinoma (OCCC), gastric, pancreatic and breast cancer (Jones et al., 2010; Shain 
et al., 2012; Wang et al., 2011; Wiegand et al., 2010).  
Wnt signalling plays a key role in the development and growth of ovarian 
cancers (Arend et al., 2013). However, activating mutations in the Wnt/-catenin 
pathway are rare in ovarian clear cell carcinomas (Dubeau, 2008). The work 
presented in this thesis shows ARID1a is a repressor of Wnt signalling, therefore 
mutation of ARID1a in these carcinomas may provide the upregulation of Wnt 
signalling characteristic of ovarian tumours. Indeed loss of ARID1a is an early 
event in the progression of OCCC and therefore may act to establish an active-
Wnt state that is permissive to cancer formation (Yamamoto et al., 2011). To 
date, no link has been made between the ability of ARID1a to regulate the        
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Wnt signalling pathways and its role as a tumour suppressor gene. It would 
therefore be valuable to know whether loss of ARID1a in human cancer causes 
an increase in paracrine Wnt signalling.  
C-myc is a well studied oncogene (Conacci-Sorrell et al., 2014). ARID1a binds to 
the c-myc promoter and inhibits cell cycle progression (Nagl et al., 2006; Nagl et 
al., 2007). As c-myc is also a target of Wnt signalling (He et al., 1998), ARID1a 
may be acting at multiple levels to suppress tumour formation. Indeed, ARID1a 
reportedly binds to p53 and promotes transcription of target genes such as 
CDKN1a and SMAD3 (Guan et al., 2011). These observations indicate that 
ARID1a-containing BAF complexes may be key tumour suppressor “nodes” 
controlling various cell-cycle regulators to prevent proliferation. Further 
investigation into the molecular functions of ARID1a and its regulatory role 
within the BAF complex will provide greater understanding of the consequences 
of ARID1a mutations in human disease.   
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Appendix 
Mass Spectrometry Screen: GFP Interacting Proteins 
 
ACLY GAPDH KRT7 PKM2 
ACTA1 GART KRT8 PLEC 
ACTB GFAP KRT9 POTEE 
ACTN1 GMPS KRT10 POTEF 
ACTN2 GNB2 KRT13 POTEKP 
ACTN4 GNB2L1 KRT14 PPA1 
ACTR2 HIST2H2BF KRT15 PPP1CA 
ACTR3 HNRNPA1 KRT16 PPP1CC 
ADD1 HNRNPA2B1 KRT17 PPP1R9B 
ADD3 HNRNPA3 KRT18 PPP2CA 
AHCY HNRNPA3 KRT19 PPP2CB 
ALB HNRNPC KRT24 PRKDC 
ANXA2 HNRNPF KRT25 PRKDC 
ARPC2 HNRNPH1 KRT26 PSMC4 
CAD HNRNPK KRT28 PTBP1 
CAPZA1 HNRNPL KRT32 RCC2 
CAPZA2 HNRNPM KRT37 RPLP0 
CCT2 HNRNPU KRT38 RPSA 
CCT3 HSP90AA1 KRT71 RUVBL2 
CCT4 HSP90AB1 KRT73 SDHA 
CCT5 HSP90AB2P KRT75 SEC23B 
CCT7 HSP90AB4P KRT76 SERBP1 
CCT8 HSP90B1 KRT77 SPTBN1 
CLTC HSPA1A KRT79 SPTBN2 
CORO1C HSPA1L KRT80 TCP1 
CRKL HSPA5 KRT81 TMOD3 
CTNNA1 HSPA6 KRT84 TP53 
CTNNA2 HSPA8 MATR3 TRAP1 
CTNNB1 HSPA9 MCM3 TRIM28 
DARS HSPD1 MCM5 TUBA1A 
DBN1 HSPD1 MCM7 TUBA1B 
DDX1 IPO5 MTHFD1 TUBA1C 
DDX17 IQGAP1 MYH9 TUBA4B 
DDX3X IRS4 MYO1C TUBB 
DDX6 JUP MYO6 TUBB2B 
DES KHSRP NONO TUBB3 
DHX15 KIF5B NPM1 TUBB4A 
DSG2 KPNB1 PABPC1 TUBB4B 
DSP KRT1 PARP1 TUBB6 
EEF1A1 KRT2 PCBP2 TUBB8 
EEF2 KRT3 PCM1 TUFM 
EIF4A1 KRT4 PDIA3 UBA1 
EPPK1 KRT5 PDIA6 VIM 
FASN KRT6A PFKP XRCC5 
FLNA KRT6B   
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Mass Spectrometry Screen: Proteins Identified From Xenopus 
Lysate  
 
Protein 
MW (Da) 
Mascot 
Score Coverage Gene Name 
124428 1948 145%** MGC80068 protein 
56328 1764 207%** 
ATP synthase, H+ transporting, mitochondrial F1 complex, 
beta polypeptide 
58006 1461 162%** 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily d, member 1 
113202 1347 90%** 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 4 
50256 1305 129%** tubulin, beta 2C 
25245 1289 264%** elogation factor 1 beta 
55488 1267 161%** similar to SWI/SNF related 
25274 1191 211%** elogation factor 1 beta 
95821 1056 172%** 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily c, member 2 
136835 911 50%** 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily c, member 1 
72739 878 75%** heavy-chain binding protein BiP 
72489 869 71%** 
heat shock 70kDa protein 5 (glucose-regulated protein, 
78kDa) 
43556 844 209%** MGC80271 protein 
28526 833 173%** MGC81833 protein 
16211 792 259%** hypothetical protein MGC83076 
50714 772 97%** MGC97820 protein 
50739 753 76%** similar to alpha-Tubulin at 84B 
50459 743 70%** tubulin, beta 6 
50559 743 70%** hypothetical protein MGC52834 
50754 737 72%** hypothetical protein LOC446922 
48468 730 195%** 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily e, member 1 
29831 720 133%** 40S ribosomal protein S4 
50173 653 96%** elongation factor 1 gamma 
20810 610 210%** hypothetical protein MGC64263 
20938 608 209%** similar to ribosomal protein L18a 
17666 593 161%** hypothetical protein MGC82306 
18737 584 104%** hypothetical protein MGC64285 
22056 579 149%** ribosomal protein L9 
83304 576 56%** heat shock 90kDa protein beta 
45192 555 75%** ribosomal protein L4 
24981 549 153%** ribosomal protein L10 
51771 531 45%** tubulin, alpha 8 
50433 518 139%** elongation factor 1-alpha O 
50505 508 131%** elongation factor 1 alpha, oocyte form 
19868 495 131%** hypothetical protein LOC100124811 
46354 474 117%** ribosomal protein L3 
57612 469 55%** keratin 5, gene 7 
16434 459 117%** ribosomal protein S16 
15274 443 166%** hypothetical protein MGC64320 
96603 419 58%** eukaryotic translation elongation factor 2 
30092 418 74%** ATP synthase, H+ transporting, mitochondrial F1 complex, 
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gamma polypeptide 1 
Protein 
MW (Da) 
Mascot 
Score Coverage Gene Name 
13101 399 134%** ribosomal protein L30 
224826 394 14%** laryngeal-specific muscle myosin heavy chain 
32610 387 80%** hypothetical protein MGC82276 
50633 386 112%** elongation factor 1 gamma 
22621 375 100%** ribosomal protein S9 
28830 370 54%** ribosomal Protein, Small subunit (28.1 kD) (rps-6) 
54298 359 56%** MGC86299 protein 
50540 355 40%** mec-12 protein 
15930 333 142%** MGC86316 protein 
50775 310 35%** eukaryotic translation elongation factor 1 alpha 2 
50088 309 24%** hypothetical LOC496021 
15571 308 129%** MGC82841 protein 
84539 293 17%** MGC82579 protein 
16655 269 141%** ribosomal protein L22 
24497 257 62%** RAN, member RAS oncogene family 
24280 256 55%** ribosomal protein L13 
50524 245 30%** 
eukaryotic translation elongation factor 1 alpha, somatic 
form 
24241 242 70%** ribosomal protein L13 
161626 241 14%** hypothetical protein LOC443585 
50355 237 29%** hypothetical protein LOC100145396 
30092 225 67%** hypothetical protein LOC100126639 
16434 216 135%** ribosomal protein S14 
14956 215 61%** MGC82808 protein 
13339 213 54%** ribosomal protein S26 
55820 212 31%** keratin 8 
33147 204 26%** 
solute carrier family 25 (mitochondrial carrier; adenine 
nucleotide translocator), member 5 
9811 189 89%** ribosomal protein S27 
15376 186 135%** H3 histone, family 3B (H3.3B) 
15376 186 135%** MGC81913 protein 
18296 173 37%** MGC81889 protein 
49150 167 26%** hypothetical protein LOC100037222 
58093 166 35%** MGC81949 protein 
13958 159 90%** hypothetical protein MGC130860 
46263 158 30%** hypothetical protein LOC100145042 
42225 153 26%** similar to actin, alpha 1, skeletal muscle 
42225 153 26%** hypothetical protein LOC779096 
60582 151 21%** aspartyl-tRNA synthetase 
54531 151 35%** hypothetical protein LOC100037087 
33351 148 15%** 
solute carrier family 25 (mitochondrial carrier; adenine 
nucleotide translocator), member 4 
48943 146 35%** keratin 12 
45615 134 8%** hypothetical protein MGC68500 
46364 129 18%** hypothetical protein LOC100037184 
45007 117 10%** keratin 8, gene 2 
49867 116 8%** tubulin, beta 4 
34208 111 39%** 60S ribosomal protein L5-B 
100682 110 6%** middle molecular weight neurofilament protein NF-M(1) 
25109 110 61%** MGC89303 protein 
49716 103 19%** elongation factor 1 alpha, oocyte form 
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Protein 
MW (Da) 
Mascot 
Score Coverage Gene Name 
13478 96 35%** variant histone H2A.Zl1 
11177 96 91%** hypothetical protein LOC100049136 
40295 94 21%** 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 
42kDa 
18581 93 69%** ribosomal protein S11 
48903 91 17%** hypothetical LOC493206 
13291 91 19%** hypothetical LOC495401 
44829 89 13%** hypothetical protein LOC100125118 
16917 89 24%** hypothetical protein LOC414678 
29282 87 29%** 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, epsilon polypeptide 
193254 87 8%** hypothetical LOC496448 
42821 86 7%** hypothetical protein MGC81067 
30104 83 18%** rps3a protein 
55547 82 5%** MGC97634 protein 
193019 82 4%** MGC80936 protein 
98225 81 12%** 
phosphorylase, glycogen; liver (Hers disease, glycogen 
storage disease type VI)  
12139 80 32%** hypothetical protein MGC80065 
54509 77 8%** RNA helicase p54 
40337 75 5%** 
solute carrier family 25 (mitochondrial carrier; phosphate 
carrier), member 3 
17675 75 75%** MGC89958 protein 
24687 74 12%** hypothetical protein MGC68604 
65062 74 9%** hypothetical protein LOC100189561 
87585 72 2%** hypothetical protein LOC100216266 
34580 70 29%** succinate-CoA ligase, alpha subunit 
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Mass Spectrometry Screen: Set 1 
 
Protein MW (Da) 
Mascot  
Score Peptides matched Coverage Gene Symbol 
185100 6055 257 55% SMARCA4 
133196 5223 270 64% SMARCC2 
123303 3829 238 69% SMARCC1 
42334 3496 220 68% ACTC1 
181794 3356 162 47% SMARCA2 
58481 3291 141 93% SMARCD1 
59112 2722 115 68% SMARCD2 
85630 2436 149 71% LIMA1 
42318 2435 137 46% ACTBL2 
46678 1774 79 73% SMARCE1 
55528 1704 68 73% INA 
80895 1617 90 67% SCIN 
44398 1569 64 78% SMARCB1 
31616 1399 61 63% CAPZB 
55210 1360 67 62% SMARCD3 
18229 1352 62 71% PPIA 
103917 1282 43 16% ACTN3 
47944 1152 70 71% ACTL6A 
22324 1132 72 80% PRDX1 
27025 1093 52 78% EFHD1 
86043 1091 55 43% GSN 
45268 1054 43 60% DPF2 
20761 1054 56 74% ARPC3 
47554 907 27 46% FLOT1 
61720 834 44 48% CTTN 
12639 719 24 71% MIF 
22853 697 41 43% BCL7A 
42381 696 40 37% ACTA2 
38151 686 23 55% GNB1 
22049 678 23 50% PRDX2 
242805 667 45 6% ARID1A 
26842 663 34 73% RPS3 
122858 651 43 12% POTEI 
23511 641 24 57% BCL7C 
229827 634 44 22% MYH10 
37961 625 28 40% PPP1CB 
71610 625 41 38% ATAD3A 
24792 617 18 55% HPRT1 
17114 611 33 64% AIF1L 
111016 579 34 28% KIF23 
16367 570 20 72% ARPC5 
19768 564 19 52% ARPC4 
249417 550 41 24% SVIL 
58168 534 19 37% KPNA2 
13981 529 19 50% HIST1H2BM 
100203 525 28 26% CDH2 
195682 519 25 18% TJP1 
16827 510 23 62% CALM1 
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Protein MW (Da) 
Mascot  
Score Peptides matched Coverage Gene Symbol 
118740 490 39 14% POTEJ 
27134 485 16 66% HSD17B10 
47434 477 24 48% FLOT2 
18719 468 26 63% CFL1 
53732 465 16 8% PRPH 
18296 459 26 31% RPS27A 
69618 452 30 37% DDX5 
66065 452 23 26% PPP2R1A 
17249 449 13 53% SSBP1 
61054 447 24 37% PSMD3 
116927 447 39 29% MYO1D 
73564 443 26 30% DDX3Y 
17090 436 17 58% MYL6 
97868 433 22 26% PKP2 
23928 424 20 68% BAG2 
28633 396 27 46% PSMB5 
16549 393 22 57% RPS16 
14087 391 18 57% HIST2H2AA3 
73399 381 24 26% LZTS2 
18487 369 11 39% ACP1 
61536 357 17 24% NEFL 
69620 357 14 23% RBM14 
43900 349 17 37% DPF1 
110601 346 23 21% RAI14 
32213 342 26 48% PGAM5 
21935 340 25 48% LIN7C 
80837 340 26 24% NEXN 
33059 339 22 43% SLC25A5 
23682 327 23 72% SNAP23 
30749 323 11 20% PRDX4 
23033 322 12 34% RPS5 
15378 321 13 50% PFN2 
36049 312 7 12% MYADM 
22548 312 15 64% TAGLN2 
197617 311 20 12% KIAA1671 
136532 308 23 18% CGN 
20704 307 14 42% CNBP 
17708 306 17 51% RPS18 
11360 298 19 52% HIST1H4A 
28017 295 13 39% PRDX3 
20468 293 21 31% RPL11 
134104 290 18 15% TJP2 
24792 286 26 55% PCMT1 
29326 286 19 44% YWHAE 
187743 285 12 6% KIF14 
117260 281 11 13% MPRIP 
27838 276 11 19% PSMA6 
85391 275 15 21% LRCH2 
123585 269 15 19% WDR6 
25996 261 18 44% PSMA2 
73098 260 23 17% ATAD3B 
76022 259 17 25% GAS2L3 
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Protein MW (Da) 
Mascot  
Score Peptides matched Coverage Gene Symbol 
67332 259 8 15% CTPS1 
61276 258 21 25% YES1 
17979 254 9 33% RPL12 
244289 253 25 16% DOCK7 
16434 250 9 31% RPS14 
48090 249 11 11% ACTR3B 
123552 245 16 13% PPP1R9A 
61237 245 13 21% FYN 
68721 240 6 10% EWSR1 
17309 235 16 53% NME1 
14970 234 6 32% RPL23 
17401 232 17 56% NME2 
24579 231 28 38% RAN 
100877 228 9 15% PSMD2 
18398 223 13 26% PPIAL4A 
19839 218 9 47% MYL12A 
53622 217 18 22% FUS 
33073 216 17 27% SLC25A6 
15004 215 15 45% UBA52 
13478 214 14 35% RPS20 
66653 212 12 11% LMNB1 
15597 209 15 178%** RPS17L 
16931 208 13 67% ARPC5L 
19824 207 8 47% MYL12B 
21852 207 15 45% CSRP2 
25133 207 9 34% PRDX6 
26794 202 17 33% EFHD2 
118469 199 16 18% AMOT 
70084 196 30 41% XRCC6 
26700 196 9 25% PSMB1 
47303 192 8 19% ACTL6B 
18839 191 11 40% CFL2 
14083 191 6 35% HIST1H2AG 
20050 190 18 48% PARK7 
28032 188 9 21% YWHAQ 
120772 186 13 12% LUZP1 
17049 185 11 45% EIF5A 
56961 185 8 13% CAMK2D 
12015 184 8 40% TXN 
26565 183 9 34% PSMA5 
29033 181 6 25% EMD 
10530 179 10 51% DYNLL1 
9797 179 10 14% RPS27 
115610 177 7 6% PPP1R12A 
20630 175 14 44% CAV1 
71666 175 21 29% RACGAP1 
12947 172 11 62% RPL30 
18817 172 6 25% SKP1 
84026 167 8 9% IMMT 
27095 167 10 37% EIF6 
93943 167 10 13% NUP93 
69874 164 10 18% NF2 
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Protein MW (Da) 
Mascot  
Score Peptides matched Coverage Gene Symbol 
63254 162 6 9% COIL 
198016 157 10 7% KIDINS220 
11190 154 7 30% CSTB 
24475 150 6 30% RPS8 
71279 147 14 22% PLS3 
46013 146 11 20% SS18 
18590 139 21 54% RPS11 
21172 137 9 25% UBE2M 
40525 134 8 17% SLC25A3 
8115 127 6 59% GNG12 
26421 127 6 19% CHCHD3 
85762 127 7 10% PFKL 
22993 124 8 40% PSMB2 
67762 124 16 16% LMNB2 
135242 123 10 9% PLEKHG3 
26095 120 15 25% LIN7A 
15725 119 10 31% ATP6V0C 
15436 118 24 63% HIST2H3A 
25151 118 17 41% UCHL1 
28643 116 12 26% PSMA3 
25304 115 13 54% GRB2 
28179 114 11 34% YWHAB 
22239 112 12 53% BCL7B 
14225 111 9 35% HIST1H2AA 
18783 109 9 34% DCTPP1 
27899 108 6 20% YWHAZ 
66701 106 10 14% FARSB 
55688 103 10 28% C22orf28 
30097 99 9 40% LASP1 
63958 96 6 11% RANGAP1 
122531 94 8 10% AZI1 
29264 93 11 23% RPL7 
41722 93 8 21% ARPC1B 
62021 93 7 19% TAF15 
28512 91 7 27% SNRPA1 
132585 91 9 11% PKP4 
70215 91 6 10% PABPC3 
18971 90 8 29% PTGES3 
106795 88 9 10% PSMD1 
13791 87 7 30% RPS25 
57585 85 6 7% FARSA 
58993 85 6 11% LYN 
6900 84 6 19% RPS29 
42113 83 7 21% ARPC1A 
8270 82 6 50% RPL38 
14905 80 8 42% RPS12 
57203 80 6 11% DNAJC7 
29822 78 13 24% PSMA1 
25044 76 9 34% RPL10 
71990 76 6 9% SSX2IP 
14944 75 8 57% RPS15A 
30288 74 7 8% PSMB7 
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Protein MW (Da) 
Mascot  
Score Peptides matched Coverage Gene Symbol 
10281 73 10 69% BOLA2 
15788 72 12 36% RPL27 
32856 71 8 19% TPM3 
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Mass Spectrometry Screen: Set 2 
 
Protein MW (Da) 
Mascot 
Score Peptides matched Coverage Gene Symbol 
133196 6089 281 63% SMARCC2 
185100 5358 225 57% SMARCA4 
123303 4865 276 67% SMARCC1 
58481 3109 107 72% SMARCD1 
47944 2832 125 86% ACTL6A 
181794 2828 150 34% SMARCA2 
44398 2790 109 80% SMARCB1 
42334 2382 140 44% ACTC1 
45268 1975 81 74% DPF2 
46678 1731 76 71% SMARCE1 
42318 1669 108 38% ACTBL2 
59112 1310 66 54% SMARCD2 
55210 1008 48 40% SMARCD3 
35903 880 24 37% YBX1 
28512 823 19 37% SNRPA1 
11360 795 34 54% HIST1H4A 
70263 785 34 17% HSPA2 
14087 693 24 57% HIST2H2AA3 
242805 682 43 9% ARID1A 
13896 621 19 41% HIST1H2BJ 
13944 614 20 41% HIST1H2BL 
103917 610 22 21% ACTN3 
47554 557 19 32% FLOT1 
283140 526 42 11% HRNR 
22853 525 29 43% BCL7A 
23511 512 15 56% BCL7C 
85630 424 34 28% LIMA1 
43900 403 21 41% DPF1 
15436 385 22 57% HIST2H3A 
14113 379 13 35% HIST3H2A 
46365 369 19 31% RPL3 
17708 354 17 50% RPS18 
15509 350 23 57% HIST1H3A 
42381 337 18 33% ACTA2 
17979 327 11 39% RPL12 
19768 320 10 41% ARPC4 
45995 314 23 34% LANCL1 
84531 313 15 20% GYS1 
14970 309 8 38% RPL23 
31616 296 11 37% CAPZB 
76216 292 32 31% SFPQ 
18296 286 16 42% RPS27A 
29807 286 15 41% RPS4X 
14225 281 13 35% HIST1H2AA 
93943 270 11 15% NUP93 
47303 263 8 16% ACTL6B 
32765 263 11 23% RPL6 
229827 245 22 10% MYH10 
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Protein MW (Da) 
Mascot  
Score Peptides matched Coverage Gene Symbol 
15376 245 20 57% H3F3A 
13987 230 8 35% HIST2H2AB 
87804 229 18 20% DDX21 
45768 225 11 28% PSMC5 
26842 218 7 21% RPS3 
68721 217 6 9% EWSR1 
27899 216 9 28% YWHAZ 
24304 215 10 29% RPL13 
44254 214 14 29% DPF3 
53732 212 8 8% PRPH 
24475 212 7 24% RPS8 
47434 204 11 16% FLOT2 
13501 204 10 62% H2AFV 
31590 202 17 41% RPS2 
29264 195 19 48% RPL7 
24245 195 9 28% RPL15 
29326 193 8 29% YWHAE 
58168 186 7 13% KPNA2 
100877 178 9 9% PSMD2 
16434 173 7 31% RPS14 
49002 169 6 15% PSMC2 
55528 162 13 18% INA 
28235 152 10 41% RPL8 
48090 147 10 14% ACTR3B 
36960 138 7 10% HNRNPH3 
21735 135 7 26% RPL18 
22239 134 7 50% BCL7B 
23531 132 6 22% RPL14 
17248 132 13 33% RPL26 
17212 127 10 42% RPS13 
39764 126 8 26% H2AFY 
46013 124 6 7% SS18 
26872 121 8 27% ALYREF 
69620 111 6 7% RBM14 
24579 105 6 20% RAN 
42113 103 7 19% ARPC1A 
23928 102 9 44% BAG2 
20761 101 10 26% ARPC3 
96250 101 12 16% HNRNPUL1 
15969 99 8 20% RPS23 
30148 94 9 25% RPL7A 
22324 92 7 23% PRDX1 
15795 88 6 31% RPL28 
69618 87 12 13% DDX5 
66065 86 7 10% PPP2R1A 
47719 84 5 13% PSMD11 
47126 84 6 17% EIF4A3 
29822 77 8 13% PSMA1 
42306 75 14 23% RBMX 
18229 74 9 43% PPIA 
12947 71 6 46% RPL30 
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Mass Spectrometry Screen: Set 3 
 
Protein MW (Da) 
Mascot  
Score Peptides matched Coverage Gene Symbol 
185100 3970 161 49% SMARCA4 
133196 3964 202 63% SMARCC2 
123303 3524 206 69% SMARCC1 
42334 2983 187 50% ACTC1 
181794 2339 112 35% SMARCA2 
58481 2284 92 72% SMARCD1 
47944 1965 100 58% ACTL6A 
44398 1954 84 77% SMARCB1 
42318 1818 121 38% ACTBL2 
45268 1606 56 70% DPF2 
46678 1522 68 73% SMARCE1 
59112 1256 56 50% SMARCD2 
70263 885 31 15% HSPA2 
103917 794 25 12% ACTN3 
85630 701 58 46% LIMA1 
14087 663 17 50% HIST2H2AA3 
229827 648 38 19% MYH10 
118740 637 35 6% POTEJ 
55210 632 31 25% SMARCD3 
13942 611 15 35% HIST1H2BB 
13981 600 15 36% HIST1H2BM 
43900 599 22 42% DPF1 
22853 533 29 35% BCL7A 
76216 503 28 35% SFPQ 
242805 499 36 7% ARID1A 
47554 473 16 27% FLOT1 
11360 460 23 52% HIST1H4A 
45995 447 25 37% LANCL1 
28512 444 15 42% SNRPA1 
31616 422 18 41% CAPZB 
96250 332 14 17% HNRNPUL1 
38151 312 15 35% GNB1 
17979 308 9 24% RPL12 
19768 298 14 48% ARPC4 
15436 293 16 49% HIST2H3A 
73564 280 16 17% DDX3Y 
35903 277 11 31% YBX1 
44254 266 7 11% DPF3 
23511 259 7 48% BCL7C 
26842 258 9 27% RPS3 
55528 256 18 39% INA 
47303 255 8 16% ACTL6B 
18296 252 14 37% RPS27A 
15004 252 14 44% UBA52 
15509 244 14 49% HIST1H3A 
26872 238 9 34% ALYREF 
45768 231 10 21% PSMC5 
37961 230 9 24% PPP1CB 
53732 226 9 8% PRPH 
47434 224 10 23% FLOT2 
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Protein MW (Da) 
Mascot  
Score Peptides matched Coverage Gene Symbol 
46365 220 8 22% RPL3 
122858 215 12 7% POTEI 
16434 214 8 22% RPS14 
17708 214 9 41% RPS18 
20761 210 15 52% ARPC3 
29807 205 13 37% RPS4X 
100877 204 7 12% PSMD2 
80895 201 9 18% SCIN 
42381 196 14 25% ACTA2 
15376 196 13 49% H3F3A 
42113 192 11 36% ARPC1A 
29264 182 13 30% RPL7 
86043 162 10 12% GSN 
28235 156 8 28% RPL8 
283140 150 18 6% HRNR 
31590 149 13 32% RPS2 
23928 138 13 44% BAG2 
249417 137 13 8% SVIL 
24304 117 10 27% RPL13 
84531 116 7 14% GYS1 
24245 116 6 21% RPL15 
29326 111 6 21% YWHAE 
45581 108 8 25% DNAJA1 
15969 107 8 23% RPS23 
69618 102 6 8% DDX5 
15788 96 6 20% RPL27 
18229 75 9 53% PPIA 
51480 72 8 24% TUBG1 
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